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CHAPTER I 
 
GENE-ENVIRONMENT INTERACTIONS AND NEURODEGENERATION: 
ASSOCIATION BETWEEN HUNTINGTON’S DISEASE AND METALS 
 
Introduction 
Synergism of genes and environment in neurodegenerative diseases 
We live in a world where we are constantly bombarded with a plethora of toxic 
substances that converge on genetically regulated pathways to modify the susceptibility, 
age of onset, and progression of neurodegenerative diseases. Neurodegenerative diseases 
affect millions of people worldwide and is estimated to insidiously cause considerable 
financial and emotional burdens on the society1. There are several neurodegenerative 
diseases, but the most common progressive forms include Huntington’s disease (HD), 
Parkinson’s disease (PD), Alzheimer’s disease (AD), and Amyotrophic lateral sclerosis 
(ALS). The familial forms of the aforementioned diseases are caused by discrete 
mutations in susceptibility genes and/or resistance alleles2. For example, mutations in the 
glutamine encoding triplet repeat (CAG) region of the Huntingtin (HTT) gene is 
associated with HD, single nucleotide polymorphism in α-synuclein and mutations in 
parkin, PINK1, DJ-1, and other genes cause PD, mutation in β-amyloid precursor protein 
(APP) gene has been implicated in AD, and mutations in the copper-zinc superoxide 
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dismutase (SOD1) gene is associated with ALS3-6. Although HD, PD, AD, and ALS 
exhibit different genetic mutations and distinct pattern of selective neuronal degeneration, 
they all display common and broad disease symptoms, for example; motor, cognitive, and 
psychiatric deficits, and others. In fact, since Archibold Garrod first suggested that some 
of the inborn errors of metabolism may be masked by diet and diseases, there has been an 
increasing acceptance of a combinatorial effect of genes and other causative factors to 
modulate the susceptibility, age of onset, and progression in neurodegenerative diseases7. 
Emerging evidence from association studies has identified modulators/factors that 
influence disease-causing genes to induce idiopathic neurodegenerative diseases. 
Importantly, the modulators/factors in neurodegenerative diseases can be classified as 
genetic (single nucleotide polymorphisms), environmental (extrinsic neurotoxins, e.g. 
metals, pesticides), excitotoxic (intrinsic neurotoxins, e.g. excitatory amino acids and 
altered metal homeostasis), autoimmunity, ageing, metabolic (oxidative injury), and 
biological (accumulation of aberrant proteins)8. Unfortunately, it is still unclear which of 
the above modulators/factors are the predominant initiators of gene-environment 
interactions in neurodegenerative diseases. Furthermore, the segregation and examination 
of only genes and environment in neurodegenerative diseases, and ignoring their 
pathophysiological interactions has for several decades limited our understanding of 
neurodegenerative diseases. The rationale that gene-environment interactions are 
essential in the development of common neurodegenerative diseases has been supported 
by the following experimental observations. First, incomplete penetrance of some 
monozygotic forms of HD, PD, AD, and ALS; second, similarities in disease phenotypes 
caused by neurotoxicants and genetic mutations; third, the ability of genetic factors to 
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dictate disease risk following exposure to environmental toxins; fourth, discordance in 
disease diagnosis, for example, age of disease onset amongst monozygotic twins; finally, 
the effects of environmental enrichment on motor and cognitive deficits, synaptogenesis, 
transcription, and development9-15. All these observations highly suggest the involvement 
of environmental factors to modulate the risk association of a genetic mutation. Despite 
the hypothetical and suggested ideas that gene-environment interactions may underlie 
neurodegenerative and other diseases, there has been paucity of studies that have directly 
provided experimental evidence to support it. 
Exemplary studies that strongly argue in favor of gene-environment interactions 
in neurodegenerative diseases are summarized below. Emerging evidence in AD research 
has identified a genetic association between a single nucleotide polymorphic form of the 
lipoprotein metabolism gene, ε4 allele of the apolipoprotein E gene (APOE4), and 
cholesterol levels that increase the risk of AD. Specifically, possession of one or two 
alleles of APOE4 is sufficient to increase the risk of AD to approximately two or five 
fold, respectively16,17. Secondly, a conventional example of environmental influence in 
PD is the ability of the neurotoxin, 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine 
(MPTP) to induce PD-like symptoms in rodents, non-human primates, and humans.  
MPTP is a non-toxic compound that possess toxic properties once metabolized by the 
glial enzyme, monoamine oxidase B (MAO-B), to 1-methyl-4-phenylpyridinium 
(MPP+). The toxic MPP+ cation selectively annihilates dopaminergic neurons in the 
substantia nigra pars compacta18,19. Impairment in metal ions and metal-dependent 
enzymes has been reported in HD. For example, Dexter and colleagues have provided 
evidence for elevated copper (Cu) and iron (Fe) levels in the corpus striatum of 
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postmortem human brain tissues20,21. In fact, several metal-dependent enzymes have also 
been shown to be altered in the striatum of HD patients22. Furthermore, the full-length 
Huntingtin protein (HTT) has been reported to interact with Cu2+ ions in mouse brains. 
This interaction decreases the solubility of HTT and induces aggregation23. Finally, the 
inclusion bodies formed by CAG expansion in mutant HTT fragments are associated with 
iron-dependent oxidative events24. 
Metals have also been suggested to exhibit gene-environment interactions in other 
neurodegenerative diseases20,21,25-27. Thus, it is not surprising that a recurring theme in 
neurodegenerative disease research has been to understand how neurotoxic metals 
modulate disease-causing genes to modify the age of disease onset, susceptibility, and 
disease progression. 
 
Role of metals in neurodegenerative diseases 
Over the past decade, there has been a growing interest to understand the 
metabolism of neurotoxic metals and their influence on various neurodegenerative 
diseases, including manganism, Wilson’s disease (WD), PD, and AD. However, less 
attention has been focused on the role of metals in HD. Occupational and environmental 
exposures to neurotoxic metals, including, Mn2+, Hg2+, Cu2+, Zn2+, As2+, Cr2+, Pb2+, and 
Al3+ have been associated with neurodegeneration and modulation of the age of disease 
onset and severity in neurodegenerative diseases. Metals play a critical role as cofactors 
of enzymes required for cellular processes, but can exert deleterious effects in the brain 
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and peripheral tissues when not properly regulated. Metals exposure may occur in large 
or trace quantities via diet, drinking water, auto exhaust, cosmetics, toothpaste, and many 
others. The brain is capable of efficiently regulating these metals under physiological 
conditions. However, excessive exposure to neurotoxic metals can accumulate in the 
brain. The distribution of metals throughout the brain is not uniform, albeit specific brain 
region accumulation of metals insinuates neurotoxicity. For example, Mn accumulation 
and neurotoxicity in the globus pallidus results in manganism. Alterations in metal 
homeostasis have been suggested to cause neurodegeneration via its association with 
proteins and subsequent induction of aggregate formation. Moreover, metals can cause 
neurodegeneration through a vicious cycle by disrupting mitochondrial function, which 
would deplete ATP, induce reactive oxygen species (ROS) production, and ultimately 
cause cell death by apoptotic and/or necrotic mechanisms.  
It has been recently reported that acute exposure of a transgenic C. elegans model 
of PD to Mn results in degeneration of dopaminergic neurons28. Experimental studies in 
PD postmortem brain tissues have elucidated a strong link between oxidative stress and 
PD through increased Fe levels, markers of oxidative stress, and lipid peroxidation in the 
substantia nigra. Interestingly, pharmacological chelation of elevated Fe levels in an 
MPTP-induced neurotoxicty model of PD prevents and delays degeneration of midbrain 
dopaminergic neurons29. These studies indicate the potential neurotoxic contributions of 
metals (Fe, Mn) in PD neuropathology. On the other hand, Zn has been proposed to have 
distinct functions as an enzyme cofactor and involvement in normal neurological 
functions based on its significant levels (10 µM) present in the brain30.  While some of 
the brain Zn levels are associated with proteins, the neocortex and hippocampus possess a 
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substantial amount of Zn that exist in its chelatable form30-33. The defined physiological 
functions of Zn are currently unclear, but it has been suggested to play an important role 
in the stabilization of glutamate-containing vesicles at the synapse of secretory cells34,35. 
In addition, in vitro experimental studies have elucidated Zn’s ability to attenuate NMDA 
induced toxicity36. However, intracerebroventricular administration of Zn in rats causes 
epileptic seizure-induced hippocampal neurodegeneration37. 
 In fact, other studies have also shown that Mn and other metals (e.g. Cu, Al, Zn) 
can interact and promote amyloid fibrillogenesis and aggregation of proteins such as 
prion protein (PrP) and α-synuclein8. These proteins are metal binding proteins that 
interact with metals and contribute to their altered conformational state, solubility, and 
aggregation38-42. However, in vitro analysis of PrP aggregates has demonstrated that Mn 
can promote aggregation independent of the PrP metal binding site41. In AD, Cu has been 
shown to bind Aß peptides with high affinity and modulate its conformational state and 
peptide length43,44. Other in vitro studies have demonstrated that Aß interacts with Fe and 
Zn to promote amyloidogenesis. Interestingly, these findings have been corroborated in 
AD postmortem brains that show elevated Fe and Zn in the neocortex and amyloid plaque 
deposits compared to control patients44. All these studies indicate that metal interactions 
with PrP, α-synuclein, and Aß proteins can cause cell death by inducing the formation of 
aberrant and toxic aggregates as well as activating redox cycling via Fenton and Haber-
Weiss reactions, which depletes cellular antioxidants, including glutathione and trigger 
ROS (·O2-, OH·, or H2O2) production. The generation of these highly reactive species can 
cause oxidative stress that would damage lipids, proteins, and DNA and further deplete 
ATP to cause cell death. In spite of the reports that have implicated metals in 
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neurodegenerative diseases, including; PD and AD, there has been paucity of evidence to 
support a functional role of metals in the pathophysiological mechanisms and 
neuropathology of HD. HTT has been demonstrated to be essential in the regulation of 
vesicular compartmentalization of Fe and its metabolism45. Finally, Williams and 
colleagues have recently reported a gene- environment interaction between mutant HTT 
and Mn46,47. The rationale and findings of the mutant HTT and Mn interaction would be 
discussed in depth in the discovery of a gene-environment interaction: PolyQ-expanded 
HTT and manganese sub-chapter of this thesis. 
 
Huntington’s disease 
Overview 
Huntington’s disease (HD) is a late-onset and progressive neurodegenerative 
disorder that was first described by George Huntington in 1872. HD is inherited in an 
autosomal dominant pattern whereby an affected individual has one mutated and one 
normal gene on a pair of chromosomes and possesses a 50/50 chance of transmitting the 
mutant gene and disorder to their offspring. Prevalence of HD is approximately 5 in 
100,000 worldwide and 1 in 10,000 in the United States with a median age of onset at 
thirty-nine3. HD is characterized by motor impairment, cognitive deterioration, emotional 
disturbance, and psychiatric deficits. Some of the early motor symptoms include chorea, 
postural imbalance, dystonia, incoordination, and oculomotor apraxia. Conversely, 
akinesia is observed in HD patients at the later stages of the disease. HD patients also 
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exhibit depression, temper, apathy, and irritability during the course of the disease. The 
cognitive deficits observed in HD include short‐term memory, attention, and learning. In 
fact, it has been reported that the cognitive and emotional features of HD precede the 
motor symptoms by several years48,49. The development of drugs and other therapeutic 
strategies to combat HD progression is still in its infancy. Tranquilizers and lithium have 
been used to control the anxiety and severe mood instability symptoms respectively in 
HD patients. Furthermore, antipsychotic drugs such as the dopamine receptor antagonist, 
haloperidol, alleviate some of the disabling abnormal movements, emotional, and 
psychological deficits albeit, the side effects that it causes including sedation50. Current 
strategies to improve the lives of HD patients have combined a multidisciplinary 
approach including medication, nutrition, psychosocial support, genetic counseling, 
physical, occupational, and speech therapies. Unfortunately, there is currently no 
effective treatment to halt or reverse the course of the disease. Life expectancy from the 
age of disease onset usually spans between 10 to 30 years. Moreover, cause of death is 
usually through complications such as pneumonia.   
 
HD Neuropathology 
The neuropathology of HD is characterized by selective degeneration of 
GABAergic medium-sized spiny neurons (MSNs) in the corpus striatum that innervate 
the globus pallidus and substantia nigra. The highly selective loss of the MSNs results in 
the symptoms observed in HD. The striatum is a ‘master regulator’ and a subset of the 
basal ganglia nuclei, which includes the subthalamic nucleus, globus pallidus, substantia 
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nigra, thalamus, and cortex. These subcortical nuclei are involved in the generation and 
integration of complex information to initiate voluntary movements through a large-scale 
neural circuit referred to as the basal ganglia circuitry. In the early stages of HD, the first 
neurons to degenerate are the dopamine expressing MSNs (D2-like). This results in a loss 
of inhibitory input to the thalamus from the globus pallidum externa (indirect pathway) 
and enhanced stimulation of the cortex, which causes the excessive movements observed 
in HD. However, as the disease progresses, the striatal dopamine receptor 1 (D1) 
expressing MSNs that project to the globus pallidus interna (direct pathway), other 
striatal neuronal populations, including the cholinergic and nitric-oxide synthase 
containing interneurons, and cortical pyramidal neurons in layers III, V, and VI are lost, 
whereas the brainstem, cerebellum and hippocampus remain unaffected3,51,52. In the late 
stages of HD, broad brain atrophy occurs in the basal ganglia nuclei, pons, medulla, 
hippocampus, cerebellum, and other brain regions53. However, the most striking neuronal 
loss (95%) in the brain is in the corpus striatum54. Although the impaired basal ganglia 
circuitry underlying HD is fairly understood, it is still unclear why the MSNs are the most 
vulnerable in HD. 
 
Huntingtin protein function 
The Huntingtin protein (HTT) is a large soluble cytoplasmic protein of 3,144 
amino acids that is ubiquitously expressed in all regions of the brain and peripheral 
tissues55. The protein is enriched in the soma, dendrites, and synaptic terminals of 
neurons with similar expression patterns for wild-type and mutant HTT3,56,57. Mutated 
  10 
HTT causes progressive degeneration of the MSNs in the corpus striatum. Expansion of 
the polyglutamine (polyQ) tract alters the conformational state and biophysical properties 
of mutant HTT and modifies its fragmentation by proteolytic processing. The HTT 
protein has several domains and binding partners (Figure I.1.). Importantly, in vivo and in 
vitro HD models have demonstrated and suggested that HTT has multiple roles in 
development, vesicular and axonal transport, gene transcription, anti-apoptosis, synaptic 
function, and metal homeostasis. Three independent studies have demonstrated that wild-
type HTT is essential for normal embryonic development and neurogenesis. Its complete 
inactivation in HTT-knockout mice (Hdh-/-) results in embryonic lethality before E7.5 in 
mouse (prior to gastrulation and the formation of the nervous system)58-60. In addition, 
Lumsden and colleagues have reported that morpholino knockdown of wild-type HTT 
results in developmental defects and premature death in zebrafish45. Wild-type HTT is 
also essential for the vesicular transport of brain-derived neurotrophic factor (BDNF) 
along microtubules. Finally, wild-type HTT has functional roles in post-mitotic brain 
development61.  
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Figure I. 1.  Schematized representation of the HTT protein amino acid sequence. 
The above markings on the HTT protein indicate the following: (Q)n (number of 
polyglutamine (polyQ) repeats in the poly Q domain); (P)n (polyproline sequence rich 
domain). Red boxes (HEAT repeat clusters); Black box (NES - nuclear export sequence); 
Brown shaded area (Huntingtin interacting protein, HIP14-interaction domain); Green 
arrowhead (palmitoylation site); Purple arrowheads (calpain cleavage sites); Red arrows 
(caspase cleavage sites); blue octagons (clusters of phosphorylation); Green and black 
octagons (post-translational modifications: ubiquitination and sumoylation). Modified 
from62. 
 
Genetics of HD 
The HTT gene that encodes a ubiquitously expressed HTT protein is located on 
human chromosome 4, position 16.363. In the first exon of the HTT gene are trinucleotide 
repeats (CAG) that encode for the amino acid, glutamine (Q), in the HTT protein64,65. HD 
is one of nine neurodegenerative diseases that are caused by an expansion in the 
trinucleotide-encoding region of the disease-causing gene. HD is caused by an expansion 
in the glutamine-encoding triplet repeat (CAG) of the normal HTT gene3,64,65. The 
majority of HD patients have repeat lengths between 40 and 50 CAGs 66. Importantly, 
there is an inverse correlation between age of disease onset and repeat length66,67. 
However, the correlation between repeat length and age of disease onset is significantly 
weaker in HD patients with 40-50 CAGs66. Although HD is thought to be an adult-onset 
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neurodegenerative disease, approximately 5% of HD patients have the juvenile form of 
the disease with patients exhibiting symptoms in their early teens. In addition, the 
juvenile form of HD is characterized by increased repeat length (70 or more) in 
comparison to adult HD onset (40-60). Juvenile HD patients show early cerebellar 
degeneration and enhanced disease progression compared to adult-onset. The largest 
CAG repeat that has been documented so far is approximately two hundred and fifty60,68.  
Importantly, most in vivo (e.g. YAC128) and in vitro HD models (e.g. mutant 
STHdhQ111/Q111) currently used in HD research and in our studies express a longer repeats 
length similar to what is observed in the juvenile form of HD. The longer repeats length 
provides an efficient and practicable experimental duration to observe disease 
phenotypes69. In unaffected individuals, the HTT protein contains between 6 to 37 CAGs. 
Alleles of CAG between 36 and 39 increase the likelihood of developing HD. In fact, 
CAGs above 40 are fully penetrant and cause HD70. HD and other polyQ diseases share a 
genetic anticipation phenomenon. In this phenomenon, successive generations of mutant 
HTT inheritance result in an increase polyQ length and a concomitant earlier age of 
disease onset. HD patients exhibit a striking variability in age of disease onset and 
severity. 
 
Genetic and environmental modifiers of HD 
The autosomal dominant inheritance pattern in HD follows Mendelian genetics. 
Affected individuals have at least one mutated allele and a 50% probability of 
transmitting the mutant gene and disorder to their offspring. The CAG repeat length 
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increases through successive generations. Interestingly, inheritance of the mutated HTT 
allele does not follow an equal sex transmission rate. Specifically, same-sex (mother to 
daughter or father to son) has a greater sex transmission rate compared to different-sex 
(mother to son or father to daughter) transmission. In addition, same-sex siblings have 
been reported to have a greater tendency to have higher transmission rates66. Although 
HD is caused solely by mutation in HTT and expansion in the CAG tract, the 
susceptibility and precise age of onset is modified by other genetic and/or environmental 
factors. Interestingly, kindred studies have reported that the length of the polyQ repeat in 
the HTT protein accounts for approximately 60% of the variance in age of disease onset 
and severity. Importantly, Wexler and colleagues show that repeat lengths between 40 
and 50 CAGs account for 44% of the variability and exhibit decreased correlation 
between CAG repeat length and age of disease onset. In essence, the shorter the repeat 
length (<50), which is prevalent in majority of HD cases, the greater the influence of 
genetic and environmental influence on age of onset and susceptibility66. Furthermore, 
the kindred studies have also indicated that a significant segment of the variability in age 
of onset is familial and accounts for as much as 84% of the residual variance66.  
Importantly, twin studies have demonstrated that siblings with the same CAG 
repeat length may have striking differences in their symptoms, clinical manifestation, and 
over 20 year difference in age of disease onset66,71-73. Moreover, after accounting for the 
effect of CAG repeat length, other twin studies have reported a high degree of heritability 
(h=0.56) in the residual variance. These studies have implicated genetic modifiers as the 
potential modulators of residual variability in age of onset and severity in HD74-76. The 
findings from the kindred and twin studies strongly suggest that the variability in age of 
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disease onset and susceptibility may be due to other genetic/and or environmental factors 
and not the HD gene itself.  
Current strategies including, linkage analysis, candidate approach, and genetic 
screens have been utilized to explore genetic modifiers in HD. Despite the identification 
of several genetic modifiers in HD, for example genes implicated in lipoprotein 
metabolism (APOE), axonal trafficking (HAP1), energy metabolism (PPARGC1A), and 
many others, it is still unclear how they modify the pathogenesis of HD. However, 
several positive findings of polymorphic genes that modify age of onset in HD have been 
negated in subsequent studies. For example, APOE, HAP1, UCHL, MTHFR, and 
GRIN2B. The discrepancies in the modifier investigation and identification has been 
proposed to be due to sample size, failure to account for multiple hypotheses when many 
genes are involved, and confounding factors of population stratification and relatedness 
of the samples used in the study77. Conversely, one of the earliest identified genetic 
modifiers, GRIK2, which is a glutamate receptor gene, has been demonstrated to have an 
effect on age of onset in multiple studies. Specifically, modifications in a particular allele 
of the 3’ untranslated region TAA trinucleotide repeat of GRIK2 that encodes for the 
GluR6 subunit of the kainate receptor is associated with earlier age of onset than 
expected77-79. Unfortunately, the Venezuelan kindred studies failed to identify any 
association between GRIK2 and age of onset. This discrepancy has been attributed to the 
rareness of GRIK2 in the Venezuelan kindred80. Nevertheless, Andresen and colleagues 
have reported that the Venezuelan kindred has a genetic polymorphism in the NR2A and 
NR2B subunits of the NMDA receptor that modify the age of disease onset80. Finally, 
recent genetic modifier studies have also demonstrated that a genetic polymorphism in 
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hOGG1, a DNA repair gene, increases the CAG repeat length and decreases the age of 
disease onset in HD81,82. 
Environmental factors, including, exercise and environmental enrichment has 
been implicated in HD progression using animal models83-85. In fact, exercise and 
environmental enrichment is known to exhibit neuroprotective effects, including, 
memory enhancement and neurogenesis through in vivo alterations of brain derived 
neurotrophic factor (BDNF) levels86,87.  
The Venezuelan kindred studies have reported that the environment accounts for 
63% of the residual variance in age of onset that is not attributed to repeat length. Despite 
the earlier age of onset in the Venezuelan kindred compared to Canadian and American 
HD patients, they do not exhibit significant differences in life expectancy. Wexler and 
colleagues have postulated that the destitute sanitation conditions along Lake Maracaibo 
where the Venezuelan kindred reside may potentially increase their likelihood of being 
exposed to environmental factors, such as pollutants that may modify age of disease 
onset76. Unfortunately, the nature of the environmental factor(s) is still unknown. Given 
the previous reports of occupational neurotoxicity of mercury in Japan and Sweden, 
which causes Parkinsonian phenotypes in cats and humans, it is highly likely that the 
suggested environmental factors that modify age of onset may potentially be metals.  
 
Association between metals and HD 
Due to the essentiality of metals in the brain, alteration in their homeostasis is 
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detrimental. Out of all the metals that have been hypothesized to possibly influence HD 
pathophysiology, it is only Fe and Cu that have been extensively examined to substantiate 
their potential roles in HD. In fact, magnetic resonance imaging (MRI) studies have 
demonstrated a significant increase in in vivo Fe levels in the basal nuclei, specifically; 
caudate, putamen, and globus pallidus of HD patients88. Fe levels have been reported to 
be elevated in the caudate and putamen of HD postmortem tissues by 56% and 44% 
above controls, respectively, albeit no significant changes in ferritin, an intracellular iron 
storage protein, levels in the aforementioned regions20,21. Conversely, other studies have 
demonstrated elevated ferritin levels in HD brains and animal models of HD89,90. The 
discrepancies in ferritin level reports may possibly be due to experimental and technical 
issues used to assess ferritin levels in the tissues.  Although ceruloplasmin, a ferroxidase 
enzyme and copper transport protein, levels is increased in HD brains, emerging reports 
have demonstrated a significant decrease in ceruloplasmin ferroxidase activity in the 
cerebrospinal fluid of HD patients91. Interestingly, other studies have suggested that Fe 
may influence the expression of HTT, as chelation of Fe by deferoxamine results in 
increased HTT expression92. Thus, it is possible that loss of wild-type HTT function may 
elevate the levels of free Fe pools in the brain to induce oxidative injury through the 
Harber-Weiss fenton reactions, which would ultimately result in cell death. Nevertheless, 
the formation of inclusion bodies by CAG expansion in mutant HTT protein fragments 
have also been suggested to be associated with iron-dependent oxidative events24.  
Current experimental reports aimed at elucidating the molecular mechanisms 
underlying altered Fe homeostasis in HD patients, postmortem tissues, and animal 
models have suggested a possible regulatory role of HTT in Fe compartmentalization. In 
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fact, wild-type HTT has been demonstrated to be important for Fe metabolism and 
oxidative energy production in zebrafish. Specifically, morpholino knockdown of HTT 
causes Fe-deficiency albeit the availability of cellular Fe pools. In addition, there are 
enhanced transcript levels of transferin receptor 1, a trivalent Fe uptake transporter, in the 
HTT knockdown zebrafish45. HTT protein has been implicated in the modulation of Fe 
release from endocytic vesicles into the cytosol via the transferrin-mediated pathway45,93. 
Nevertheless, myelination impairments are known to occur in HD patients94. 
Interestingly, the differentiation and proliferation of oligodendroglia, myelinating cells in 
the CNS, have been reported to be dependent on the availability of Fe93,95. In addition, 
HD patient brains exhibit elevated oligodendrocyte density96. Interestingly, the increased 
Fe levels in the HD brains have been suggested to mediate the sustainment of 
oligodendrocyte-mediated myelination in the brain94. 
Fe-dependent enzymes, including; the energy metabolism enzymes, mitochondrial 
complexes I-IV and aconitase are decreased in HD patients and animal models97,98. The 
activity of aconitase, an Fe-sulfur (Fe-S) containing enzyme, essential for Fe homeostasis 
and the conversion of citrate to isocitrate in the tricarboxylic acid cycle99,100 as well as the 
mitochondrial complexes II and III are inhibited by ROS production101,102. Thus, it is 
possible that elevated Fe levels in HD brains may impair energy production and induce 
ROS production, which would inhibit aconitase and mitochondrial complexes II and III 
to cause cell death. 
Alterations in Cu homeostasis have been implicated in HD. A regional 
comparison of the concentration of ceruloplasmin in HD patients showed a significant 
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increase in the hippocampus, parietal cortex, and substantia nigra compared to control 
patients103. In addition, Dexter and colleagues have reported increased Cu levels in the 
putamen of HD postmortem tissues compared to controls21. Finally, recent evidence has 
demonstrated that the wild-type HTT protein interacts with Cu and decreases its 
solubility23. Although Dexter and colleagues observed no alterations in Mn levels in HD 
postmortem brains, several Mn-dependent enzymes, including transglutaminase, 
arginase, gluatmine synthetase, pyruvate carboxylase, and Mn superoxide dismutase 2 
(SOD2) are impaired in human HD postmortem brains and toxicant models of 
HD22,104,109.  
In essence, the above studies elucidating the association of metals in HD 
pathophysiology strongly insinuate that alterations in metal homeostasis may modify age 
of onset and disease progression in HD. Thus, future studies would have to focus on the 
possible influence of other metals in HD neuropathology.  
 
Discovery of a gene-environment interaction: PolyQ-expanded HTT and manganese 
 Over a decade after the identification of the HD mutation, there has been conflicting 
reports linking complete or incomplete penetrance of HD to triplet repeat expansion 
length. Although longer repeat length has been associated with earlier onset, repeat length 
only accounts for 60% of the variability in age of disease onset and severity. Emerging 
reports have suggested the possibility of both genetic and environmental factors in 
playing important roles in HD neuropathology, with environmental factors being the 
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largest share of the residual variability in age of disease onset and severity66,110. 
Moreover, Gómez-Esteban and others have implicated environmental influences to 
modify age of disease onset and clinical presentation in monozygotic twin studies that 
have the same number of expanded repeats71-73,111. Unfortunately, these twin studies 
failed to reveal the nature of the environmental factors involved. Furthermore, animal 
models of HD have provided further support for the influence of environmental factors 
on HD onset and progression110,112. Indeed, exercise, environmental enrichment, and 
dietary changes have demonstrated neuroprotective effects in HD. With the increasing 
and compelling evidence to support a strong association between metals and protein 
aggregation, altered metal ion homeostasis in HD, and the differential accumulation of 
various metals across neuronal subtypes, it is highly rationale to propose that metals with 
neurotoxic properties are the strongest candidates for the largest residual environmental 
variability in HD that modify age of onset, severity, and selective neuropathology. 
 In an attempt to identify the metals that contribute or share pathophysiologial 
mechanisms and potentially modify the age of disease onset, severity, and 
neuropathology in HD, our lab has previously performed a disease-toxicant screen. We 
evaluated the potential effects of Mn2+, Fe3+, Cu2+, Zn2+, Pb2+, Cd2+, Co2+, and Ni2+ to 
modify cell survival in an established knock-in immortalized murine striatal cell line 
model of HD that express either wild-type HTT (STHdhQ7/Q7) or the polyQ-expanded 
form of the protein (STHdhQ111/Q111)113-115. We discovered a novel gene-environment 
interaction between the mutant HTT protein and Mn. Specifically, acute Mn exposure of 
the cultured striatal cells produced an unexpected result, wherein mutant (STHdhQ111/Q111) 
expressing cells showed decreased vulnerability to Mn cytotoxicity compared to wild-
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type (STHdhQ7/Q7)47. Furthermore, a measurement of total intracellular Mn levels 
following Mn exposure by graphite furnace atomic absorption spectrometry (GFAAS) in 
STHdhQ7/Q7 and STHdhQ111/Q111 cells showed a significant decrease in net accumulated 
Mn levels in mutant compared to wild-type cells. Moreover, the mutant HTT–Mn 
interaction was corroborated in vivo using the YAC128 mouse model of HD. 
Specifically, we demonstrated a striatal specific decrease in Mn uptake in the YAC128 
compared to wild-type animals following subcutaneous injections with 50mg/Kg of Mn 
chloride tetrahydrate46,47,116. Finally, we have reported a significant decrease in basal Mn 
levels in mutant compared to wild-type cells46. Furthermore, recent evidence from 
Madison and colleagues has demonstrated an in vivo impairment effect of Mn exposure 
on medium spiny neuron morphology and architecture in the YAC128 mouse model of 
HD (personal communication). In essence, while the studies by Williams and Madison 
are the first to demonstrate a gene-environment interaction between mutant HTT and Mn 
as well as the ability of Mn to alter neuronal architecture in the corpus striatum 
respectively, they strongly suggest that Mn may be one of the environmental factors 
proposed to modify the age of disease onset, progression, and severity in HD. However, it 
is still unknown how mutant HTT protein expression modulates Mn homeostasis. Hence, 
further studies that we have performed and would be discussed in subsequent chapters 
would focus on deciphering the regulatory function of mutant HTT protein on Mn 
transport, transporter systems, and homeostasis to elicit decreased susceptibility to Mn 
toxicity. 
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Manganese 
Overview 
Mn is an essential ubiquitous trace element required for normal growth, 
development and cellular homeostasis117. Specifically, Mn is important in bone 
formation, fat and carbohydrate metabolism, blood sugar regulation, and calcium 
absorption. In humans and animals, Mn functions as a required cofactor of several 
enzymes necessary for neuronal and glial cell function, as well as enzymes involved in 
neurotransmitter synthesis and metabolism22,118,119. Furthermore, in vitro data has 
implicated Mn in the induction of stellate process formation of astrocytes120. Mn exists in 
various chemical properties including, oxidataion states (Mn2+, Mn3+, Mn4+ Mn6+, Mn7+), 
salts (sulfate and gluconate), and chelates (aspartate, fumarate, succinate). The versatile 
chemical properties of Mn has enabled for its industrial usage in making glass and 
ceramics, adhesives, welding, paint, and gasoline anti-knock additive 
[methylcyclopentadienyl manganese tricarbonyl (MMT)]. While uncommon, Mn 
deficiency can contribute to birth defects, decreased fecundity, bone malformation, 
weakness, and enhanced susceptibility to seizures121,122.  The routes of Mn exposure are 
mainly through dietary intake, dermal, and inhalation. Moreover, Mn in the diet is found 
mostly in whole grains, nuts, and seeds, tea, legumes, pineapples, and beans. Despite its 
essentiality in multiple metabolic functions and industrial usage, excessive levels of Mn 
exposure can accumulate in the brain and has been associated with dysfunction of the 
basal ganglia system to cause an irreversible neurological disorder similar to PD123. 
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Manganese neurotoxicity 
The average Mn levels in brain tissue is approximately 1-2 µg/g dry weight124. 
The concentration of Mn in the brain is very heterogenous under excessive physiological 
exposures. Importantly, the highest Mn level is in the globus pallidum of humans and 
hypothalamus of rats124,125. Mn exposure is mediated through diet, inhalation, or the skin. 
Excessive and prolonged exposure to Mn via occupations including welding, mining, 
combustion products from the anti-knock agent in fuel, for example; MMT, and highly 
concentrated Mn concentrations in ground/well water results in its the accumulation in 
the dopamine rich regions of the basal ganglia. In fact, spectroscopy data in rats has 
demonstrated that the mitochondria accumulate the highest amount of Mn in the basal 
ganglia following exposure126,127. This causes a clinical disorder referred to as 
manganism that is characterized by extrapyramidal symptoms including, anorexia, 
apathy, muscle and joint pain, and many others that resemble idiopathic Parkinson’s 
disease (IPD). Shortly after the onset of the symptoms, patients also exhibit memory loss, 
compulsive behavior, visual impairments, illusions and delusions, disorientation, which is 
clinically referred to as locura manganica, meaning manganese madness128. Two vital 
organs are affected following excessive Mn accumulation in the body, specifically; the 
brain and lungs, with the latter mediated through inhalation129,130. Elevated Mn levels in 
the brain is associated with impaired Fe homeostasis, excitotoxicity, mitochondrial 
dysfunction, oxidative stress, induction of protein aggregation, and alteration in the 
homeostatic conditions of other metals that share similar transporter systems with Mn. 
Although the relationship between increased Mn levels and its disruptive effects on the 
neurochemistry of neurotransmitters has been debatable, elevated Mn levels have been 
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suggested to alter γ-aminobutyric acid (GABA), dopamine, and glutamate 
neurotransmitters levels in the brain131-133. Mn associates with several proteins to 
facilitate its physiological functions. 
 
Functions of Mn-binding proteins  
Mn is a necessary cofactor of several physiological enzymatic activities. Although 
Cu and Mg can substitute the essential physiological roles of Mn, a subset of enzymes 
solely depend on Mn for their physiological roles in neuron and/or glial function. These 
discrete Mn-binding proteins (manganoproteins) include, the glutamine synthetase, 
superoxide dismutase 2 (SOD2), arginase, pyruvate carboxylase, serine/threonine 
phosphatase125,134,135.  
 Glutamine synthetase (GS) is the most abundant manganoprotein and 
predominantly expressed in astrocytes. GS synthesizes glutamine through the conversion 
of glutamate to glutamine. Importantly, Mn has been reported or proposed to regulate GS 
activity. GS contains four Mn ions per octamer136. In fact, decrease GS activity in the 
brain has been proposed to increase the functional glutamate trafficking, glutamatergic 
signaling, and excitotoxicity137. Interestingly, it has been proposed that the increased 
susceptibility of seizures observed in individuals with Mn deficiency may be due in part 
to diminish or aberrant GS levels and/or activity138. SOD2 is a mitochondrial enzyme that 
detoxifies superoxide anions through the formation of hydrogen peroxide (H2O2). 
Although the concentration of Mn within neurons is low (<10-5 M), its high 
mitochondrial energy demands is correlated with a propensity of increased SOD2 in 
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neurons compared to glia124,129. Furthermore, loss of SOD2 activity increases the 
susceptibility of cells to mitochondrial inhibitors induced toxicity and cause oxidative 
injury109. In the brain, arginase plays an important role in regulating the levels of L-
arginine, an amino acid that helps eliminate ammonia from the body. Arginase catalyzes 
the production of L-ornithine and urea from L-arginine in the urea cycle. Moreover, L-
arginine is converted to nitric oxide by the neuronal nitric oxide synthetase. Proper 
regulation of arginase has been demonstrated to promote neuronal survival by impairing 
nitric oxide signaling139,140. Pyruvate carboxylase is an essential enzyme required for 
glucose metabolism. It interacts with Mn for the generation of oxaloacelate, a precursor 
of the tricarboxylic acid (TCA) cycle141,142. Interestingly, in the brain, pyruvate 
carboxylase is predominantly expressed in astrocytes143,144. Protein phosphatase 1 is a 
manganoprotein that is essential for glycogen metabolism, cell progression, regulation of 
neurotrophin synthesis and release for neuronal survival, and synaptic membrane 
receptors and channels145.  
 
Regulation of plasma manganese homeostasis 
The intricate regulation of Mn is crucial for its absorption and tissue specific 
accumulation. Furthermore, it contributes to our understanding of Mn essentiality and 
toxicity in the brain and periphery. Three major factors have been postulated to be highly 
important in the modulation of plasma Mn levels. First, given that the main source of Mn 
exposure is via diet, it is crucial to tightly regulate gastrointestinal absorption of Mn. 
Secondly, following Mn exposure and a concomitant increase in plasma Mn levels, 
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excretion of Mn to target organs, including the liver is necessary to prevent Mn induced 
toxicity in the periphery. Finally, although the liver detoxifies substances, the excreted 
Mn must be further eliminated from the plasma via shuttling to the bile129. The absorption 
of Mn by the gastrointestinal tract is highly dependable on the quantity of ingested Mn 
and the net accumulated levels in the plasma. In vivo data from mice and rats have 
reported a minimum variability (1-3.5%) in the GI absorption of plasma Mn146,147. While 
there is a simple diffusion-mediated transport of Mn in the large intestines, Mn is actively 
and efficiently transported in the small intestines129. The major organ required for 
eliminating accumulated Mn in the plasma is the liver. The concentration gradient-
dependent Mn excretion into the bile suggests an active mode of transport148. Interesting, 
a plethora of plasma proteins or ligands have been implicated as specific Mn carrier 
proteins. These include beta1-globuin, album, and transferrin149,150. In fact, Foradori and 
colleagues have reported that approximately 80% of plasma Mn is bound to beta1-
globuin149. Despite the demonstration that Mn preferentially binds to albumin in the 
plasma of both rabbits and humans, emerging evidence has challenged the Mn-albumin 
assertion and provided evidence for a poor binding of Mn to albumin compared to 
cadmium and zinc151,152.  
 
Manganese transport in the central nervous system (CNS) 
 Mn can cross the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier 
(BCB) on several carriers and different oxidation states. Given the essential physiological 
functions of Mn and the neurotoxicity associated with its homeostatic impairment, Mn 
  26 
absorption, transport, and tissue levels are stringently regulated. Under normal 
physiological conditions, Mn is efficiently transported across the blood-brain barrier 
(BBB) in both the developing fetus and adults129,153. Although Mn transport across the 
BBB has been actively investigated, there has been a paucity of evidence and 
controversial findings to substantiate the identities of its transporter systems. However, 
over the past two decades, different Mn transporter systems have been identified; 
including active and facilitated diffusion modes of Mn transport154-156. For example: Mn 
can be transported via several transporters/channels and candidate proteins including the 
divalent metal transporter 1 (DMT1), transferrin (Tf) receptor (TfR) that mediates 
trivalent Fe uptake, calcium channels, zinc-interacting protein transporters, huntingtin-
interacting proteins (HIP14 and HIP14L), PARK9, the transient receptor potential 7 
(TRPM7) channels, and choline transporters as schematized in Figure I.2. While the 
tissue-specific expression of each of the aforementioned Mn transporters is yet to be 
determined, it is likely that the optimal tissue Mn levels are maintained through the 
involvement of all the above and other unknown Mn transporters. In addition, other 
cellular process in response to Mn deficiency or overload in tissues may regulate the 
activity of the above transporters. Of all the above listed polyvalent transporters, TfR and 
DMT1 are the most extensively documented156. Interestingly, it is estimated that 
approximately 80% of plasma Mn is associated with albumin and beta1-globulin. 
However, a smaller fraction plasma Mn is bound to transferrin (Tf), an iron-binding 
protein149. 
 The divalent metal transporter 1 (DMT1) is a member of the family of natural 
resistance-associated macrophage proteins (NRAMP) and crucial for the maintenance of 
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essential metal homeostasis in the brain157-159. It is best known for its ability to regulate 
Fe homeostasis in the gastrointestinal lumen159. DMT1 is also known as the divalent 
cation transporter (DCT1) due its ability to competently transport divalent metals 
including, Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, Pb2+, and Fe2+157,160. There are two 
alternative splice isoforms of DMT1 that are predominantly localized at the plasma 
membrane. However, depending on the cation requirements, the different splice isoforms 
can be localized in subcellular compartments161. The transcriptional regulation of the 
gene that encodes DMT1 protein is modulated by Fe concentration via an iron-response 
element (IRE) located on its mRNA125,158. DMT1 transports metals across the plasma 
membrane into the cytosol. The relative high affinity of DMT1 for Mn has been well 
established. Specifically, in vivo reports have demonstrated that mutations in the DMT1 
gene of the Belgrade rats and microcytic anemia mouse results in significant decrease in 
Mn and Fe tissue levels162-164. Furthermore, the use of magnetic resonance imaging 
(MRI) in a recent study demonstrated the consistency of a shared transport mechanism (s) 
between Mn and Fe165. Other in vitro experiments have also elucidated the role of DMT1 
in Mn transport across the BBB. In fact, DMT1 mediated metal transport across the rat 
brain endothelial cells in culture has been reported to be pH, temperature, and Fe-
dependent166,167.  
  The TfR is the major cellular receptor for Tf bound Fe, but can also mediate the 
transport of extracellular Mn with a 3+ valence. Once Mn3+ is internalized through the 
endocytic pathway, it is reduced to Mn2+ and transported through DMT1 to the cytosol. 
Mn binding to Tf is time-dependent and Tf receptors are also present on the surface of 
cerebral capillaries156,168. Additionally, the TfR is an active transporter that is pH and Fe-
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dependent168. Both in vivo and in vitro studies have reported that Mn is efficiently 
transported via the TfR. For example, a spontaneous mutation in the murine gene that is 
linked to the TfR and referred to as hypotransferrinemic, results in a drastic serum TfR 
deficiency, impairs Mn transport, as well as disrupts Fe deposition169,170. Interestingly, 
autioradiography reports have indicated that the TfR is generally localized in the gray 
matter regions, but not the white matter tracts that contain Mn levels in humans and 
rodents171-173.  
The zinc-interacting protein 8 (ZIP8) and 14 (ZIP14) proteins are divalent 
metal/bicarbonate ion symporters known to transport Mn, Zn, and Cd under normal 
conditions174,175. ZIP8 and ZIP14 are members of the solute carrier-39175,176 that are 
glycosylated and expressed on the apical surface of brain capillaries. Mn uptake through 
ZIP8 or ZIP14 is driven by the extracellular carbonate (HCO3-). The expression of ZIP8 
and ZIP14 in the brain are relatively lower compared to the liver, duodenum, and 
testis177. On the other hand, the voltage-gated Ca2+ channels, including; L and P-types178, 
ligand-gated Ca2+ channels, for example; store-operated Ca2+ channels (SOCCs)179, and 
the ionotropic glutamate receptor Ca2+ channels180 have been implicated in Mn transport 
across the BBB. 
Over the past decade, there has been an increasing interest in the exploration and 
identification of novel candidate Mn transporters. Emerging experimental data has 
indicated the role of the magnesium transporter, huntingtin-interacting protein 14 and 
14L (HIP14, HIP14L) in mediating Mn2+ and other divalent metals (Mg, Sr, Ni, Ca, Ba, 
Zn2+) transport across cell membranes181,182. HIP14 is the mammalian ortholog of the 
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ankyrin repeat protein 1 (Akr1p) that is primarily expressed in neurons and not glia. 
HIP14 is involved in the palmitoylation of several neuronal proteins including HTT183. In 
addition, it is required for endo and exocytisis, as well as targeting of cysteine string 
protein (CSP) and synaptosomal-associated protein 25 (SNAP25) to the synapse184,185. 
HIP14 is predominantly expressed in the presynaptic terminal, golgi apparatus, and 
vesicular structures localized in the axon, dendrites, and soma of neurons186. Biochemical 
studies, including; yeast-two-hybrid has demonstrated that the interaction between HIP14 
and HTT is inversely correlated to the poly-Q length in the HTT protein185. Furthermore, 
Gitler and colleagues have recently reported that the PARK9 gene responsible for early-
onset Parkinsonism also transports Mn182. The PARK9 gene encodes a putative P-type 
transmembrane ATPase (ATP13A2) protein. Although the exact function of PARK9 is 
unknown, it is generally thought to be a transmembrane cationic metal transporter that 
shuttles cations, including Mn across the cell. Biochemical studies have demonstrated 
that the highest and lowest PARK9 mRNA levels are localized within the substantia nigra 
and cerebellum respectively187. 
In spite of the inhibitory roles of Mn on the choline transporter at the BBB, it has 
been suggested that Mn transport during periods of high-throughput may be mediated 
through the choline transporter. In addition, the choline transporter has a higher affinity 
for Mn compared to the other metals (Cd2+ and Al3+) that it transports188-190. Mn transport 
across the choline transport is sodium-independent, carrier-mediated, and saturable168.  
The TRPM7 transporter is ubiquitously expressed in vertebrates as a Ca2+ 
selective channel, and a serine/threonine protein kinase. Transport of cations across 
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TRPM7 channel is energy dependent. Furthermore, the kinase activity is important for 
the TRPM7 metal transport function. Specifically, the kinase operates by regulating the 
intracellular Ca2+ levels and Mg2+ homeostasis through the creation of an inward current. 
Thus, contributing to the establishment of a cell membrane potential. The selective 
permeability of cations through TRPM7 has been reported to be as follows: Zn2+, Ni 2+> 
Ba2+, Co2+> Mg2+> Mn2+> Sr2+> Cd2+> Ca2+. Finally, physiological levels of Mg2+ and 
Ca2+ are necessary for maintaining the permeability of Mn2+, Co2+, and Ni2+ through 
TRPM7168. 
The homomeric purinorecptors, including P2X and P2Y have been suggested to 
participate in Mn transport. These receptors are ATP-dependent and ubiquitously 
expressed on endothelial cells191-193. Purinoreceptors have a relatively lower affinity for 
Mn compared to other divalent metals that it transports (Ca> Mg> Ba> Mn)168. Finally, 
the citrate transporter has been implicated in Mn transport across the BBB194.  
Intracellular Mn2+ is sequestered into the mitochondria of brain and liver via the 
Ca2+ uniporter195,196. There has been conflicting reports to support either the mitochondria 
or nuclei as the cellular organelle that accumulates the primary pool of Mn in the 
cell143,197,198. In fact, Suzuki and colleagues have reported that both brain mitochondria 
and lysosomes accumulate a substantial amount of unbound Mn following Mn 
administration199. The efflux mechanism of cellular mitochondrial Mn2+ is mediated 
preferentially through an active, but slow Na+-independent mechanism with minimal 
transport over the Na+-dependent efflux mechanism125. This slow Mn efflux is suggested 
to account for the net accumulation of Mn in the mitochondria. Nevertheless, the 
  31 
cytoplasmic Fe2+ exporter, ferroportin-1, has been hypothesized and reported to be a 
candidate Mn exporter. Interestingly, ferroportin-1 surface localization and protein 
expression is perturbed following Mn exposure200. 
 
 
Figure I. 2.  Identified and putative Mn transporters. These illustrated Mn 
transporters have been demonstrated to facilitate Mn trafficking (uptake, storage, efflux) 
between the extra and intra-cellular milieu. Each of these transporter proteins has also 
been implicated in the transport of other metals.  
 
Methods for detecting manganese levels in biological specimens 
Over the past two decades, several analytical methods have been developed for 
detecting Mn levels and monitoring Mn homeostasis in biological samples. Although 
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most methods used to detect Mn in biological samples require digestion of the organic 
matrix prior to analysis, a recently developed method has successively measured trace 
concentrations of metals without sample digestion201. In fact, the biological sample-type 
determines the method of digestion to be used. For example, blood or saliva may be 
digested by an ion exchange resin while tissue samples would require acid (nitric or 
sulfuric) digestion. Exogenous Mn can contaminate the accuracy of detecting and 
measuring Mn levels in biological samples, especially low Mn levels. The current 
methods used for measuring Mn levels in biological specimens include atomic absorption 
spectroscopy (AAS), atomic emission spectroscopy (AES), inductively coupled plasma-
atomic emission spectrometry (ICP-AES) and mass spectrometry (ICP-MS), neutron 
activation analysis, x-ray fluorimetry, spectrophotometry, and radioactive trace assays.  
 AAS and ICP-MS are the most common methods used for measuring Mn levels in 
biological samples. AAS analysis requires aspiration of the sample into a flame or 
graphite furnace (GFAAS) that is further detected on a photoelectric detector for 
elemental measurements. GFAAS is mostly used for the determination of very low 
analyte levels as well as solid sample analysis202. ICP-MS provides multi-element 
analysis of biological specimens, including Mn. In fact, ICP-AES and ICP-MS can often 
measure analytes at the part per trillion levels203. In addition, ICP-AES and ICP-MS can 
be used to measure both liquid and solid analytes. While measurements of analytes in 
solid samples require a laser ablation system, liquid samples are introduced into the ICP 
by a nebulizer for analyte (Mn) measurements. Conversely, neutron activation analysis 
minimizes potential contamination of biological Mn levels through minimal sample 
handling and no reagent usage. Furthermore, neutron activation analysis has a low 
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detection limit and capable of accurate detection of 4ng/g of analytes in biological 
samples202. However, none of the above Mn detection methods is capable of 
distinguishing between different Mn compounds or oxidation states. 
 In spite of the several advantages that the current Mn detection techniques 
provide, for example; multi-elemental analysis, excellent specificity, extremely high 
sensitivity and limited chemical interference, they are not feasible to assess Mn transport 
kinetics in a high-throughput manner. This is mainly due to the large number of samples 
required, duration of experimental analysis and cost of analysis.  
 
Rationale behind the development of a high-throughput manganese detection assay 
 We have previously identified a disease-toxicant interaction between mutant HTT 
and Mn, wherein expression of the mutant HTT protein decreases net Mn uptake in both 
cellular and mouse models of HD46,47. However, it is still unknown how expression of 
mutant HTT protein modulates Mn transport dynamics and homeostasis. Unfortunately, 
the current Mn detection methods described above are not feasible to assess Mn transport 
kinetics in a high-throughput manner. Therefore, we sought to develop a high-throughput 
assay that could accurately measure cellular Mn levels following detergent extraction and 
enable efficient assessment of Mn transport kinetics. The remaining chapters of this 
thesis would focus on the development of a novel high-throughput assay and its usage in 
the functional characterization of Mn transport kinetics and dissection of metal 
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transporter systems that underlie the Mn accumulation deficiency observed in a mutant 
expressing cellular model of HD.  
 
Summary 
 The above-discussed chapters have elucidated and provided experimental evidence 
to support the idea of gene-environment interactions in modifying age of onset, 
progression, and severity in neurodegenerative and other diseases. Importantly, metals 
have been reported to exhibit gene-environment interactions in other neurodegenerative 
diseases, including HD20,21,25-27. Moreover, we have reported that acute Mn exposure of 
cultured mutant (STHdhQ111/Q111) expressing cells exhibit decreased vulnerability and 
accumulate significantly less Mn levels compared to wild-type (STHdhQ7/Q7) following 
Mn exposure47. Unfortunately, it is still unknown how mutant HTT expression modulates 
Mn homeostasis. Nevertheless, the current methods used to measure Mn levels in 
biological specimens lack the practicability to assess Mn transport kinetics in a high-
throughput manner. Therefore, it is necessary to develop a high-throughput Mn detection 
assay that enables functional assessment of Mn transport dynamics and can be utilized to 
dissect the metal transporter systems that underlie the decreased Mn accumulation 
observed in mutant HTT expressing cells.  
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Overview of Specific Aims 
 Emerging evidence from the kindred and twin studies have indicated that the polyQ 
repeat length in the HTT protein accounts for approximately 60% of the variance in age 
of disease onset and severity. Interestingly, both genetic and environmental factors have 
been suggested to modulate the susceptibility, age of onset, and selective neuropathology 
in HD66,110. However, the nature of the environmental factor(s) is still unknown. Given 
that there is a strong association between metals and protein aggregation, similarities 
between metal cytotoxicity and cellular pathways of neurodegeneration, alterations in 
metal homeostasis, and the differential brain region accumulation of metals across 
neuronal subtypes, it is rationale to propose that metals with neurotoxic properties are the 
prime candidates for the largest residual environmental variability that has been indicated 
to modulate the age of onset, severity, and selective neuropathology in HD.  
 In fact, we have previously reported a disease-toxicant interaction between the 
polyQ-expanded HTT protein and Mn in an established knock-in immortalized murine 
mutant (STHdhQ111/Q111) striatal cell line and the YAC128 mouse models of HD. We have 
demonstrated that mutant HTT protein (STHdhQ111/Q111) expressing cells exhibit 
decreased vulnerability to Mn cytotoxicity compared to wild-type (STHdhQ7/Q7) 
following MnCl2 exposure47. Importantly, assessment of intracellular Mn levels by 
GFAAS has shown that mutant STHdhQ111/Q111 cells exhibit a significant decrease in net 
accumulated Mn levels compared to wild-type STHdhQ7/Q7 46. In essence, these findings 
imply that Mn is a major environmental factor that may potentially modify the 
susceptibility, age of onset, and progression in HD. Prominently, the discovery of the 
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disease-toxicant interaction between the glutamine-expanded HTT protein and Mn 
established the significance of deciphering how mutant HTT protein modulates Mn 
transport and transporter systems to elicit decreased susceptibility to Mn toxicity. 
  Our over-arching hypothesis is that mutant HTT alters the regulation of cellular 
Mn by aberrant interactions with the normal cellular Mn transport system. To test this 
hypothesis, we propose to do the following:  1) Develop a novel high-throughput assay to 
assess cellular Mn levels and transport dynamics in cultured striatal cells.  2) Measure 
Mn transport kinetics to functionally characterize the decreased Mn accumulation in 
mutant STHdh cells. 3) Dissect and examine metal transport pathways that contribute to 
the mutant HTT-Mn gene-environment interaction. 
 
Specific Aim 1: Develop a novel high-throughput assay to assess cellular Mn levels and 
dynamics. 
We have established and developed a novel high-throughput fluorescence-
quenching extraction assay (Cellular Fura-2 Manganese Extraction Assay - CFMEA). 
Furthermore, we have validated CFMEA using two alternative Mn-supplementation or 
Mn-spike methods. In addition, we have utilized GFAAS to validate the accuracy and 
specificity of CFMEA to measure cellular Mn levels in the well-established HD cellular 
model (wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells). Finally, we have 
developed a normalization assay (PicoGreen assay) to enable accurate normalization of 
cellular Mn levels in cell-extracts to dsDNA post CFMEA analysis.  
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Specific Aim 2: Assess Mn transport kinetics to functionally characterize the decreased 
Mn accumulation in mutant STHdh cells. 
Here, we explored the nature of the Mn transport defect that we had previously 
discovered with the mutant HTT protein. To determine whether the decreased cellular 
Mn accumulation in mutant STHdhQ111/Q111 compared to wild-type STHdhQ7/Q7 cells is 
due to an impairment in Mn uptake, decreased cellular Mn storage capacity, or enhanced 
efflux processes, we utilized the CFMEA assay to measure net cellular Mn levels in the 
STHdh cell lines following Mn exposure. In addition, we used a kinetic fluorescence 
assay to assess real-time Mn transport kinetics in the STHdh cells.  
 
Specific Aim 3: Dissect metal transport pathways underlying the mutant HTT-Mn gene-
environment interaction. 
We explored the transporter system(s) and pathway(s) underlying mutant HTT-
Mn interaction by systematic dissection of various known and putative metal transporters 
and the cellular pathways that facilitate Mn uptake, cellular Mn storage, and efflux. We 
investigated the nature of the impaired metal transporter implicated in the Mn 
accumulation deficit observed in mutant HD cells. Furthermore, we explored the 
requirement of other metals for the establishment of a disease-toxicant interaction in the 
STHdh cells. Additionally, we utilized different metal transporter agonist or antagonists 
to examine their contributions in the disease-toxicant interaction. Moreover, we examined 
the protein and transcript expression levels of known and putative Mn transporters by 
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western blotting analysis. Finally, we examined the relationship between Mn induced 
cytotoxicity, cellular Mn pools, and changes in ROS levels in the STHdh cells. 
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CHAPTER II 
 
DEVELOPMENT OF A NOVEL HIGH-THROUGHPUT ASSAY TO ASSESS 
CELLULAR MANGANESE LEVELS AND TRANSPORT DYNAMICS† 
 
Introduction 
Manganese (Mn) is an essential ubiquitous trace element required for normal 
growth, development and cellular homeostasis1. In humans and animals, Mn functions as 
a required cofactor of several enzymes necessary for neuronal and glial cell function, as 
well as enzymes involved in neurotransmitter synthesis and metabolism2-4. Despite its 
essentiality in multiple metabolic functions, excessive levels of Mn exposure via 
occupational routes such as farmers exposed to Mn-based pesticides, industrial welders 
and miners5-7, and dietary intake, which include high concentrations of Mn in drinking 
water and long-term parenteral nutrition8, can accumulate in the brain and have been 
associated with dysfunction of the basal ganglia system9. We have previously reported 
decreased net Mn accumulation in a mutant STHdhQ111/Q111 cell line model of 
Huntington’s disease (HD) relative to wild-type STHdhQ7/Q7 cells by GFAAS10,11. Given 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
† The contents of this chapter were first published as: 
Gunnar F. Kwakye, Daphne Li, and Aaron B. Bowman. Novel high-throughput assay to assess cellular 
manganese levels in a striatal cell line model of Huntington's disease confirms a deficit in manganese 
accumulation. Neurotoxicology	  (2011) PMID 21238486. 
Gunnar F. Kwakye, Daphne Li, Olympia Kabobel, and Aaron B. Bowman. Cellular fura-2 Manganese 
Extraction Assay (CFMEA). Curr Protoc Toxicol Chapter 12: Unit 12:18 (2011) PMID 21553393. 
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the decreased net Mn uptake in both cellular and mouse models of HD following Mn 
exposure, we sought to decipher the transport mechanism underlying the decreased net 
Mn accumulation in mutant STHdhQ111/Q111 cells. 
Development of cellular fura-2 manganese extraction assay (CFMEA) 
Available methods to measure Mn levels in cultured cells and tissues include 
GFAAS, radioactive trace assays and inductively coupled plasma mass spectrometry 
(ICP-MS). Although these techniques include multi-elemental analysis, excellent 
specificity, extremely high sensitivity and limited chemical interference, they are not 
feasible to assess Mn transport kinetics in a high-throughput manner. This is mainly due 
to the large number of cells required, duration of experimental analysis, and cost of 
analysis. Therefore, we sought to develop a high-throughput assay that enables rapid and 
efficient assessment of Mn transport kinetics and mechanism underlying the Mn 
accumulation deficit in mutant STHdh cells. After a literature search aimed at guiding the 
development of the high-throughput Mn assessment assay, we were intrigued by the 
relationship between Mn and the ratiometric calcium fluorophore fura-2, specifically, the 
Mn quenching properties of fura-2.  
The development and utilization of the fluorescent calcium (Ca2+) indicator, fura-
2, by R.Y. Tsien and colleagues for both the determination of intracellular Ca2+ 
concentrations and its regulation by extracellular stimuli has improved our understanding 
of calcium signaling events and dysfunction in neurodegenerative diseases, including 
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HD12-17. Fura-2 is the most commonly used 1,2-bis (o-aminophenoxy) ethane-N,N,N',N'-
tetraacetic acid (BAPTA) based metal-binding fluorophore for microscopy of individual 
loaded cells. The spectral properties of these fluorophores change upon binding to Ca2+ 
ions and are modeled after the octacoordinate binding sites of the Ca2+ selective chelator 
ethylene glycol tetraacetic acid (EGTA). In comparison to other Ca2+ indicators such as 
quin-2, fura-2 has a larger fluorophore that slightly increases its wavelengths and makes 
it compatible with glass microscope optics18. Upon Ca2+ binding to fura-2, the excitation 
spectrum shifts about 30 nm to shorter wavelengths. Hence, the ratiometric fluorescence 
intensity measurements obtained from the F340/380 nm excitation pair (ratio of 
fluorescence yield following excitation at 340 nm over excitation at 380 nm) is 
considered to be a good measure of intracellular calcium concentration, and is 
unperturbed by variable dye content or cell thickness12. The green emission of fura-2 
does not usually shift with calcium binding and peaks between 505 – 520 nm19. 
Published data examining the influence of metal ions on fura-2 suggest an 
interaction between endogenous metal ions and fura-2 loaded cells by either quenching 
(Mn2+, Cu2+, Fe2+) or increasing (Zn2+, Cd2+) fura-2 fluorescence12,20. Consequently, other 
studies have utilized fluorescence quenching assays to assess intracellular metal ion 
concentration and transport in loaded cells and demonstrated a rapid and time-dependent 
quenching of fura-2 and calcein fluorescence following Mn2+, Fe2+, Co2+, and Cu2+ 
exposure12,20-24. However, all these studies were conducted on single cultured cells, which 
limit high-throughput measurements of Mn levels. We reasoned that a high-throughput 
manganese extraction based fura-2 assay might enable efficient and accurate 
measurements of Mn levels in cultured cells and allow for assessment of Mn dynamics in 
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cellular models. Importantly, fura-2 has a Ca2+ isosbestic point at 360 nm, a wavelength 
at which fura-2 fluorescence emission properties are independent of Ca2+ concentration. 
Interestingly, Snitsarev and colleagues reported that Mn2+ effectively quenches fura-2 
fluorescence, even at the Ca2+ isosbestic wavelength20.   
 
Development of quantitative PicoGreen assay for normalization of extracted cellular 
manganese levels to dsDNA  
Protein detection methods (for example, Lowry and Bradford assays) have been 
extensively used to measure protein levels in cultured cells and animal tissues. However, 
their sensitivity and accuracy depends on the number of cells required for minimum 
detection, and are influenced by interfering agents (e.g. detergents and amino acid 
concentrations). Unfortunately, some cultured cells do not possess sufficient cell density 
in the 96 well plate format to be detected by these traditional protein assays. Quant-iT™ 
PicoGreen dsDNA reagent is an ultrasensitive asymmetrical fluorescent nucleic acid dye 
that has previously been used to quantify the concentration of dsDNA in solution29-31. 
The free dye fluoresces upon binding to dsDNA, but not RNA. Thus, alterations in RNA 
levels in cultured cells do not influence the sensitivity of the PicoGreen assay. Quant-
iT™ PicoGreen reagent is capable of quantifying at least 25 pg/mL dsDNA with a 
standard fluorometric plate reader32. The long stability of PicoGreen to photobleaching 
enables longer exposure times and assay flexibility30. We have modified and utilized the 
Quant-iT™ PicoGreen dsDNA assay to measure dsDNA in cell-extracts following MnCl2 
exposure. This method enables normalization of extracted cellular Mn concentration to 
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dsDNA levels in cell-extracts following MnCl2 exposure. In essence, the aim of the study 
was to determine if a cellular fura-2 manganese extraction assay (CFMEA) could 
accurately measure Mn content in MnCl2 exposed striatal cells.  
 
Materials and Methods 
Chemicals, reagents, and cell culture supplies 
Cell culture media and supplements were obtained from Mediatech (Manassas, 
VA) unless indicated. Cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, and 
Sigma, St. Louis, MO), L-glutamine, 400µg/ml G418 and Penicillin-Streptomycin. 
Calcium (II) chloride dihydrate (CaCl2 . 2H2O), cadmium (II) chloride heptahydrate 
(CdCl2 . 7H2O), cobalt (II) chloride hexahydrate (CoCl2 . 6H2O), copper (II) chloride 
dihydrate (CuCl2 . 2H2O), iron (II) chloride (FeCl2), magnesium (II) chloride tetrahydrate 
(MgCl2 . 4H2O), manganese (II) chloride heptahydrate (MnCl2 . 7H2O), nickel (II) 
chloride hexahydrate (NiCl2 . 6H2O), lead (II) chloride (PbCl2), zinc (II) chloride (ZnCl2) 
were from Alfa Aesar (Ward Hill, MA). Ultra-pure fura-2 salt (cell-impermeable, ENZ-
52007) was obtained from ENZO Biochem (New York, NY). The HEPES salt exposure 
buffer consisted of 25mM HEPES buffer (pH 7.2), 140mM NaCl, 5.4mM KCl, and 5mM 
D-glucose (Sigma). 1X ultra-pure phosphate-buffered saline (PBS), pH 7.4, without 
calcium and magnesium was used for post Mn exposure washes. Triton X-100 and 
sodium dodecyl sulfate (SDS) were obtained from Sigma.  
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Deoxyribonucleic acid sodium salt from salmon testes (Catalog # D1626) was 
obtained from Sigma (St. Louis, MO). Quant-iT™ PicoGreen dsDNA Reagent (Catalog # 
P7589) was obtained from Molecular Probes (Carlsbad, CA). 1x TE buffer used for the 
dilution of PicoGreen reagent was composed of 1 M Tris-HCl (pH 7.5) and 0.5 M EDTA 
(pH 8.0) prepared with DNase-free water and pH adjusted to 7.5. 
 
Cell-free fura-2 assays 
Cell-free system was composed of the indicated stock metal ions and fura-2 in 
either PBS with 0.1% Triton X-100 (PTx) or PBS with 0.8% SDS and assayed in a clear 
96-well assay plate. After 5 seconds orbital shake, fura-2 fluorescence was measured at 
the Ca2+ isosbestic point of Ex360 (bandwidth of filter = ± 35 nm) and Em535 (bandwidth 
of filter = ± 25 nm) with a Beckman coulter DTX 880 multimode plate reader using 
multimode analysis software (version 3.2.0.6) and top read settings.  
 
Saturation binding curve and mathematical modeling of Mn-fura-2 interaction 
Saturation binding curve experiments were performed using a ten point Mn-fura-2 
curve with samples containing 1 µL of different 100X stock Mn standards (0 – 100 mM) 
added to 99 µL of 0.5 µM fura-2 in PTx and assayed in a clear 96-well assay as described 
in the cell-free fura-2 assays section. The average raw fluorescence signal values (RFU) 
of the 0 µM Mn samples within each independent standard curve were defined as the 
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100% maximal fluorescence for that experiment after background subtraction. RFU of 
each well were then normalized as percent maximal fluorescence (%MAX) to this value. A 
one-site specific saturation-binding curve with Hill slope could be fit to log10 Mn 
concentration (x-axis) and either %MAX (y-axis) or RFU (y-axis) by non-linear regression 
analysis using graphpad prism software (version 5.0b). As utilization of  %MAX rather 
than RFU was found to control better for the experimental variation, we preferred use of  
%MAX for experimental determination of extracted Mn concentrations. To permit back 
calculations of extracted Mn levels from experimentally determined %MAX values we 
used the trend line command in Microsoft Excel to fit power (Mn concentration = 
A•(%MAX)B) and logarithmic (Mn concentration = A•ln(%MAX)+B) equations to the 
standard curve data and calculated binding curve from non-linear regression analysis. 
Power curves were used for %MAX values less than 50% and logarithmic curves for values 
greater than 50%, on either side of the inflection point of the saturation-binding curve 
plotted with Mn concentration (x-axis) and %MAX (y-axis). These mathematical models 
used for calculating extracted Mn concentration routinely fit the saturation binding curves 
and standards data with r2 values greater than 0.995. 
 
Cell culture 
The striatal cell lines – wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 were a 
generous gift from Marcy Macdonald, PhD (Massachusetts General Hospital, Boston, 
MA, USA) and Gail Johnson, PhD (University of Rochester, Rochester, NY, USA) and 
grown at 33°C11,25-27. Briefly, wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells 
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were plated in a clear 96 well plate at 8,000 cells per 0.32 cm2 (surface area) respectively 
the evening before treatment and allowed to grow in a 33°C incubator. MnCl2 was added 
to the complete culture media or HEPES salt exposure buffer the morning of exposure. 
Total extracted Mn levels were assessed by CFMEA.  
 
Cellular fura-2 manganese extraction assay (CFMEA) 
Wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 were cultured in clear 96 well 
tissue plates and exposed to varying MnCl2 concentrations. After exposure, the media 
was discarded and cells quickly washed three times with 200 µL PBS. The cells were 
extracted at 33°C for 1 hour in 100 µL PTx with 0.5 µM fura-2. Changes in fura-2 
fluorescence caused by Mn quenching were measured on a plate reader as described in 
the cell-free fura-2 assays section. Extracted Mn concentrations from cultured cells were 
calculated using the logarithmic and power Mn standard curves, described in the 
saturation binding curve and mathematical modeling of Mn-fura-2 interaction section, 
with the %MAX of each sample. Experimental sample %MAX was determined by 
normalizing the RFU of each Mn-exposed sample with the RFU of vehicle-only samples 
(untreated), which was defined as the experimental 100% maximal fluorescence signal. 
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Mn-supplementation (Mn-spike) methods  
Wild-type STHdhQ7/Q7 cells were cultured and plated as described above in the 
cellular fura-2 manganese extraction assay (CFMEA) section. Briefly, cells were plated 
in a clear 96 well tissue culture plate and exposed to 0, 50, 100, and 200 µM MnCl2 for 4 
hours in media. Cells were washed three times with 200 µL PBS and extracted at 33°C 
for 1 hour in 100 µL PTx buffer containing 0.5 µM fura-2 followed by measurements of 
fura-2 fluorescence as described in cell-free fura-2 assays section. Cell-extracts were 
quickly supplemented (i.e. “spiked”) with Mn and changes in fura-2 fluorescence re-
measured at the aforementioned wavelengths (post-supplement). Mn concentrations in 
the cell extracts (pre and post-Mn spike) were computed by substituting the %MAX of each 
experimental well after background subtraction for pre and post Mn spike measurements 
into a generated Mn standard curve. The difference in Mn levels in each well between pre 
and post Mn-spike (difference) was calculated. Alternatively, wild-type STHdhQ7/Q7 cells 
were exposed to 100 µM MnCl2 and extracted in known concentrations of Mn spiked 
fura-2 containing extraction buffers (0 µM, 250 µM, 500 µM, 1000 µM MnCl2). Both the 
cellular and spiked Mn levels in cultured cell-extracts were measured by CFMEA. The 
difference in Mn levels in each well between unspiked and Mn-spiked fura-2 containing 
extraction buffers in vehicle exposed and Mn-exposed cultured cells (measured 
difference) was calculated by substituting the %MAX of each experimental well after 
background subtraction for unspiked and Mn spiked measurements into a generated Mn 
standard curve. The measured difference between known and expected Mn 
concentrations was compared. 
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Graphite furnace atomic absorption spectroscopy (GFAAS) 
Total Mn concentrations were measured with GFAAS (Varian Inc., AA240, Palo 
Alto, CA). Cultured wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells were plated at 
20,000 cells/well in clear 96 well plates and treated as described above for CFMEA. 
After CFMEA analysis of net cellular Mn levels in wild-type STHdhQ7/Q7 and mutant 
STHdhQ111/Q111 cells, the cell-extracts (100 µL per well) were quickly transferred into an 
eppendorf tube, flash-frozen and shipped on dry ice for GFAAS. To increase sensitivity 
for determination of Mn levels by GFAAS, six eppendorf tubes containing 100 µL cell-
extracts from each set of experiment were thawed and combined together based on their 
genotype and exposure conditions before GFAAS analysis. For analysis, cell-extracts 
were digested in 200 µL ultrapure nitric acid for 24 hours in a sandbath (60°C). Mn 
content was determined by the following protocol: A 20 µL aliquot of the digested 
sample was brought to 1 ml total volume with 2% nitric acid for analysis. Bovine liver 
(NBS Standard Reference Material, USDC, Washington, DC) (10 µg Mn/g) was digested 
in ultrapure nitric acid and used as an internal standard for analysis (final concentration 5 
µg Mn/L) as previously published11,28. 
 
PicoGreen dsDNA standard curve 
PicoGreen standard curve was generated in a clear polystyrene 96 well plate by 
combining 100 µL salmon testes dsDNA standards (0 – 1000 µg/mL) prepared in 0.1% 
PTx and 50 µL of PicoGreen reagent diluted in 1x TE buffer (1:400) in a 96 well plate. In 
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addition, the background was determined by adding 100 µL 0.1% PTx and 50 µL 1x TE 
buffer. The standard curve plate was incubated at room temperature in the dark for 5 
minutes and the fluorescence in each well measured with the Beckman coulter DTX 880 
multimode plate reader at Ex485 (bandwidth of filter = ± 20 nm), Em535 (bandwidth of 
filter = ± 25 nm), and integration time of 200 ms with the indicated plate reader using 
multimode analysis software (version 3.2.0.6) and top read settings. The average 
background fluorescence read was subtracted from each of the salmon testes dsDNA 
PicoGreen fluorescence tested in the standard curve. The data points were plotted as 
average PicoGreen RFU of the DNA standards (y-axis) and their concentrations (x-axis) 
by non-linear regression analysis using Microsoft Excel. A standard linear regression 
analysis in Microsoft Excel was used to obtain a linear equation (PicoGreen Fluorescence 
= A•(x) + B) from the standard curve data; where A is the coefficient, rate and slope of 
the trend line, x is the unknown concentration of dsDNA in the cell-extract, and B is the 
y-intercept or where the line crosses the y-axis. 
 
Measurement of dsDNA concentration in cell-extracts 
After CFMEA analysis, 20 µL of cell-extract from each well was transferred into 
a clear polystyrene 96 well plate and 80 µL of 1:400 PicoGreen solution in 1x TE buffer 
added to each well. The cell extracts were further incubated with PicoGreen at room 
temperature for 5 minutes and changes in fluorescence measured as described in the 
PicoGreen dsDNA standard curve section. The concentration of dsDNA in each cell-
extract was calculated using the linear equation generated from the salmon DNA standard 
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curve. In order to normalize cellular extracted Mn levels to dsDNA, we divided the 
calculated concentration of extracted Mn levels in each well (e.g. nanomoles) to its 
respective dsDNA concentration (e.g. microgram). 
 
Statistical Analysis 
Univariate and repeated-measures ANOVA tests were performed using SPSS 18 
software (IBM, Inc., Chicago, IL). Post hoc analyses were done using Microsoft Excel 
(Microsoft, Redmond, WA) and assuming equal variances. Standard deviations of the 
mean for change in net Mn uptake or fura-2 fluorescence above basal levels or vehicle 
were calculated by appropriate propagation of uncertainty calculations for subtraction of 
sample means, with significant differences between vehicle and Mn exposed wild-type by 
non-overlap of the standard deviation. 
 
Results 
Establishment of essential conditions for CFMEA  
To establish the basic CFMEA conditions, we first compared buffer conditions for 
detection of Mn-fura-2 interaction and found no significant difference between PBS and 
HEPES buffers (Figure II. 1.A.). Previous studies using fura-2 AM loading in single cells 
exhibited a temperature-dependent subcellular localization of fura-233-35. Hence, we 
sought to determine the optimal temperature for detection of Mn quenched fura-2 
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fluorescence. Using a cell-free system, with varying MnCl2 concentrations and fura-2, we 
observed a minimal influence of temperature on the Mn-fura-2 interaction (Figure II. 
1.B.). Finally, we evaluated the ideal detergent concentration for maximum Mn extraction 
and detection by fura-2 from the striatal cells following a 100 µM MnCl2 exposure. 
Maximal extraction was indicated by the greatest degree of fura-2 fluorescence 
quenching (i.e. decrease in RFU relative to the fura-2 containing detergent-buffer alone). 
After 45 minutes MnCl2 exposure, cells were extracted in different concentrations of SDS 
or Triton X-100 in PBS for 1 hour at 33°C. RFU of fura-2 after the cell extraction (Mn 
extraction) and the baseline control (RFU of fura-2 containing buffer prior to extraction) 
were plotted for the different concentrations of detergent (Figure II. 1.C. and 1.D.). In the 
absence of detergent, fluorescence quenching was not observed, indicating the post-
exposure PBS washes were sufficient to remove fura-2 detectable extracellular Mn. As 
little as 0.001% Triton X-100 or 0.01% SDS was sufficient to extract Mn from Mn-
exposed cells. Although 0.01% SDS exhibited the greatest quenching following 
extraction of Mn-exposed cells, we selected 0.1% Triton X-100 in PBS for subsequent 
Mn extraction experiments in the cultured striatal cell line based on its maximal 
quenching and relatively minor changes in baseline RFU compared with SDS. SDS 
exhibited a dramatic phasic response in average RFU following Mn extraction of exposed 
cells. Moreover, we observed a concentration-dependent influence of both detergents on 
the baseline control fura-2 fluorescence. Specifically, SDS exhibited ~170 to 250% 
increase in control baseline RFU between 0.001 and 1% SDS. Triton X-100 showed a 10 
to 20% increase in control baseline RFU at concentrations below 0.1 and 30% decrease at 
1% Triton X-100. Furthermore, we observed an increase in control and Mn-exposed 
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baseline fluorescence for both detergents at concentrations above 1% (data not shown). 
These results elucidated the optimal buffer, temperature, and detergent concentration for 
CFMEA in the striatal cells. 
 
Figure II. 1. Optimization of buffer, temperature, and detergent for CFMEA. (A) 
No significant difference in two commonly used buffers (PBS and HEPES) on Mn-fura-2 
fluorescence quenching. (B) Minimal influence of temperature (15, 28, and 33°C) on Mn-
fura-2 fluorescence quenching. Data is represented as RFU (y-axis) versus transformed 
log10 Mn concentration on a linear scale (x-axis). A one-site specific saturation-binding 
curve with Hill slope was fit to log10 Mn concentration (x-axis). N=3; 8 wells/experiment. 
Mean levels are indicated as ± standard deviation for (A) and (B). Fura-2 concentrations 
for (A) and (B) are 0.05 µM and 0.5 µM respectively. Cellular Mn was extracted with 
different concentrations of (C) Triton X-100 or (D) SDS in PBS containing 0.5 µM fura-
2. Arrow (red) indicates the maximum intracellular Mn extracted by each buffer. Data is 
represented as RFU of baseline control (fura-2 containing buffer with the indicated 
concentration of detergents) and Mn exposed cell-extracts (Mn-extraction). N=3; 4 
wells/experiment. Mean levels are indicated as ± standard deviation. 
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Relationship between fura-2 concentration and Mn detection 
In order to explore the optimal fura-2 concentration for detection of Mn, we 
utilized the aforementioned cell-free system with PTx and 0.5 µM fura-2. Owing to the 
sigmoidal nature of the fura-2 fluorescence response to Mn, we defined the optimal 
detection range for Mn by fura-2 to be between 10% and 85% the maximal baseline 
control fura-2 fluorescence. The detection range for Mn by fura-2 was explored by 
examining concentration-response curves for Mn at three fura-2 concentrations (0.05, 0.5, 
and 2 µM), and then fitting one-site specific binding curves to RFU values and Mn 
concentration by non-linear regression (Figure II. 2.). Specifically, 0.05 µM and 2 µM 
fura-2 accurately detected extracted Mn concentrations between about 50 nM – 6,000 nM 
and 300 nM – 10,000 nM respectively while 0.5 µM fura-2 detected Mn concentrations 
between about 70 nM – 10,000 nM (Table II. 1.). Although 0.05 µM fura-2 was capable 
of detecting lower Mn concentrations (50 nM), the lower absolute RFU values led to an 
inferior signal to noise ratio. Based on the signal to noise ratio, detection range, and 
expected concentration of Mn in cellular extracts, we selected 0.5 µM fura-2 as the 
optimal concentration for detection of extracted Mn from striatal cell lines.  
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Figure II. 2. Optimal fura-2 concentration for CFMEA. The detection range for Mn 
concentration by fura-2 was explored by examining concentration-response curves for 
Mn at three fura-2 concentrations (0.05, 0.5, and 2 µM) in a cell-free system. Dotted lines 
represent the estimated Mn detection range of each fura-2 concentration and were chosen 
based on an arbitrary 10 to 85 % maximal fluorescence intensity range. The width of 
arrowhead line also indicates fura-2 detection range. Mn-fura-2 concentration-response 
curves are analyzed by nonlinear regression to fit one-site specific binding curves with 
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Hill slope, and plotted as RFU, left column, or normalized to unbound fura-2 (%MAX), 
right column, versus transformed log10 Mn concentration on a linear scale for each fura-2 
concentration. N=3; 8 wells/experiment. Mean levels are indicated as ± standard 
deviation. 
 
Fura-2 concentration (µM) ~ Optimal Mn2+ detection range (nM) 
0.05 50 - 6,000 
0.5 100 - 10,000 
2 300 - 10,000 
Table II. 1. Optimal Mn detection concentrations by fura-2. These concentrations 
were calculated based upon the defined 10% - 85% range extrapolated from each % 
maximal fura-2 concentration response curve shown in Figure II. 2. 
 
Quantitative relationship between Mn concentration and fura-2 fluorescence  
To generate a Mn-fura-2 standard curve for back calculation of total extracted Mn 
levels from cultured cells, we utilized the cell-free system described in the methods and 
materials (cell-free fura-2 assays). Eight independent Mn-fura-2 standard curves 
generated over an extended period of time exhibited a fairly consistent relationship 
between absolute RFU values and Mn concentration across experiments, with higher 
variability in the absolute values of the low Mn concentration samples (Figure II. 3.A.). 
To minimize this variability, we averaged the RFU values of the 0 µM Mn samples 
within each independent standard curve and defined this value as the 100% maximal 
fluorescence for that experiment. RFU of each well were then normalized as %MAX to this 
value and plotted as %MAX (y-axis) by non-linear regression analysis (Figure II. 3.B.). 
Importantly, we observed significantly less experimental variability in the standard 
	  	   77 
curves when represented as %MAX rather than RFU (y-axis).  To explore the binding 
relationship between Mn and fura-2 in our standard curves, we generated a one-site 
specific saturation-binding curve with Hill slope as discussed in methods and materials 
(saturation binding curve and mathematical modeling of Mn-fura-2 interaction), which 
tightly fit four averaged independent cell-free system experiments (Figure II. 3.C.). 
Binding curve data was fit to exponential and logarithmic curves to enable back 
calculation of extracted Mn levels from experimentally determined %MAX values. These 
curves could be generated alongside Mn-exposure experiments to accurately quantify 
extracted Mn levels, and consistently demonstrated nearly identical Mn-fura-2 saturation 
binding curves and equations (Figure II. 3.B.).  
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Figure II. 3. Mn-fura-2 standard curves. Mn-fura-2 standard curves were generated 
using a cell-free system with 0.5 µM fura-2 in PTx at Ex360/Em535. (A) Eight independent 
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fura-2 standard curves were generated over an extended period of time (> 1 year). Data is 
plotted as RFU versus log10 transformed Mn concentration on a linear scale. (B) The 
same curves as shown in (A) were plotted instead as %MAX versus log10 transformed Mn 
concentration on a linear scale. Data in (A) and (B) were used to fit one-site specific 
binding curves with Hill slope (dashed lines). Mean values for (A) and (B) are indicated 
as ± standard deviation, N=3; 8 wells/experiment. (C) A one-site specific binding curve 
with Hill slope (black, equation indicated on plot) was fit by non-linear regression to 
%MAX values obtained from four independent cell-free experiments (blue). The 95% 
confidence interval of the calculated binding curve constants are indicated on the plot. 
N=4; 4 wells/exposure condition. Mean levels are indicated as ± standard deviation. 
 
Effect of metal ions on fura-2 fluorescence at Ex360 
Previous studies investigating the effect of metal ions on fura-2 fluorescence have 
demonstrated that other metal ions influence fura-2 fluorescence (increase or decrease) at 
the F340/380 excitation/emission wavelengths12,20-23. In addition, Snitsarev and colleagues 
have shown that Zn2+, Ca2+, and Mn2+ influence fura-2 fluorescence between 300 nm and 
400 nm excitation wavelengths20. To evaluate the potential of other metal ions to 
influence CFMEA, we examined the effect of other metal ions on our fura-2 cell-free 
system. Specifically, we generated Ex360/Em535 concentration-response curves for 
different metal ions with 0.5 µM fura-2 in PTx buffer. The influence of these metal ions 
on fura-2 fluorescence was measured and fitted by nonlinear regression analysis to a one-
site competitive binding curve (Figure II. 4.). We determined the approximate %MAX at 
saturated metal binding of fura-2 (Bmax) and half maximal effective concentration (EC50) 
values for each metal ion from the one-site binding curves (Table II. 2.). Here, we show 
that while Mn2+, Fe2+, Co2+, Ni2+, Cu2+, and Cd2+ quenched fura-2 fluorescence at varying 
concentrations, Pb2+, Ca2+, and Mg2+ had no effect on fura-2 fluorescence at the Ca2+ 
isosbestic wavelength.  Furthermore, we observed an increase in fura-2 fluorescence in 
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the presence of Zn2+. This suggests a need to control for the influence of some of these 
intracellular metal ions on CFMEA. 
 
Table II. 2. Effect of metals on fura-2 fluorescence at Ex360/Em535. Examination of 
approximate %MAX at saturated metal binding of fura-2 (Bmax) and half maximal effective 
concentration (EC50) values for each metal ion extrapolated from the one-site binding 
curves (Figure IV.2.). (~) Indicates approximated value extrapolated from the one-site 
competition binding curves (Figure IV.2.). (*) Represents decrease effect on fura-2 
fluorescence at concentrations above 10 µM.  
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Figure II. 4. Effect of metal ions on fura-2 fluorescence at Ex360/Em535. 
Concentration-response curves were generated for 10 different divalent metal cations 
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with 0.5 µM fura-2 in PTx. The influence of these metal ions on fura-2 fluorescence was 
measured and fitted by nonlinear regression analysis to a one-site competitive binding 
curve. Mn concentrations were transformed to log10 Mn concentration versus normalized 
response curves and represented as transformed log10 Mn concentration on a linear scale. 
N=3; 8 wells/exposure condition. Mean levels are indicated + standard deviation. 
 
Competitive influence of metal ions on CFMEA 
Although our experiments above and previous experimental reports suggest that 
intracellular metal ions could influence fura-2 fluorescence, it was unclear whether the 
concentrations of abundant endogenous cellular metal ions 12 would competitively 
influence Mn quantification by fura-2 in CFMEA. Therefore, we assessed the 
competitive influence of the two most abundant cellular metal ions, Ca2+ and Mg2+, on 
the Mn-fura-2 interaction at the Ca2+ isosbestic wavelength of 360 nm using a cell-free 
system with varying concentrations of either CaCl2 or MgCl2 at different MnCl2 levels. 
We observed no competitive influence of either Ca2+ or Mg2+ ions on Mn induced fura-2 
quenching at concentrations of 10 µM or lower for all tested Mn concentrations (Figure 
II. 5.A. and 5.B.). However, we observed a competitive quenching effect on fura-2 
fluorescence with increasing Ca2+ concentrations above 10 µM Ca2+ for all tested Mn 
concentrations (data not shown). Given the considerable affinity of Co2+, Cu2+, and Fe2+ 
for fura-2, we examined the possible competitive interference of the aforementioned 
metal ions on the Mn-fura-2 interaction at the Ca2+ isosbestic wavelength of 360 nm 
using a cell-free system with varying concentrations of either CoCl2, CuCl2, and FeCl2 at 
different MnCl2 levels. We observed a concentration-dependent quenching effect of all 
three metals on fura-2 fluorescence at the Ca2+ isosbestic wavelength of 360 nm. 
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However, there was no significant competitive influence of Co2+ concentrations below 1 
µM on Mn induced fura-2 quenching at 0.05 µM and 0.2 µM MnCl2. Importantly we 
observed minimal competitive quenching influence of the differently tested Co2+ 
concentrations on 2 µM and 20 µM MnCl2 concentrations (Figure II. 5.C.). Moreover, we 
observed a similar effect of Cu2+ on Mn-fura-2 interaction (data not shown). In addition, 
Fe2+ demonstrated a minimal additive quenching effect on Mn-Fura-2 interaction at all 
the tested concentrations (Figure II. 5.D.).   
 
Figure II. 5. Competitive interference of metal ions on CFMEA. To examine the 
competitive interference of metal ions that have considerable affinity for fura-2 on 
CFMEA, we utilized 0.5 µM fura-2 in PTx and different concentrations of (A) CaCl2  
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(B) MgCl2, (C) CoCl2 and (D) FeCl2 with or without different concentrations of MnCl2. 
N=3; 8 wells/exposure condition. Mean levels are indicated + standard deviation.  
 
Validation of CFMEA by Mn supplementation 
To determine if other metal ions present in cultured striatal cells influence the 
specificity and accuracy of CFMEA, we validated the accuracy of Mn determination by a 
Mn supplementation test (Mn spike method 1). This method measures Mn levels in 
extracts of MnCl2 exposed cultured cells before (pre) and after (post) the addition of a 
fixed concentration of Mn to the cell extract. We reasoned that if metal ions other than 
Mn present in the cultured cells have a significant influence on measured Mn 
concentrations, then the different concentrations of Mn and other ions in the cell-extracts 
following exposure would impede our ability to accurately measure a known quantity of 
Mn spiked into the samples (“post” minus “pre”). Upon comparison of measured Mn 
levels in the cultured striatal cell-extracts following MnCl2 exposure, pre, and post-Mn 
spike, we observed a concentration-dependent increase in measured Mn levels in pre and 
post Mn-spiked conditions. However, there was no statistically significant difference in 
the calculated concentration of supplemented Mn measured over the full range of MnCl2 
exposure conditions. This data suggests that CFMEA is capable of accurately measuring 
Mn concentrations in extracted cultured cells over a two log10 scale concentration range 
of extracted Mn (Figure II. 6.A. and 6.B.). Conversely, we validated the accuracy of 
CFMEA by an alternative Mn supplementation method (Mn spike method 2). This 
method measures Mn levels in cultured cells extracted in differently spiked (0 µM, 250 
µM, 500 µM, and 1000 µM MnCl2) fura-2 containing extraction buffer. We reasoned that 
	  	   85 
if endogenous cellular metal ions other than Mn present in the cultured cells would 
competitively influence measured Mn concentrations, then CFMEA would be incapable 
of accurately measuring both the known concentration of Mn spiked into the fura-2 
containing extraction buffer and cellular Mn levels. Upon comparison of the difference in 
Mn levels in each well containing cell-extract between unexposed and Mn-exposed 
cultured cells extracted in unspiked or Mn-spiked (measured difference) fura-2 
containing extraction buffers, we observed an increase in measured Mn levels under all 
Mn-spiked conditions. Moreover, we observed no statistically significant difference 
between the known and measured Mn concentration difference at all the tested Mn spike 
concentrations (Figure II. 6.C. and 6.D.). The findings in both Mn spike methods (1 and 
2) suggest that CFMEA is proficient in accurately and specifically measuring Mn 
concentrations in both Mn spiked extracted cultured cells and fura-2 containing 
extraction buffer. 
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Figure II. 6. Validation of CFMEA by Mn-supplementation. Mn-spike methods 
accurately measured supplemented Mn levels in cultured wild-type neuronal cells. (A) 
Wild-type striatal cells were exposed to MnCl2 and cellular Mn levels measured by 
CFMEA. Cell-extracts were quickly supplemented/spiked with Mn (~285 nM final Mn 
concentration) and changes in fura-2 fluorescence re-measured (post-supplement). (B) 
The difference in Mn levels in each well between pre and post Mn-spike (difference) was 
calculated. N=3; 4 wells/exposure condition. Mean levels are indicated + standard 
deviation. (*) Indicates a significant concentration-dependent net Mn uptake (p <0.0001, 
post-hoc t-test) in wild-type striatal cell lines. (C) Wild-type striatal cells were exposed to 
MnCl2 and extracted in 0 µM, 250 µM, 500 µM, and 1000 µM MnCl2 spiked fura-2 
containing extraction buffers and total Mn levels assessed by CFMEA. (D) The 
difference in Mn levels in each well between unspiked and Mn-spiked (measured 
difference) fura-2 containing extraction buffers was calculated and compared to the 
known and expected Mn concentration. N=4; 4 wells/exposure condition. Mean levels are 
indicated + standard deviation. 
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Validation of CFMEA by GFAAS 
To further validate the accuracy and specificity of CFMEA, we measured and 
compared Mn levels in HD striatal cells by both CFMEA and GFAAS following 30 
minutes MnCl2 exposure in HEPES salt buffer. We observed a close-agreement in the 
measured intracellular Mn levels between CFMEA and GFAAS (Figure II. 7.). Repeated 
measures ANOVA showed a significant decrease in mutant STHdhQ111/Q111 Mn 
accumulation compared to wild-type STHdhQ7/Q7 cells (p < 0.0001) when assayed by 
both CFMEA and GFAAS. Importantly, we did not observe a significant difference in the 
levels of Mn measured between CFMEA and GFAAS in either wild-type or mutant cells. 
In addition, we did not observe a genotype by assay effect. This data suggest that both 
CFMEA and GFAAS exhibit similar sensitivity and are capable of accurately and 
specifically measuring cellular Mn levels.  
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Figure II. 7. Close-agreement between CFMEA and GFAAS in the measured net 
intracellular Mn levels in cultured HD striatal cells. Wild-type STHdhQ7/Q7 (blue) and 
mutant STHdhQ111/Q111 (red) cells were cultured in a 96 well tissue culture plate and 
exposed to the indicated MnCl2 concentrations for 30 minutes in HEPES salt buffer and 
total extractable Mn levels measured by CFMEA and GFAAS. N = 3; 6 wells/exposure 
condition. Note: 1 nM (nanomolar/L) = 0.001 nanomoles per mL. The mean total Mn 
levels (±SEM) are plotted as indicated. (*) Indicates a significant effect of genotype on 
net Mn uptake (p < 0.0001, repeated measures ANOVA) between wild-type STHdhQ7/Q7 
and mutant STHdhQ111/Q111 cells assessed with either CFMEA or GFAAS. 
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PicoGreen standard curve 
We observed that cultured striatal cells plated at cell densities below 20,000 cells 
per well in a 96-well tissue culture plate had insufficient protein levels to be detected by 
standard protein assays, including Bradford and Lowry. Hence, we generated a 
PicoGreen standard curve using a cell-free system (Figure II. 8.A) as detailed in Table II. 
3 and a striatal cell-extract system (Figure II. 8.B.) using the PicoGreen assay (described 
in methods and materials section) to enable efficient and accurate normalization of 
cellular Mn levels in the cell-extracts to dsDNA content (Figure II. 8.A) or cell number 
(Figure II. 8.B.) following CFMEA analysis. We observed a linear relationship between 
the concentrations of dsDNA, cell number and PicoGreen fluorescence. Importantly, the 
concentrations of dsDNA in the striatal cells pre and post Mn exposure were within the 
lower and upper limits of the PicoGreen standard curve.  
Well number on 
96-well plate 
Stock [DNA] 
(µg/ml) 
DNA stock 
(µl) 
PicoGreen 
solution (µl) 
A1, B1, C1, D1 0.00381 100 50 
A2, B2, C2, D2 0.00763 100 50 
A3, B3, C3, D3 0.01526 100 50 
A4, B4, C4, D4 0.03052 100 50 
A5, B5, C5, D5 0.06104 100 50 
A6, B6, C6, D6 0.12207 100 50 
A7, B7, C7, D7 0.24414 100 50 
A8, B8, C8, D8a 0 (100 µl extraction 
buffer) 
(50 µl 1x TE 
buffer) 
Table II. 3. Format to generate a PicoGreen dsDNA standard curve. aRepresents 
wells used for PicoGreen background subtraction. 
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Figure II. 8. Quantitative relationship between PicoGreen fluorescence, 
concentration of dsDNA, and cell number. (A) A seven-point PicoGreen standard was 
generated using a cell-free system composed of a 1:400 dilution of PicoGreen reagent in 
1x TE buffer and varying salmon testes dsDNA concentrations and measured at 
	  	   91 
Ex485/Em535 nm. (B) A five-point PicoGreen fluorescence versus number of cells standard 
curve was generated using striatal cells extracted in 0.1% PTx containing 0.5µM final 
concentration of fura-2. N = 4 wells/dsDNA concentration or cell number for (A) and (B) 
respectively. Mean levels are indicated as 95% confidence intervals. 
 
Examination of endogenous cellular Mn levels in HD striatal cells 
To investigate the basal levels of Mn in vehicle exposed wild-type STHdhQ7/Q7 
and mutant STHdhQ111/Q111 cells, we measured changes in fura-2 fluorescence and 
utilized a Mn-fura-2 standard curve (as depicted in Figure II. 3.) to calculate for total 
extracted cellular Mn levels following 1 hour exposure to vehicle (0 µM MnCl2) in 
HEPES salt buffer. To enable efficient normalization of net dsDNA levels in the striatal 
cells, we used the PicoGreen assay (described above) and PicoGreen standard curve 
(depicted in Figure II. 8). We observed ~ 5-10 % quenching in both wild-type 
STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells (Figure II. 9.A.). Furthermore, there were no 
statistical differences in the quantified total endogenous Mn levels expressed in 
nanomolar (nM) between wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells (Figure 
II. 9.B.). In addition, both genotypes exhibited equivalent dsDNA levels (Figure II. 9.C.) 
and similar net Mn levels following normalization by dsDNA (Figure II. 9.C.).  
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Figure II. 9. Assessment of endogenous Mn levels in HD striatal cells. Wild-type 
STHdhQ7/Q7 (blue) and mutant STHdhQ111/Q111 (red) cells were cultured in a 96 well tissue 
culture plate and exposed to vehicle (0 µM MnCl2) for 30 minutes in HEPES salt buffer. 
CFMEA was used to measure (A) changes in % maximal fura-2 fluorescence and (B) 
total extracted cellular Mn levels expressed in nanomolar (nM) concentration. (C) 
dsDNA levels in the same striatal cells were assessed by PicoGreen assay. (D) Net Mn 
levels in each well/experiment were normalized to their corresponding dsDNA content. 
Note: 1 nM (nanomolar/L) = 0.001 nanomoles per mL. N = 11; 6 wells/experiment. The 
mean levels are indicated as 95 % confidence interval.  
 
 
 
 
	  	   93 
Conclusions 
We have developed a high-throughput fluorescence quenching assay, CFMEA, by 
establishing the critical extraction and assay conditions (e.g. extraction buffer, 
temperature, and fura-2 concentration) required for quantitative detection of extracted Mn 
from cultured striatal cell lines by fura-2. The assay utilizes changes in fura-2 
fluorescence as an indirect read-out of intracellular Mn concentrations. In contrast to the 
typical usage of fura-2 following cell loading, this high-throughput and cost-effective 
assay extracts intracellular Mn in cultured striatal cells following MnCl2 exposure and 
allows for rapid assessment of Mn dynamics. In this assay, cultured cells are thoroughly 
washed following Mn exposure and intracellular Mn is extracted by detergent 
solubilization in the presence of fura-2. Fluorescence is then measured at Ex360/Em535. 
We have shown that a Mn standard curve, based on saturation one-site specific binding 
kinetics, can be generated to enable back calculation of Mn concentration from Mn 
quenching of fura-2 fluorescence. We have also examined the influence of other metal 
ions on CFMEA at this Ca2+ isosbestic wavelength (Ex360/Em535). In addition, we have 
also developed a quantitative PicoGreen assay for accurate and efficient normalization of 
cellular Mn levels in cell-extracts following Mn exposure. 
We report that the ideal detergent concentration for Mn extraction from the 
striatal cell lines is 0.1% Triton X-100 (Figure II. 1.C.). Furthermore, detergent was 
required for detection of fura-2 quenching by CFMEA, suggesting that extracellular Mn 
is not a significant component of the Mn detected by this assay. We observed minimal 
influence of Triton X-100 on baseline fura-2 fluorescence relative to SDS. In addition, 
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the unexpected biphasic increase in fura-2 RFU of both baseline control and cell extracts 
from 0 to 1% SDS may possibly be due to an interaction between SDS and fura-2. 
Interestingly, previous experimental evidence suggests that SDS can exist either as 
monomers or micellar aggregates in aqueous solutions depending on the total 
concentration, ionic strength, and temperature. Moreover, increasing total concentration 
of SDS at a given ionic strength impedes the ability to measure increases in monomer 
concentration above the critical micelle concentration (CMC)36. The phasic Mn 
quenching observed in both SDS and Triton X-100 at higher concentrations might be due 
to alterations in the CMC of both detergents used for Mn extraction in the cultured 
striatal cells.  
The generation of a Mn-fura-2 standard curve enabled back calculation of Mn 
levels in cultured striatal cells. However, we observed experimental variability in RFU 
between independent standard curves generated over an extended period of time. This 
variability may be due to experimental differences in fura-2 concentration, fluorometric 
plate reader sensitivity, and detection of Mn quenched fura-2. Thus, the use of %MAX to 
calculate Mn levels in cell extracts may improve the accuracy of Mn determination across 
experiments. We observed agreement in the quantitative relationship between Mn 
concentration and fura-2 fluorescence in the eight independent standard curves, which 
had a tight fit to a one-site specific binding curve with Hill slope (Figure II. 3.). This data 
argues for the possibility of using a single Mn-fura-2 standard curve for multiple 
independent experiments to facilitate high throughput analysis.  
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Owing to the published effect of metal ions on fura-2 fluorescence at the F340/380 
excitation ratio wavelengths 12,20-23, we examined and demonstrated a similar influence of 
Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Ca2+, Mg2+, Pb2+, and Zn2+ on fura-2 fluorescence in our 
cell-free system at Ex360/Em535 (Figure II. 4. and Table II. 1) and published data that used 
single cell loaded fura-2 AM at F340/380 nm excitation ratio12,20,37,38. However, in contrast 
to published evidence of an increase in fura-2 fluorescence by Cd2+ at the F340/380 ratio 
12,20, we observed a quenching effect at high Cd2+ concentrations with an EC50 of 0.3 µM 
(Figure II. 4. and Table II. 1). In addition, we observed an unexpected fura-2 quenching 
effect (~10%) with Ca2+ concentrations above 10 µM, regardless of the concentration of 
Mn present in the cell-free system (data not shown). It is possible that the competitive 
quenching effect of Ca2+ may be due to detection limits of the plate reader or changes in 
fura-2 and Mn binding stoichiometry that would induce molecular crowding of fura-2 by 
Ca2+ ions and decrease fura-2 fluorescence. Furthermore, we demonstrated that not only 
do Co2+ and Cu2+ quench fura-2 fluorescence in a concentration-dependent manner, but 
also they can competitively interfere with Mn-fura-2 interaction at concentrations above 
1 µM (Figure II. 5.C. and data not shown). Although Fe2+ quenched fura-2 in a 
concentration-dependent manner, it had minimal influence on the Mn-fura-2 interaction 
(Figure II. 5.D.). However, we did not observe any significant influence of basal cellular 
metal ions on the quantified Mn levels in the striatal cell extracts by the CFMEA assay. 
This may be due in part to the fact that cells were extracted in a large volume of fura-2 
detergent-based extraction buffer (100 µL) that reduced the concentration of endogenous 
metal ions that might otherwise influence the assay. However, CFMEA may fail to 
provide accurate measurements of cellular Mn levels following exposure to mixtures of 
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toxicants containing multiple fura-2 binding metals if levels reach concentrations high 
enough to influence fura-2 fluorescence. On the other hand, given the substantial affinity 
of Cu2+, Co2+, Ni2+, and Fe2+ for fura-2, it is likely that CFMEA could be adapted for 
studies examining the cellular uptake of these other metals.  
We observed approximately 5 - 10% quenching effect of endogenous metal ions 
in untreated cell-extracts (Figure II. 9.A.). To account for the potential effect of 
endogenous metal ions in the striatal cells on fura-2 fluorescence, we defined the 
fluorescence of untreated cells as the 100% maximal fluorescence rather than the fura-2 
fluorescence value obtained from the cell-free system. The Mn-spike validation assays 
(Mn-spike methods 1 and 2) strongly suggest a minimal influence of endogenous metal 
ions on the accuracy of CFMEA. Specifically, the Mn-spike methods revealed that 
irrespective of the basal metal levels in cells exposed to different MnCl2 concentrations 
or extracted in different Mn-spiked fura-2 containing extraction buffer, CFMEA is 
capable of accurately measuring a known quantity of supplemented Mn over a wide 
range of measured Mn concentrations (Figure II 6.A. – 6.D.). In addition, the Mn-spike 
method B demonstrated that Mn spiking of the fura-2 containing extraction buffer before 
cellular Mn extraction did not saturate the fura-2 metal binding sites.  
We observed a close-agreement in the measured Mn levels between CFMEA and 
GFAAS (Figure II. 7.). We demonstrate that while both assays are specific and accurate 
in the detection of reduced Mn accumulation in mutant HD striatal cells compared to 
wild-type over a wide-range of concentrations, we did not observe a genotype by assay 
effect. We observed a substantial difference in the time required for measurement of 
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extracted cellular Mn and data acquisition between both assays. Specifically, the high-
throughput nature of CFMEA enabled for feasible assessment of Mn levels in cultured 
wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells within two hours following 
exposure to Mn. Conversely, independent cell-extracts had to be pooled together for 
GFAAS measurements and analysis, which required several weeks.  
We observed that cultured striatal cells plated at lower cell densities (<20,000 
cells/well on a 96 well plate) were undetectable my traditional protein detection assays. 
Thus, we developed a quantitative PicoGreen assay that enabled efficient normalization 
of cellular Mn levels in the striatal cell following CFMEA analysis. Importantly, we 
demonstrated a linear relationship between PicoGreen fluorescence and either the 
concentrations of dsDNA (Figure II 8.A.) or cell number (Figure II 8.B.) in the striatal 
cell-extracts. Moreover, the concentrations of dsDNA in the striatal cells pre and post Mn 
exposure were within the lower and upper limits of the PicoGreen standard curve. We 
demonstrated that both wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells exhibit 
similar dsDNA levels after vehicle exposure (Figure II. 9.C.). In addition, pre and post 
normalization of net extracted Mn levels in vehicle exposed striatal cells to dsDNA levels 
does not change the net Mn levels between both genotypes (Figure II. 9.B. and 9.D.).  
It is possible that the extraction conditions and fura-2 concentration of CFMEA 
could be modified and applied to rapidly assess different metal ion levels and dynamics 
in other cells and animal tissues. Furthermore CFMEA has the potential to provide Mn 
kinetic measurements (i.e. Bmax, EC50, Km) in cells and tissues. This approach has the 
potential to extend our understanding of Mn transport kinetics and homeostasis. In 
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conclusion, we have developed, optimized, validated and applied a functional high-
throughput fluorescence-quench extraction assay (CFMEA) to accurately assess Mn 
levels in a striatal cell line. Importantly, CFMEA provides a rapid means to evaluate Mn 
transport kinetics in cellular toxicity and disease models. Given the close-relationship in 
measured Mn levels, similarities in sensitivity, accuracy, specificity between CFMEA 
and GFAAS, and most importantly, the high-throughput nature of CFMEA, we used 
CFMEA as the preferred assay to investigate the Mn transport dynamics underlying 
decreased Mn accumulation in mutant HD striatal cells. 
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CHAPTER III 
 
ASSESSMENT OF MANGANESE TRANSPORT KINETICS TO 
FUNCTIONALLY CHARACTERIZE THE DECREASED MANGANESE 
ACCUMULATION IN MUTANT COMPARED TO WILD-TYPE STHdh CELLS 
 
Introduction 
Manganese (Mn) is stringently regulated in the brain and necessary for normal 
growth, cellular homeostasis, and development. However, excessive levels through 
dietary intake and occupational routes can accumulate in the brain and alter the basal 
ganglia function to induce neuron dysfunction and neurodegeneration1-4. Impairment in 
metal ions and metal-dependent enzymes has been reported in HD. For example, Dexter 
and colleagues have provided evidence for elevated Cu and Fe levels in the corpus 
striatum of postmortem human brain tissues5,6. Moreover, emerging reports have 
elucidated striking similarities in the pathophysiological mechanisms between HD and 
metal toxicity3,7-11.  
Several modes of Mn uptake transport across the blood brain barrier have been 
reported and suggested to occur via facilitated diffusion, active transport through DMT1, 
voltage-regulated and stored operated Ca2+ channels, ZIP8, citrate, and the TfR 
transporters3. Approximately 80% of Mn in plasma is bound to proteins and a smaller 
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fraction bound to Tf, an iron-binding protein12. Mn transport through TfR is exclusively 
present in the trivalent oxidation-state13. Intracellular Mn2+ is sequestered into the 
mitochondria of brain and liver via the Ca2+ uniporter14,15. However, there has been 
conflicting reports to support either the mitochondria or nuclei as the cellular organelle 
that accumulates the primary pool of Mn in the cell16-18. The efflux mechanism of cellular 
mitochondrial Mn2+ is mediated preferentially through an active, but slow Na+-
independent mechanism with minimal transport over the Na+-dependent efflux 
mechanism19. This slow Mn efflux has been suggested to account for the net Mn 
accumulation in the mitochondria. Nevertheless, the cytoplasmic Fe2+ exporter, 
ferroportin-1, has been hypothesized and reported to be a candidate Mn exporter because 
its surface localization and protein expression is perturbed following Mn exposure20.  
 In spite of the numerous reports implicating altered metal homeostasis in in vitro 
and in vivo models of HD, it is still unclear the nature of the metal transport dynamics 
that underlie the altered metal homeostasis observed in HD. However, two independent 
studies have examined Mn transport in glia cells (astrocytes) using radiotracer 54Mn(II) 
and reported discrete modes of Mn transport dynamics21,22. In fact, while Wedler and 
Aschner have demonstrated that astrocytes can efficiently transport Mn through specific 
transporter systems that are inhibited by excess extracellular Ca2+, they also show that 
astrocytes exhibit saturation kinetics and accumulate Mn. Furthermore, Mn efflux in 
astrocytes is biphasic and comprised of a slow and rapid efflux modules21,22. 
Nevertheless, we have previously reported and described a disease-toxicant screen that 
was performed using a neuronal striatal cell line model of HD (wild-type STHdh(Q7/Q7) 
and mutant STHdh(111/Q111)). The screen revealed a gene-environment interaction between 
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mutant HTT and Mn. Specifically; expression of mutant HTT decreased net Mn 
accumulation in mutant STHdh(Q111/Q111)  cells and the striatum of a mouse model of HD. 
In addition, the decreased Mn accumulation correlated with diminished vulnerability to 
Mn induced cytoxicity23,24.   
 In chapter II, we reported the establishment, development, and validation of a novel 
fluorescence-based Mn detection assay (CFMEA). This assay accurately measures 
cellular Mn levels in cultured HD striatal cells following Mn exposure (Figure II. 6. and 
7.). The discovery of the HD-Mn disease-toxicant interaction further supports the need to 
investigate the Mn transport kinetics that underlies the Mn accumulation deficit in mutant 
HTT striatal cells. Based on the unique transport dynamics reported in glia cells and the 
alterations in metal homeostasis caused by expression of mutant HTT protein, we 
hypothesized that expression of mutant HTT impairs Mn homeostasis to cause decreased 
Mn accumulation via alterations in Mn transport kinetic mechanisms, specifically; 
uptake, cellular storage, or efflux. Importantly, these three possible transport mechanisms 
are not mutually exclusive. The Mn transport dynamics in wild-type STHdh(Q7/Q7) and 
mutant STHdh(111/Q111) cells was assessed with CFMEA and the traditional fura-2 loaded 
Mn-quenching kinetic assays. Finally, other studies have previously utilized the 
traditional fura-2 loaded Mn-quenching assays to assess intracellular metal ion 
concentration and transport in loaded cells and demonstrated a rapid and time-dependent 
quenching of fura-2 fluorescence following metals, including Mn exposure25-30. 
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Materials and Methods 
Chemicals, reagents, and cell culture supplies 
Unless indicated, cell culture media and supplements were obtained from 
Mediatech (Manassas, VA). Cell lines were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, 
and Sigma, St. Louis, MO), L-glutamine, 400µg/ml G418 and Penicillin-Streptomycin. 
Manganese (II) chloride heptahydrate (MnCl2 . 7H2O) was from Alfa Aesar (Ward Hill, 
MA). Ultra-pure fura-2 salt (cell impermeable, ENZ-52007) and fura-2 AM salt (cell 
permeable, ALX-620-005) were obtained from ENZO Biochem (New York, NY). The 
HEPES salt exposure buffer consisted of 25mM HEPES buffer (pH 7.2), 140mM NaCl, 
5.4mM KCl, and 5mM D-glucose (Sigma). The Krebs-Ringers (KR) buffer consisted of 
135mM NaCl, 5mM KCl, 0.4mM KH2PO4, 1.8mM CaCl2, 1mM MgSO4, 20mM HEPES, 
and 5.5mM D-glucose, pH 7.4 (Sigma). 1X ultra-pure phosphate-buffered saline (PBS), 
pH 7.4, without calcium and magnesium was used for post Mn exposure washes. Triton 
X-100 was obtained from Sigma. Deoxyribonucleic acid sodium salt from salmon testes 
(Catalog # D1626) was obtained from Sigma (St. Louis, MO). Quant-iT™ PicoGreen 
dsDNA Reagent (Catalog # P7589) was obtained from Molecular Probes (Carlsbad, CA). 
1x TE buffer used for the dilution of PicoGreen reagent was composed of 1 M Tris-HCl 
(pH 7.5) and 0.5 M EDTA (pH 8.0) prepared with DNase-free water and pH adjusted to 
7.5. 
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Cell culture 
Wild-type STHdh(Q7/Q7) and mutant STHdh(111/Q111) were grown as previously 
described 24,31-33. In brief, wildtype STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells were 
plated in a clear polystyrene 96 well plate at 20,000 cells per 0.32 cm2 (surface area) 
respectively the evening before treatment and allowed to grow in a 33°C incubator. 
MnCl2 was added to the KR buffer, complete culture media, or HEPES salt exposure 
buffer the morning of exposure. Total extracted cellular Mn levels were assessed by 
CFMEA or the traditional fura-2 loaded Mn-quenching kinetic assay.  
 
Mn-fura-2 standard curve 
Cell-free Mn-fura-2 saturation binding curve was generated using a ten point Mn-
fura-2 curve with samples containing 1 µL of different 100X stock Mn standards (0 – 100 
mM) added to 99 µL of 0.5 µM fura-2 in PBS with 0.1% Triton X-100 (PTx) and assayed 
in a clear polystyrene 96-well assay. After 5 seconds orbital shake, fura-2 fluorescence 
was measured at the Ca2+ isosbestic point of Ex360 (bandwidth of filter = ± 35 nm) and 
Em535 (bandwidth of filter = ± 25 nm) with a Beckman coulter DTX 880 multimode plate 
reader using multimode analysis software (version 3.2.0.6) and top read settings. The 
average raw fluorescence signal values (RFU) of the 0 µM Mn samples within each 
independent standard curve were defined as the 100% maximal fluorescence for that 
experiment after background subtraction. RFU of each well was then normalized as 
percent maximal fluorescence (%MAX) to this value. A one-site specific saturation-
	  	   108 
binding curve with Hill slope could be fit to log10 Mn concentration (x-axis) and either 
%MAX (y-axis) or RFU (y-axis) by non-linear regression analysis using graphpad prism 
software (version 5.0b). As utilization of  %MAX rather than RFU was found to control 
better for the experimental variation, we preferred use of  %MAX for experimental 
determination of extracted Mn concentrations. To permit back calculations of extracted 
Mn levels from experimentally determined %MAX values we used the trend line command 
in Microsoft Excel to fit power (Mn concentration = A•(%MAX)B) and logarithmic (Mn 
concentration = A•ln(%MAX)+B) equations to the standard curve data and calculated 
binding curve from non-linear regression analysis. Power curves were used for %MAX 
values less than 50% and logarithmic curves for values greater than 50%, on either side 
of the inflection point of the saturation-binding curve plotted with Mn concentration (x-
axis) and %MAX (y-axis). These mathematical models used for calculating extracted Mn 
concentration routinely fit the saturation binding curves and standards data with r2 values 
greater than 0.995. 
 
Quantification of net cellular Mn levels in cultured cell-extracts by CFMEA 
Wildtype STHdhQ7/Q7 and mutant STHdhQ111/Q111 were cultured in clear 
polystyrene 96 well plates and exposed to varying MnCl2 concentrations. After exposure, 
the media was discarded and cells quickly washed three times with 200 µL PBS. The 
cells were extracted at 33°C for 1 hour in 100 µL PTx with 0.5 µM fura-2. Changes in 
fura-2 fluorescence caused by Mn quenching were measured on a plate reader as 
described in the Mn-fura-2 standard curve section. Extracted Mn concentrations from 
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cultured cells were calculated using the logarithmic and power Mn standard curve 
(generated in the cell-free Mn-fura-2 standard curve section) with the %MAX of each 
sample. Experimental sample %MAX was determined by normalizing the RFU of each 
Mn-exposed sample with the RFU of vehicle-only samples (untreated), which was 
defined as the experimental 100% maximal fluorescence signal. 
 
PicoGreen dsDNA standard curve 
PicoGreen standard curve was generated as previously published34 and described 
in chapter II. In brief, 100 µL salmon testes dsDNA standards (0 – 1000 µg/mL) prepared 
in 0.1% PTx was added to 50 µL of PicoGreen reagent diluted in 1x TE buffer (1:400) in 
a 96 well plate. In addition, the background was determined by adding 100 µL 0.1% PTx 
and 50 µL 1x TE buffer. The standard curve plate was incubated at room temperature in 
the dark for 5 minutes and the fluorescence in each well measured with a plate reader at 
Ex485 (bandwidth of filter = ± 20 nm), Em535 (bandwidth of filter = ± 25 nm), and 
integration time of 200 ms with the indicated plate reader using multimode analysis 
software (version 3.2.0.6) and top read settings. The average background fluorescence 
read was subtracted from each of the salmon testes dsDNA PicoGreen fluorescence tested 
in the standard curve. A standard linear regression analysis in Microsoft Excel was used 
to obtain a linear equation from the standard curve data.  
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Normalization of cellular Mn levels to dsDNA 
Following CFMEA analysis, 50 µL of 1:400 PicoGreen solution in 1x TE buffer 
was added to each well containing cell-extract (100 µL). The cell extracts were further 
incubated and changes in fluorescence measured as described in the PicoGreen dsDNA 
standard curve section. The concentration of dsDNA in each cell-extract was calculated 
using the linear equation generated from the salmon DNA standard curve and normalized 
to Mn levels in the cell-extracts.   
 
Traditional fura-2 loaded Mn-quenching kinetic assay  
Wild-type STHdh(Q7/Q7) and mutant STHdh(111/Q111) cells were plated in a clear 
polystyrene 96 well plate at 20,000 cells per 0.32 cm2 (surface area) the evening before 
exposure.  Cells were washed three times with 200 µL KR buffer to remove residual 
culture media. To obtain equal loading of the high affinity cell permeable Ca2+ probe 
fura-2 AM in both genotypes, wildtype and mutant striatal cells were loaded with 100 µL 
of 5 and 10 µM fura-2 AM dissolved in KR buffer at room temperature, respectively. 
After 30 minutes loading in the dark, cultured HD striatal cells were washed three times 
with 200 µL KR buffer and allowed to de-esterify in 100 µL KR buffer for an additional 
15 minutes at room temperature and stored in the dark. Following completion of de-
esterification in the cultured HD striatal cells, the buffer was replaced with fresh KR 
buffer. The baseline intracellular fura-2 fluorescence was measured for both genotypes at 
the Ca2+ isosbestic point (Ex360) and emission (Em535) nm with a plate reader using top 
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read and 33°C settings. The cultured HD striatal cells were exposed with 100 µL of 0, 
100, or 250 µM MnCl2 prepared in KR buffer. Changes in fura-2 fluorescence induced by 
intracellular Mn quenching was measured at an integration time of 200 ms in increments 
of 1 minute for up to 30 minutes at the Ca2+ isosbestic point (Ex360) and emission (Em535) 
nm and compared to vehicle. The vehicle fluorescence was subtracted from each MnCl2 
exposed cell sample within the same increment read. The difference in fura-2 quenching 
(ΔF) in each cell sample was calculated as ([F(i)- F(o)]/F(i)) and averaged across six 
replicates for each genotype per exposure concentration. F(i) is the initial fluorescence 
following MnCl2 exposure and F(o) is the second increment fluorescence read of the same 
well. The F(i) and F(o) from each well on the 96 well plate decreases over the exposure 
duration. Thus, enabling for indirect assessment of Mn uptake and cellular storage 
properties. 
 
Statistical Analysis 
Univariate and repeated-measures ANOVA tests were performed using SPSS 18 
software (IBM, Inc., Chicago, IL). Post hoc analysis and pairwise comparisons were 
done using Microsoft Excel (Microsoft, Redmond, WA) by Student's t-tests (two tailed) 
or testing for nonoverlap of the 95% confidence interval for normalized ratios; error bars 
are expressed as standard error of the mean (SEM). Standard deviations (SDEVs) for the 
difference in net Mn levels were calculated by appropriate propagation of uncertainty 
calculations for subtraction of sample means, with significant differences between 
wildtype and mutant cells evaluated by non-overlap of the 95% confidence interval.  
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Results 
Mutant HTT expression impairs net Mn accumulation in a broad concentration- and time-
dependent manner 
To determine if CFMEA was capable of detecting net Mn accumulation deficit in 
mutant STHdh(Q111/Q111)  cells previously identified by GFAAS 23,24, we exposed cultured 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells to different MnCl2 
concentrations for 27 hours in media. After Mn exposure, net Mn accumulation was 
measured with CFMEA. We observed a concentration-dependent increase in net Mn 
accumulation in both wild-type STHdh(Q7/Q7) and mutant STHdh(111/Q111) cells (Figure III. 
1.A.). Repeated-measures ANOVA showed a significant main effect of Mn-exposure (F(3, 
12) = 176.84, p<0.0001) and genotype (F(1, 4) = 14.02, p = 0.02), as well as exposure by 
genotype interaction (F(3, 12) = 5.215, p< 0.02). To explore the minimum duration required 
for the detection of mutant Mn accumulation deficit, we exposed wild-type STHdh(Q7/Q7) 
and mutant STHdh(111/Q111) to 100 µM MnCl2 for 6 and 27 hrs and measured net Mn 
accumulation with CFMEA. Repeated-measures ANOVA showed a significant main 
effect of duration (F(1, 4) = 100.4, p = 0.001) and genotype (F(1, 4) = 19.93 p = 0.01) on Mn 
accumulation (Figure III. 1.B.). However, the magnitude difference in net Mn 
accumulation between wild-type and mutant cells was substantially enhanced after 6 hrs 
exposure compared to 27 hrs. This data confirms a concentration- and time-dependent 
Mn accumulation deficit in mutant HD striatal cells. In addition, it suggests that future 
studies aimed at understanding the mutant Mn transport defect could be performed at 
earlier time points other than 27 hrs. 
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Figure III. 1. Mutant HTT striatal cells exhibit defect in net Mn accumulation 
across a broad exposure concentration and duration range. (A) Wild-type 
STHdhQ7/Q7 (blue) and mutant STHdh(Q111)/(Q111) (red) cells were exposed to MnCl2 for 27 
hrs in media. (B) Wild-type STHdhQ7/Q7 and mutant STHdh(Q111)/(Q111) cells were exposed 
to 100 µM MnCl2 for 6 and 27 hrs in media. Net Mn accumulation in (A) and (B) were 
measured with CFMEA. Changes in Mn levels following Mn exposure were first 
normalized to vehicle and further normalized to dsDNA levels on a per well basis. N=3; 8 
wells/exposure condition. Mean levels are indicated + SEM. (*) Indicates significant 
main effect of exposure and genotype on Mn accumulation in wild-type STHdh(Q7/Q7) and 
mutant STHdh(111/Q111). 
 
Di-/or trivalent metal ions and serum proteins are not required for the decreased Mn 
accumulation phenotype in mutant HTT striatal cells 
To examine the requirement of metal binding proteins and co-transporter ions in 
the Mn accumulation deficit observed in mutant HTT striatal cells, we exposed wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells to different MnCl2 concentrations for 1 
hour in HEPES salt buffer (Figure III. 2.). We reasoned that if mutant striatal cells’ Mn 
accumulation deficit is solely dependent on di-/or trivalent metals, serum proteins, and 
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known Mn co-transporters present in culture media, then Mn exposure in a HEPES salt 
buffer lacking the aforementioned media components would abolish the decreased Mn 
accumulation deficit in mutant STHdh(Q111/Q111) cells. After 1 hr Mn exposure in HEPES 
salt buffer, repeated-measures ANOVA showed a significant main effect of Mn-exposure 
(F(2, 8) = 172.4, p < 0.001) and genotype (F(1, 4) = 14.51, p = 0.02), as well as exposure by 
genotype interaction (F(2, 8) = 7.582, p < 0.01) (Figure III. 2.A.). However, similar 
exposure concentrations in media resulted in ~ 2 – 3 fold decrease in net Mn 
accumulation in both genotypes. Importantly, mutant HD striatal cells accumulated less 
Mn levels as compared to wild-type (Figure 2. B.). Additionally, repeated measures 
ANOVA showed a significant main effect of Mn (F(2, 8) = 175.2, p < 0.001), genotype 
(F(1, 4) = 14.58, p < 0.05), and Mn * genotype interactions (F(2, 8) = 7.707, p < 0.05) 
following MnCl2 exposure in media containing di-/or trivalent metals, serum proteins, 
and known Mn co-transporters. This data strongly suggest that the components of media 
are not required for diminished Mn accumulation in mutant HTT striatal cells. In 
addition, our data indicates that the components of media may bind to extracellular Mn 
and decrease its availability for cellular uptake. 
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Figure III. 2. Di-/or trivalent metals, serum proteins, and known Mn co-
transporters are not required for mutant HTT Mn accumulation deficit. Wild-type 
STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells were exposed to MnCl2 in (A) 
HEPES salt buffer or (B) media and cellular Mn levels measured by CFMEA. N=3; 8 
wells/exposure condition. Mean levels are indicated + SEM. (*) Indicates significant 
effect of genotype on net accumulation of Mn (p < 0.05, repeated measures ANOVA) 
between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells. 
 
Mutant HTT alters instantaneous Mn uptake kinetics and cellular storage properties 
To investigate the effect of mutant HTT expression on instantaneous Mn uptake 
kinetics in wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells, we utilized the 
traditional fura-2 loaded Mn-quenching kinetic assay. We show that after equivalent 
loading of cultured wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells with the 
cell-permeable fura-2 dye (fura-2 AM) and exposure to 100 and 250 µM MnCl2 in KR 
buffer, the instantaneous Mn uptake kinetics in mutant STHdh(Q111/Q111) cells is 
significantly decreased (p<0.0001, post hoc t-test) compared to wild-type STHdh(Q7/Q7) 
(Figure III. 3.A.). In addition, the decreased instantaneous Mn uptake was evident as 
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early as 2 minutes following Mn exposure (Figure III. 3.A.). Furthermore, we observed 
that the decreased instantaneous Mn uptake kinetics in wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells was independent of the concentration of MnCl2 used for the 
exposure (Figure III. 3A.). Importantly, we observed significant differences (p<0.001) in 
the initial slope of Mn uptake kinetics between wild-type and mutant HTT striatal cells 
during the first 5 minutes following exposure to 100 and 250 µM MnCl2 (Table III. 2.). 
Interestingly, we observed a striking concentration-dependent difference in the 
cellular Mn saturation rates or cellular storage between wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells (Figure III. 3.A.). We show that the difference in cellular 
Mn storage in both genotypes commences approximately 15 minutes following exposure 
to 100 and 250 µM MnCl2 (Figure III. 3.A.). In addition, we demonstrate that mutant 
HTT cells exhibit a concentration- and time-dependent impairment in the instantaneous 
Mn uptake and cellular storage properties. Furthermore, we examined the uptake and 
cellular storage kinetics in wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells using 
one-site specific binding curves and observed a significant decrease in the maximum 
quenching of fura-2 by Mn (Bmax) in mutant STHdh(Q111/Q111) compared to wild-type 
STHdh(Q7/Q7) cells. In addition, the duration required for mutant to exert half maximal 
effect on fura-2 quenching after Mn uptake (Kd) was substantially decreased compared to 
wild-type cells  (Table III. 1.).  
To determine the predominant cellular Mn pools, cytosolic versus total 
(organelles and cytosolic), that contributes to the diminished cellular Mn storage in 
mutant STHdh(Q111/Q111) cells, we exposed cultured wild-type STHdh(Q7/Q7) and mutant 
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STHdh(111/Q111) cells to the same Mn concentrations as used in the kinetic studies (100 
and 250 µM MnCl2) for 30 minutes and measured net cellular Mn storage by CFMEA. 
We reasoned that fura-2 loaded Mn-quenching assay might only measure cytosolic Mn 
levels and exclude the contribution of organelle-specific Mn storage properties in the 
cells. Thus, CFMEA would be capable of detecting total extractable Mn levels in the cells 
(cytosolic and organelles) following Mn exposure. After 30 minutes MnCl2 exposure in 
KR buffer and CFMEA analysis, repeated-measures ANOVA showed a significant main 
effect of exposure (F(1, 6) = 67.13, p< 0.001) and genotype (F(1, 6) = 177.1 p = 0.02) on net 
cellular Mn storage (Figure III. 3.B.). This data suggests that mutant HTT expression 
impairs instantaneous Mn uptake kinetics and total cellular Mn storage properties to 
cause the observed Mn accumulation deficit in mutant HTT striatal cells. 
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Figure III. 3. Expression of mutant HTT impairs instantaneous Mn uptake kinetics 
and cellular storage properties in striatal cells. Concentration and time-dependent 
differences in instantaneous Mn uptake and cellular storage between wild-type 
STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells. Striatal cells were equally 
loaded with fura-2 AM and exposed to 100 and 250 µM MnCl2 for 30 minutes. Changes 
in intracellular fura-2 fluorescence by Mn quenching were assessed by fura-2 loaded Mn-
quenching kinetic assay. (B) Total cellular Mn storage is impaired in mutant HTT 
expressing striatal cells. Wild-type and mutant HTT striatal cells were exposed to the 
indicated MnCl2 for 30 mins in HEPES salt buffer and Mn levels measured with 
CFMEA. N=3; 8 wells/exposure condition. Mean levels are indicated + SEM. (*) 
Indicates significant effect of genotype on net cellular Mn storage between wild-type 
STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells.   
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Table III. 1. Summary of instantaneous Mn uptake and cellular storage kinetic 
properties in HD striatal cells. Examination of instantaneous Mn uptake and cellular 
storage kinetics using the 95% confidence interval values of saturated Mn binding of 
fura-2 (Bmax) and half maximal effective duration (Kd) values for Mn uptake extrapolated 
from the one-site specific binding curves (Figure III. 3A.). 
 
 
Table III. 2. Comparison of instantaneous Mn uptake kinetic slopes following 
MnCl2 exposure between wild-type and mutant HD striatal cells. Assessment of 
instantaneous Mn uptake slopes using the 95% confidence interval slope values 
extrapolated from linear regression analyses in Microsoft Excel of the uptake curves 
(Figure III. 3A.).  
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Wild-type and mutant HTT striatal cells exhibit similar net Mn efflux following equal 
intracellular Mn levels 
To explore the efflux kinetics in HTT striatal cells following MnCl2 exposure, 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells were equally loaded with fura-2 
AM and exposed to 500 µM MnCl2 in KR buffer. After 30 minutes exposure, the cultured 
cells were quickly rinsed with Mn-free KR buffer and allowed to efflux in extracellular 
Mn-free KR buffer for an additional 30 minutes. Efflux kinetics was assessed by changes 
in fura-2 fluorescence and measured by the traditional fura-2 loaded Mn-quenching 
kinetic assay. We observed a substantial time-dependent increase in Mn efflux kinetics in 
the wild-type STHdh(Q7/Q7) compared to mutant STHdh(Q111/Q111) cells (Figure III. 4.A.). 
However, this enhanced Mn efflux was mainly due to a two-fold elevated net 
accumulated Mn levels in wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells 
(Figure III. 4.A.). Hence, we examined Mn efflux kinetics after similar net Mn 
accumulation levels in the wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells. 
After exposure of cultured HTT striatal cells to 300 and 500 µM MnCl2 respectively for 6 
hours in media, net accumulated cellular Mn levels was immediately measured (prior to 
efflux) or allowed to efflux in fresh Mn-free media that was changed every 5 minutes for 
1 hour (post 1 hour Mn efflux) (Figure III. 4.A.). Net Mn accumulation levels in the prior 
and post Mn efflux were measured with CFMEA. The rationale behind this experiment 
was to change the equilibrium potential between intra and extra-cellular Mn conditions, 
which would induce the shuttling of Mn from cellular storage pools into the fresh 
extracellular Mn-free media. Thus, decreasing the net accumulated Mn levels in the HTT 
striatal cells. After equivalent cellular Mn loading between wild-type STHdh(Q7/Q7) and 
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mutant STHdh(Q111/Q111) cells, we observed no difference in net Mn efflux between both 
genotypes (Figure III. 4.B.) This data shows that wild-type and mutant cells have similar 
efflux kinetics after equivalent intracellular Mn levels and also suggest that the Mn 
accumulation deficit in mutant HTT expressing striatal cells is not due to an efficient 
efflux mechanism in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells. 
 
Figure III. 4. Wild-type and mutant HTT striatal cells exhibit similar Mn efflux 
kinetics following equivalent intracellular Mn levels. (A) The instantaneous Mn efflux 
kinetics graph shows efficient Mn efflux in STHdh(Q7/Q7) (blue) compared to mutant 
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STHdh(Q111/Q111) (red) cells following unequal cellular Mn levels. Wild-type and mutant 
cells were equally loaded with fura-2 AM and exposed to 500 µM MnCl2 for 30 minutes. 
Post Mn exposure, intracellular Mn was allowed to efflux in Mn-free KR buffer for 30 
minutes. Changes in fluorescence were assessed with fura-2 loaded Mn-quenching 
kinetic assay. (B) Wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells 
were exposed to 300 µM and 500 µM MnCl2 respectively in media for 6 hours to obtain 
equivalent intracellular Mn levels. Cellular Mn was extracted (prior to Mn efflux) or 
allowed to efflux in Mn-free media that was replaced every 5 minutes for 1 hr (post 1hr 
Mn efflux) before extraction and Mn measurements with CFMEA. N = 3; 6 
wells/exposure condition. Mean total Mn efflux levels for (A) and (B) are indicated 
±SDEV. 
 
Conclusions 
We tested the hypothesis that alterations in manganese transport kinetics (uptake, 
cellular storage, and efflux) by expression of mutant HTT contributes to the decreased net 
Mn accumulation deficit in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) 
cells following MnCl2 exposure. We demonstrate that expression of mutant HTT 
significantly reduces both the instantaneous Mn uptake kinetics and cellular Mn storage 
properties in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells following 
Mn exposure (Figure III. 3.A. and 3.B.). We show that wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells exhibit similar Mn efflux rates following equivalent cellular 
Mn loading (Figure III. 3.A. and 3.B.). In addition, we demonstrate that mutant striatal 
cells exhibit a broad concentration and time-dependent defect in Mn uptake and 
accumulation (Figure III 1.A. and 1.B. and Figure III. 3.A.). Finally, we show that di/or 
trivalent metals, serum proteins, and known Mn co-factors are not required for mutant 
Mn uptake and cellular storage deficit (Figure III. 2.A.).  
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Owing to the previously reported concentration and time-dependent Mn uptake 
and accumulation in glial cells (astrocytes)21,22, we examined and demonstrated a similar 
influence of broad Mn concentration and time-dependency on Mn accumulation in the 
neuronal striatal HTT cells (Figure III. 1.A. and 1.B.). We observed a significant 
concentration-dependent increase in net Mn accumulation in both wild-type STHdh(Q7/Q7) 
and mutant STHdh(Q111/Q111) cells. However, we noticed a significant decrease in net Mn 
accumulation in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells at all 
the tested Mn concentrations (Figure III. 1.A.). This data further support the previously 
published decreased net Mn accumulation in mutant STHdh(Q111/Q111) cells by GFAAS24. 
Given that the decreased Mn accumulation phenotype observed in mutant 
STHdh(Q111/Q111) cells was solely dependent on mutant HTT expression, we reasoned that 
the difference in Mn accumulation would be observed at an earlier exposure time point 
other than 27 hrs. Thus, we examined and demonstrated that the mutant Mn accumulation 
deficit is detectable by CFMEA as early as 6 hrs following exposure to 100µM MnCl2 in 
media (Figure III. 1.B.). Interestingly, we observed a substantial increase in the 
magnitude difference between wild-type STHdh(Q7/Q7) and mutant STHdh(111/Q111) cells 
after 6 hrs compared to 27 hrs exposure with 100 µM MnCl2 in media. This enhanced 
magnitude difference in net Mn accumulation between wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells at 6 hrs strongly argues for future assessment of Mn 
transport dynamics in media or other buffers at earlier time points. This would enable 
efficient characterization of Mn transport kinetics in the striatal HTT cells. It is possible 
that during longer Mn exposure duration, other known or putative Mn transporters that 
are not impaired by mutant HTT expression may be activated via compensatory 
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mechanisms to increase Mn uptake, intracellular trafficking, and accumulation in the 
mutant STHdh(Q111/Q111)  cells. Thus, decreasing the magnitude of Mn accumulation 
between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells. Moreover, the 
compensatory Mn transporter activation system is highly unlikely regulated directly by 
mutant HTT expression, albeit it could potentially mask discrete Mn transport kinetics 
and transporter functions between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111)  
cells.  
Metal ions, carrier proteins, and co-transporters ions have been reported to 
influence Mn uptake35-38. We examined and demonstrated that di-/or trivalent metals, 
other small anions such as nitrate (NO3-) and sulfate (SO42-), serum proteins, and known 
Mn co-transporters are not required for decreased Mn accumulation in mutant HD striatal 
cells compared to wild-type (Figure III. 2.A.). We report that 1 hr exposure of cultured 
striatal HTT cells with at least 50 µM MnCl2 in HEPES salt buffer containing NaCl, KCl, 
and glucose is sufficient to detect a significant decrease in mutant STHdh(Q111/Q111) Mn 
accumulation compared to wild-type STHdh(Q7/Q7) cells (Figure III. 2.A.). Moreover, 
similar Mn exposure concentrations and duration in media yielded ~ 2 – 3 fold decrease 
in Mn accumulation in both genotypes when compared to the HEPES salt buffer 
exposure conditions (Figure III. 2.A. and 2.B.). Importantly, we observed significant 
differences in net Mn accumulation between wild-type and mutant HTT striatal cells at 
all the tested MnCl2 exposure concentrations in media (Figure III. 2.B.). The 2 – 3 fold 
decrease in Mn accumulation in the HD striatal cells in media versus HEPES salt buffer 
exposure conditions may likely be due to the binding or association of extracellular Mn 
with high-affinity serum proteins, for example; albumin and beta1-globulin, other 
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proteins, small anions such as nitrate (NO3-) and sulfate (SO42-), which decreases the 
availability and concentration of extracellular Mn for cellular uptake.  
The premise behind the traditional fura-2 loaded Mn-quenching assay is that as 
Mn influxes into cultured HTT striatal cells, it quenches the loaded fura-2 fluorescence. 
Change in fluorescence over time is inversely correlated with Mn uptake and saturation 
levels. Thus, we combined both CFMEA and the traditional fura-2 loaded Mn-quenching 
to functionally discriminate Mn transport kinetics in wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells. We characterized the Mn2+ uptake and saturation in the HTT 
striatal cells by measuring the instantaneous rate and time-dependence, as well as net 
cellular Mn storage into cultured HTT striatal cells. We report that expression of mutant 
HTT impedes the instantaneous Mn uptake kinetics as early as 2 minutes following 
MnCl2 exposure (Figure III. 3.A. and Table III. 1.). In addition, we show that the 
maximum Mn uptake or saturation rate in the HD striatal cells exposed with MnCl2 in 
KR buffer was observed between 15 and 30 minutes. In spite of the differences in 
concentration and time-dependence uptake between wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells, we demonstrate that they exhibit similar duration (~15 minutes) in 
the initiation of Mn saturation (Figure III. 3.A.). Importantly, we show that mutant 
STHdh(Q111/Q111) cells have decreased Mn saturation rate or cellular storage compared to 
wild-type STHdh(Q7/Q7) cells following MnCl2 exposure (Figure III. 3.A. and Table III. 
1.). Importantly, examination of the Mn transport kinetics showed a significant decrease 
in the instantaneous Mn uptake and cellular storage properties between wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells as shown by the non-overlapping 95% 
confidence intervals (Table III. 1.). Furthermore, we demonstrated that the Mn uptake 
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kinetic slopes between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells is 
significantly different during the first 5 minutes following MnCl2 exposure (Figure III. 
3.A. and Table III. 2.). This data suggest that decreased Mn accumulation in mutant 
striatal cells may be due in part due to an impaired primary Mn uptake transport system 
that is inherit to mutant HTT expressing striatal cells. Our data also suggest that during 
the latter MnCl2 exposure duration (5- 15 minutes), other compensatory/secondary Mn 
uptake transporter systems may be similarly activated to facilitate Mn uptake in both 
genotypes. Although these compensatory/secondary Mn uptake transport system are 
capable of abolishing the difference in Mn uptake kinetics slope between wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells, they are incapable of rescuing the 
phenotypic Mn accumulation deficit observed in mutant HTT striatal cells (Figure III. 
3.A. and Table III. 2.). Previous studies have reported that Mn accumulates in organelles, 
including mitochondria14,39, nucleus16, and golgi40. Interestingly, it has been suggested 
that loaded fura-2 may not be efficiently sequestered into organelles, but only measures 
changes in cytosolic metal ion concentrations, including Mn.  Based on the ability of Mn 
to be sequestered into organelles that may not be detected by the traditional fura-2 loaded 
Mn quenching assay, we examined the cellular Mn pools that contributes to the 
diminished cellular Mn storage in mutant STHdh(Q111/Q111) cells.  We explored and 
demonstrated that the prevalent cellular Mn pool that involved in the diminished cellular 
Mn storage properties in mutant STHdh(Q111/Q111) cells encompasses both cytosolic and 
organelle-accumulated Mn. This was determined by the ability of CFMEA to detect both 
the cytosolic and organelle (total) accumulated Mn levels. Interestingly, we observed an 
approximately two-fold decrease in net Mn accumulation Mn in mutant STHdh(Q111/Q111) 
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compared to wild-type STHdh(Q7/Q7) cells after 30 minutes exposure to 100 and 250 µM 
MnCl2 in KR buffer and Mn levels measured by both the traditional fura-2 loaded Mn 
quenching and CFMEA assays (Figure III. 3.A. and 3.B.). In addition, we observed 
similar net cellular Mn storage between wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111)  cells exposed to 100 µM and 250 µM MnCl2 in KR buffer for 30 
minutes (Figure III. 3.B.). The instantaneous Mn uptake difference between wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells strongly suggests a defective primary Mn 
transporter system in mutant STHdh(Q111/Q111) cells. It is highly unlikely that the observed 
similar Mn saturation time points for both genotypes (~15 minutes) was due to (i) 
maximal saturation of the loaded fura-2 dye with intracellular Mn because both wild-type 
STHdh(Q7/Q7) and mutant STHdh(111/Q111)  cells were equally loaded and possess distinct 
Mn influx rates; or (ii) increased mutant HTT sequestration of the fura-2 dye into cellular 
organelles, which would decrease its availability for Mn quenching. Finally, we 
demonstrate that mutant HTT expression impairs instantaneous Mn uptake kinetics and 
total cellular Mn storage properties to cause the observed Mn accumulation deficit in 
mutant STHdh(Q111/Q111)  cells. 
We explored the role of Mn efflux kinetics in the mutant Mn accumulation deficit 
phenotype. After examination of Mn efflux rates with the traditional fura-2 Mn-
quenching assay, we observed a substantial time-dependent increase in wild-type 
STHdh(Q7/Q7) Mn efflux rates compared to mutant STHdh(Q111/Q111) cells following 
exposure to 500 µM MnCl2 (Figure III. 4.A.). However, we reasoned that the increased 
Mn efflux rates in wild-type STHdh(Q7/Q7) compared to mutant STHdh(Q111/Q111) cells 
might be due to difference in net Mn accumulation levels in the cells prior to assessment 
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of Mn efflux kinetics. Furthermore, after equal loading of wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells with 300 µM and 500 µM MnCl2 respectively in media, we 
assessed the net Mn efflux after 1 hr.  We report that both wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells exhibit similar net Mn efflux kinetics after equal 
intracellular Mn levels (Figure III. 4.B.). Unfortunately, the precise nature of Mn efflux 
mechanism in the HD striatal cells during the 1 hr Mn-free extracellular KR buffer efflux 
is unknown. However, previous reports have postulated that distinct Mn cellular pools 
exist21,22. These discrete cellular Mn pools have been speculated to be involved in the fast 
phase of Mn efflux, slow equilibrium, and irreversibly bound Mn that are unavailable for 
efflux. In addition, biphasic Mn efflux kinetic profiles have been reported to exist in 
cultured astrocytes21,22. Thus, it is possible that both wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells possess similar Mn efflux pools. However, the cellular Mn efflux 
pools that contribute to the biphasic Mn efflux kinetics may have occurred during the 
constant 5 minutes interval changes of extracellular Mn-free media and therefore was 
undetectable after 1 hr Mn efflux. Moreover, it is known that a fairly large proportion of 
Mn uptake into chick glial cells (68%) and hepatocytes (60%) associate predominantly 
with proteins in the cytosol that are unable to be dissociated via membrane 
permeabilization with dextran sulfate21,22,41. Furthermore, we observed similar net Mn 
efflux between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells following equal 
cellular Mn loading. This further supports the view that cytosolic Mn association with 
proteins is not influenced by expression of mutant HTT. Importantly, the equilibrium 
between cytosolic Mn associations with proteins may dictate the available cellular Mn 
pools for efflux. Nevertheless, our data supports the previously published evidence of 
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unchanged protein levels in the suggested Mn exporter, ferroportin-1, in both wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells following MnCl2 exposure23.  
In summary, our findings provide the framework for understanding the Mn2+ 
transport kinetics underlying the Mn accumulation deficit in mutant STHdh(Q111/Q111) 
cells. Furthermore, our data supports the postulated and accepted criteria of Mn transport 
mechanism in cells, including; Mn uptake via facilitated diffusion or active metal 
transporters, cellular Mn storage indicated by the saturation kinetics, and the ability of 
proteins and metal ions to associate with Mn and influence its transport dynamics. 
Importantly, our data elucidates a discrete nature of mutant HTT modulation of Mn 
transport kinetics as well as the need to control for equal cellular Mn levels when 
assessing Mn efflux rates in different genotypes and cell-types. The discussed findings 
above substantiate the importance of investigating the transporter system(s) underlying 
the mutant Mn uptake and cellular storage deficits. 
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CHAPTER IV 
 
FUNCTIONAL DISSECTION AND EXAMINATION OF METAL 
TRNSPORTERS UNDERLYING MUTANT HTT-MANGANESE INTERACTION 
 
Introduction 
 Huntington’s disease (HD) is a progressive autosomal dominant neurodegenerative 
disorder that is caused by an expansion of a glutamine-encoding triplet repeat (CAG) in 
the Huntingtin gene (HTT)1-4. A pathologic feature of HD is selective degeneration of the 
medium spiny neurons (MSNs) in the corpus striatum. Unfortunately, the molecular 
mechanisms underlying the selective degeneration are still not fully understood. 
However, several cellular mechanisms including alterations in metal homeostasis and 
oxidative injury have been implicated in the neuropathology of HD5-9. Although HD is 
monogenetic, both genetic and environmental factors have been reported to contribute to 
the variability in age of disease onset and progression in humans and animal models10-15. 
Previous research utilizing in vitro and in vivo models of HD have provided experimental 
evidence for altered Mn homoeostasis in the striatum16,17. 
 Mn is stringently regulated within the brain and necessary for normal growth, 
cellular homeostasis, and development. Under normal physiological conditions, Mn is 
efficiently transported across the blood-brain barrier (BBB) in both the developing fetus 
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and adults18,19. Over the past two decades, different Mn transporter systems have been 
identified; including active and facilitated diffusion modes of Mn transport20-22.  
Emerging reports have indicated that Mn can be transported via the divalent metal 
transporter 1 (DMT1), transferrin receptor (TfR), calcium, zinc, magnesium, Park9, 
HIP14 channels/transporters, and others. While the tissue-specific expression of each of 
the aforementioned Mn transporters is yet to be determined, it is likely that the optimal 
tissue Mn levels are maintained through the involvement of all the above and other 
unknown Mn transporters. Of all the above listed polyvalent transporters, TfR and DMT1 
are the most extensively documented22. Intracellular Mn2+ is sequestered into the 
mitochondria of brain and liver via the Ca2+ uniporter23,24. However, there has been 
conflicting reports to support either the mitochondria or nuclei as the cellular organelle 
that accumulates the primary pool of Mn in the cell25-27. Mn exposure occludes oxidative 
phosphorylation and causes cellular oxidative damage in the brain. In addition, Mn2+ 
oxidation to Mn3+ in the mitochondria mediates cellular oxidative injury via the oxidation 
of essential cellular components28-30. Interestingly, mutant HTT modulates the sensitivity 
of metal-induced opening of the mitochondrial permeability transition pore (mPTP)31. 
Nevertheless, emerging reports have implicated the peroxisome proliferator-activated 
receptor gamma (PPARγ) as an important pathway for mitochondrial regulation of metal 
homeostasis via modulation of mitochondrial membrane potential and reactive oxygen 
species (ROS) production31,32. Finally, there are similarities in the pathophysiological 
mechanisms, for example: oxidative injury, impaired metal homeostasis, and 
mitochondria dysfunction, between HD and metal toxicity33-38. Not only has these 
similarities been suggested to underlie the neurotoxicity implicated in HD and metal 
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overexposure, but also they indicate that metals are the prime environmental candidates 
to modulate HD pathophysiology. 
 In chapter I, I discussed the discovery of a gene-environment interaction between 
mutant HTT and Mn. Specifically, expression of mutant HTT decreased net Mn 
accumulation in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cell line 
model of HD. The decreased net Mn uptake in the mutant STHdh(Q111/Q111) cell was 
confirmed using the high-throughput Mn detection assay, CFMEA that was discussed in 
chapter II39. Moreover, the decreased Mn accumulation correlated with diminished 
vulnerability to Mn induced cytoxicity16,17.  
 In chapter III, I demonstrated discrete modes of Mn transport kinetics in the 
neuronal HD striatal cells. Specifically, I showed that expression of mutant HTT impairs 
instantaneous Mn uptake kinetics and cellular Mn storage properties, yet has no 
significant effect on Mn efflux dynamics following similar intracellular Mn levels 
between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells (Figure III. 4.B.). 
Moreover, we have previously reported that the Fe transport system is insufficient to 
explain the mutant HTT resistance and decreased Mn accumulation in the HD striatal 
cells16. Recognizing the promiscuous modes of Mn transport across and within cells, 
decreased instantaneous Mn uptake, diminished cellular Mn storage, and the availability 
of CFMEA, we sought to systematically dissect and examine known and putative Mn 
transporter system functions in Mn transport and identify their contribution to the mutant 
Mn accumulation deficit. In addition, we examined the functional relationship between 
the accumulated cellular Mn pools and oxidative injury in the HD striatal cells. 
	   138 
Materials and Methods 
Chemicals, reagents, and cell culture supplies 
Neuronal striatal cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, and 
Sigma, St. Louis, MO), L-glutamine, 400µg/ml G418 and Penicillin-Streptomycin was 
obtained from Mediatech (Manassas, VA). Dispase (catalog # 17105), 10% heat-
inactivated hoarse serum (catalog # 26050), and CM-H2DCFDA (catalog # C6827) were 
obtained from Invitrogen, Carlsbad, CA. Cadmium (II) chloride heptahydrate (CdCl2 . 
7H2O), manganese (II) chloride heptahydrate (MnCl2 . 7H2O), magnesium (II) chloride 
tetrahydrate (MnCl2 . 4H2O), calcium (II) chloride dihydrate (CaCl2 . 2H2O), and 
strontium (II) chloride hexahydrate (SrCl2 . 6H2O) were from Alfa Aesar (Ward Hill, 
MA). Ultra-pure fura-2 salt (cell-impermeable fura-2, catalog # ENZ-52007), 
rosiglitazone (Roz) [catalog # ALX-350-125], and GW9662 (catalog # BML-GR234) 
were obtained from ENZO Biochem (New York, NY). 2-Aminoethoxydiphenyl borate 
(2-APB) [catalog # 42810] and ruthenium red (RuR) [catalog # R2751] were obtained 
from Sigma, St. Louis, MO. 30% hydrogen peroxide (H2O2) [catalog # H323-500] was 
obtained from Thermo Fisher Scientific Inc, Hanover Park, IL. Ferristatin/ NSC306711 
and NSC75600 were generous gift from the Developmental Therapeutics Program 
NCI/NIH, Bethesda, MD. The HEPES salt buffer consisted of 25mM HEPES, 140mM 
NaCl, 5.4mM KCl, and 5mM D-glucose, pH 7.4 (Sigma). The Krebs-Ringers (KR) buffer 
consisted of 135mM NaCl, 5mM KCl, 0.4mM KH2PO4, 1.8mM CaCl2, 1mM MgSO4, 
20mM HEPES, and 5.5mM D-glucose, pH 7.4 (Sigma). 1X ultra-pure phosphate-
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buffered saline (PBS), pH 7.4, without calcium and magnesium was used for post Mn 
exposure washes. Triton X-100 was obtained (catalog # 17105) from Sigma. 
Deoxyribonucleic acid sodium salt from salmon testes (Catalog # D1626) was obtained 
from Sigma (St. Louis, MO). Quant-iT™ PicoGreen dsDNA Reagent (Catalog # P7589) 
was obtained from Molecular Probes (Carlsbad, CA). 1x TE buffer used for the dilution 
of PicoGreen reagent was composed of 1 M Tris-HCl (pH 7.5) and 0.5 M EDTA (pH 8.0) 
prepared with DNase-free water and pH adjusted to 7.5. 1X Tris-buffered saline and 
Tween 20 (TBST) comprised of 50 mM Tris, 150 mM NaCl and 0.05% Tween, pH 7.6. 
The 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) salt (catalog # 
6494) and dimethyl sulfoxide (DMSO) (catalog # 472301) were obtained from Sigma. 
Sorenson’s buffer consisted of 0.1 M glycine, 0.1 M NaCl, pH=10.5. 
 
Cell culture 
Neuronal HD striatal cells 
HD striatal cell lines were cultured as previously described17,40-42. In brief, wild-
type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells were plated in a 96 well plate at 
either 10,000 or 20,000 cells per well depending on the experiment and allowed to grow 
at 33°C in a 95% air/5% CO2 incubator overnight. MnCl2 exposure buffer was prepared 
in media or HEPES salt exposure buffer immediately before exposure.  
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Primary rat cortical astrocyte cultures 
Astrocytic cultures from rat cerebral cortices of newborn (1-day-old) Sprague–
Dawley rats were established as previously described43. Briefly, rat pups were sacrificed 
and the cerebral cortices removed. The meninges were carefully removed and the 
cerebral cortices digested with bacterial neutral protease (dispase). Repeated removal of 
dissociated cells from cultured brain tissues enabled astrocyte recovery. To preserve the 
adhering astrocytes and eliminate the neurons and oligodendrocytes, the media was 
changed 24 hours after the initial plating in clear polysterne 24-well plates. The cultures 
were maintained at 37 °C in a 95% air/5% CO2 incubator for 3–4 weeks in minimal 
essential medium (MEM) with Earle's salts supplemented with 10% heat-inactivated 
horse serum, 100 U/ml penicillin and 100 µg/ml streptomycin. The media was changed 
twice per week.  
 
Mn-fura-2 saturation binding curve 
In vitro cell-free Mn-fura-2 standard curve was generated using a ten point Mn-
fura-2 curve with samples containing 1 µL of different 100X stock Mn standards (0 – 100 
mM) added to 99 µL of 0.5 µM fura-2 in PBS with 0.1% Triton X-100 (PTx) and assayed 
in a 96-well assay. A change in fura-2 fluorescence was measured at the Ca2+ isosbestic 
point of Ex360 and Em535 after 5 seconds orbital shake with a plate reader. The average 
raw fluorescence signal values (RFU) of the 0 µM Mn samples within each independent 
standard curve were defined as the 100% maximal fluorescence for that experiment after 
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background subtraction. RFU of each well were then normalized as percent maximal 
fluorescence (%MAX) to this value. A one-site specific saturation-binding curve with Hill 
slope could be fit to log10 Mn concentration (x-axis) and either %MAX (y-axis) or RFU (y-
axis) by non-linear regression analysis. To permit back calculations of extracted Mn 
levels from experimentally determined %MAX values, we used the trend line command in 
Microsoft Excel to fit power (Mn concentration = A•(%MAX)B) and logarithmic (Mn 
concentration = A•ln(%MAX)+B) equations to the standard curve data and calculated 
binding curve from non-linear regression analysis. Power curves were used for %MAX 
values less than 50% and logarithmic curves for values greater than 50%, on either side 
of the inflection point of the saturation-binding curve plotted with Mn concentration (x-
axis) and %MAX (y-axis).  
 
Assessment of Mn levels in cell-extracts  
Primary rat cortical astrocytes, wildtype STHdhQ7/Q7 and mutant STHdhQ111/Q111 
cells were cultured in clear polystyrene 96 well tissue plates and exposed to varying 
MnCl2 concentrations. After exposure, the media or exposure buffer was discarded and 
cells quickly washed three times with 200 µL PBS. The cells were extracted at 33°C for 1 
hour in 100 µL PTx with 0.5 µM fura-2. Changes in fura-2 fluorescence caused by Mn 
quenching were measured on a plate reader as described in the Mn-fura-2 standard curve 
section. Extracted Mn concentrations from cultured cells were calculated using the 
logarithmic and power Mn standard curve (generated in the Mn-fura-2 saturation binding 
curve section) with the %MAX of each sample. Experimental sample %MAX was 
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determined by normalizing the RFU of each Mn-exposed sample with the RFU of 
vehicle-only samples (untreated), which was defined as the experimental 100% maximal 
fluorescence signal. 
 
Generation of dsDNA standard curve 
The PicoGreen reagent was used to generate a dsDNA standard curve as 
previously described in chapter II. Briefly, a twelve point salmon testes dsDNA curve 
with samples containing 100 µL dsDNA standards (0 – 1000 µg/mL) prepared in 0.1% 
PTx added to 50 µL PicoGreen reagent diluted in 1x TE buffer (1:400). Changes in 
fluorescence were measured at Ex485 and Em535 with a plate reader. Average background 
fluorescence was subtracted from each of the dsDNA containing PicoGreen fluorescence 
in the standard curve. A linear regression analysis in Microsoft Excel was used to obtain 
a linear equation from the standard curve data.  
 
Normalization of cellular Mn levels to dsDNA 
After CFMEA analysis, 100 µL of cell-extract (astrocytes and the neuronal HD 
striatal cells) per well was added to 50 µL of 1:400 PicoGreen solution in 1x TE buffer 
added to each well. The fluorescence was measured as described in the PicoGreen 
dsDNA standard curve section. The concentration of dsDNA in each cell-extract was 
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calculated using the linear equation generated from the salmon DNA standard curve and 
normalized to Mn levels in the cell-extracts.   
 
Westerns blot analysis 
Wildtype STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells were equally plated at 
360,000 cells per 10cm2 plate, exposed with MnCl2 for 27 hours, and harvested by 
trypsinization. Cells were spun at 5,000 rpm for 5-10 minutes to pellet and lysed in RIPA 
buffer comprised of 50mM Tris, 1.0% Nonidet 40, 150mM NaCl2, 12mM deoxcholic 
acid, 0.1% SDS, 1x phosphatase inhibitor cocktails I and II (Sigma, St. Louis), and 1x 
protease inhibitor cocktail (Sigma, St. Louis). Lysed pellets were loaded by equal protein 
for SDS-PAGE analysis. Western blots were blocked with 5% milk prepared in TBST for 
3-4 hrs at room temperature and incubated with the primary antibodies, HIP14 (Sigma, 
St. Louis), and β-actin (Developmental Studies Hybridoma Bank, Iowa City, IA) in 5% 
milk in TBST at 1:2,000 and 1:100,000 dilutions respectively overnight at 4 °C. The 
peroxidase-conjugated secondary IgG mouse and IgG rabbit were obtained from Jackson 
Immunoresearch Laboratories (West Grove, PA) and diluted at 1:10,000 in 5% milk for 
incubation of the western blots at room temperature for 2 hrs. The Western blots were 
visualized with Supersignal West Dura Extended Duration Chemiluminescent Substrate 
(Thermo Scientific Pierce Waltham, MA) on an Ultralum Omega 12iC (Claremont, CA). 
ImageJ (NIH) was used to quantify the integrated density of protein bands and 
background correction computed using a signal ratio error model, as previously 
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described44. The quantified relative signals from the protein bands were normalized to 
untreated or vehicle-exposed wild-type sample for each set. 
 
Determination of cell viability in neuronal HD striatal cells 
Wildtype STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells were plated in a clear 
polystyrene 96 well plate at 5,000 cells per well the evening before exposure and allowed 
to grow and maintained at 33°C in a 95% air/5% CO2 incubator overnight. On the day of 
the experiment, striatal HD cells were exposed to freshly prepared MnCl2, CaCl2, MgCl2, 
and SrCl2 in media for 27 hrs at 33°C. Cell viability was assessed by MTT assay as 
previously described in the established protocol45 with subtle modifications. In brief, 
culture media was removed after exposure and 100 µL of 0.5% MTT salt prepared in 
MEM containing fetal bovine serum and penicillin–streptomycin was added to each well 
and incubated at 33°C in a 95% air/5% CO2 incubator for 3 hrs. The MTT reagent 
containing minimal essential medium was gently aspirated. 100 µL of freshly prepared 
Sorenson’s buffer in DMSO (Sorenson’s buffer diluted 1 mL into 10 mL of DMSO) was 
added to the 96 well plate containing cultured and exposed striatal HD cells to dissolve 
the precipitate. The plates were incubated at 33°C until all the MTT salt precipitate could 
no longer be visualized under a microscope. The absorbance in each well on the 96 well 
was read at 570 nm with a plate reader. To calculate cell survival, the absorbance 
readings obtained from the survival data were normalized by genotype to the control 
(vehicle-only exposed) included in each independent sample set. 
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Assessment of oxidative stress in cultured HD striatal cells 
Wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells were plated in a 96 well 
plate at 20,000 cells per well the evening before exposure and allowed to grow and 
maintained at 33°C in a 95% air/5% CO2 incubator overnight. The neuronal HD striatal 
cells were washed twice with 200 µL KR buffer to remove residual media followed by 
equal loading with 100 µL of 5 µM CM-H2DCFDA dye. After 30 minutes incubation in 
the dark, the cells were washed twice with 200 µL KR buffer. The baseline fluorescence 
was measured for both genotypes at excitation (Ex485) and emission (Em535) nm with a 
plate reader using top read and 33°C settings followed by removal of the KR-buffer. 
Cultured HD striatal cells were exposed to 100 µL HEPES salt buffer containing MnCl2, 
CdCl2, H2O2 for 5, 15, and 30 minutes in the plate reader set at 33°C. Changes in 
fluorescence was measured at an integration time of 200 ms at Ex485 and Em535 and 
compared to vehicle-only. Difference in DCF fluorescence (ΔF) after exposure was 
calculated as ([F(o)- F(i)]/F(i)), where F(i) is the initial fluorescence following Mn exposure 
and F(o) is the subsequent fluorescence read of the same well. The F(i) and F(o) from each 
well on the 96 well plate increases over the exposure duration.  
 
Statistical Analysis 
Univariate and repeated measures ANOVA tests were performed using SPSS 18 
software (IBM, Inc., Chicago, IL). Post hoc analysis and pairwise comparisons were 
done using Microsoft Excel (Microsoft, Redmond, WA) by Student's t-tests (two tailed) 
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or testing for nonoverlap of the 95% confidence interval for normalized ratios; error bars 
are expressed as standard error of the mean (SEM). Standard deviations (SDEVs) for the 
difference in net Mn levels were calculated by appropriate propagation of uncertainty 
calculations for subtraction of sample means, with significant differences between 
wildtype and mutant cells evaluated by non-overlap of the 95% confidence interval. 
 
Results 
Influence of temperature on net Mn transport in HTT striatal cells 
To investigate the effect of temperature on net Mn transport in the HTT striatal 
cells, we assessed changes in net Mn uptake levels in wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells following exposure to MnCl2 at 33°C (normal growth temperature) 
or 4°C (on ice) by CFMEA. The premise behind this experiment was that changes in 
temperature conditions would decrease the activity and function of the major Mn 
transport system(s), as well as decrease cellular ATP production. Moreover, if the major 
Mn transporter system that contribute to the decreased Mn uptake in mutant compared to 
wild-type HTT striatal cells was temperature-sensitive, then a decrease in the exposure-
temperature conditions (from 33°C to 4°C) would abolish the net Mn uptake difference 
between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells or substantially 
decrease net Mn uptake levels in both genotypes. After 1 hr exposure of HTT striatal 
cells to 100 and 250 µM MnCl2 in HEPES salt buffer at 33°C or 4°C (on ice), we 
observed an overall ~ 4 – 6 fold or 50 - 80% decrease in net Mn uptake in both genotypes 
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at 4°C and 33°C MnCl2 exposures (Figure IV. 1A. and 1.B.). Additionally, repeated 
measures ANOVA with two within subject factors (Mn concentration and temperature) 
and one between subject factor (genotype) showed a significant main effect of genotype, 
Mn concentration, and temperature on net Mn uptake in the HD striatal cells (Table IV. 
1.). Moreover, there was no two-way interaction between Mn concentration * genotype, 
temperature * genotype, or a three-way interaction between Mn concentration * 
temperature * genotype effects on net Mn accumulation in the HD striatal cells (Table 
IV. 1.). Importantly, we did not observe gross cytotoxicity of the HD striatal cells upon 
visual inspection following MnCl2 exposure at 33°C or 4°C (on ice). This data suggest 
that the major Mn transport system(s) responsible for decreased net Mn accumulation in 
the HD striatal cells functions in a temperature-dependent manner. Furthermore, wild-
type and mutant HD striatal cells respond similarly in their modes of Mn uptake and flux 
following changes in temperature conditions and possibly energy status (Figure IV. 1.A. 
and 1.B.). 
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Figure IV. 1. Temperature dependence of Mn accumulation in HD striatal cells. 
Wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells were exposed to 
100 µM and 250 µM MnCl2  in HEPES salt buffer at (A) 33°C or (B) 4°C (on ice) for 1 
hr. N= 4; 4 wells/exposure condition. Changes in Mn levels following Mn exposure were 
first normalized to vehicle and further normalized to dsDNA levels on a per well basis. 
(*) Indicates a significant effect of genotype on net Mn uptake (p<0.01, repeated 
measures ANOVA). Mean total Mn levels (±SEM) for (A) and (B) are plotted as 
indicated. 
 
 
Table IV. 1. Repeated measures ANOVA results for temperature-dependence of net 
Mn uptake and cellular storage in HD striatal cells (Figure IV. 1.). 
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Role of DMT1 in the Mn transport kinetics deficit observed in mutant HD striatal cells  
To examine the contribution of DMT1 in the Mn transport kinetics and cellular 
storage deficit observed in mutant HD striatal cells, we used the specific small molecule 
DMT1 inhibitor, ferristatin/NSC306711 to inhibit Mn uptake into cultured wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells. Although ferristatin/NSC306711 has 
been previously reported to exhibit specific, reversible, and competitive inhibition of iron 
uptake in a cell line that stably overexpresses DMT146, we further tested the specificity of 
NSC306711 on cultured primary rat cortical astrocytes that have been previously 
reported to facilitate Mn uptake primarily through DMT147-50. After 30 minutes pre-
incubation with 1 and 5 µM NSC306711, cultured astrocytes were co-exposed to 100 µM 
MnCl2 with or without NSC306711 in media for 6 hours. Additionally, repeated 
measures ANOVA showed a significant inhibition of Mn uptake (F(2, 4) = 49.11, p=0.002) 
in the primary astrocytes. Post hoc analysis by t-test found a significant concentration-
dependent NSC306711 inhibition (p<0.01) of DMT1-mediated Mn uptake in astrocytes 
(Figure IV. 2.A.). However, we observed no significant inhibition of Mn uptake in the 
neuronal wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells (Figure IV. 2.B.). 
Furthermore, a comparison of Mn accumulation levels between both genotypes by 
repeated measures ANOVA revealed a significant decrease in mutant STHdh(Q111/Q111) 
Mn accumulation (p<0.001) compared to wild-type STHdh(Q7/Q7) cells with or without the 
inhibitor. In addition, we observed similar effects with another small molecule DMT1 
inhibitor (NSC75600) on Mn uptake in the neuronal HD striatal cells and primary cortical 
astrocyte cultures (data not show). Although the tested concentrations of the inhibitor had 
no effect on Mn levels in the neuronal HD striatal cells, we noticed a trend towards an 
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increase in net Mn accumulation levels for both wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells. After comparison of the net accumulated Mn levels in the neuronal 
HD striatal cells and primary cortical astrocytes following 100 µM MnCl2 exposure, we 
observed a subtle but significant decrease (p < 0.05, t-test) in net Mn accumulation levels 
in primary astrocytes compared to wild-type STHdh(Q7/Q7) cells. Furthermore, we noticed 
a significant increase (p < 0.05, t-test) in net Mn accumulation levels in primary 
astrocytes compared to mutant STHdh(Q111/Q111) cells (Figure IV. 2.A. and 2.B.). These 
data suggest that DMT1 is not involved in the mutant Mn accumulation deficit and 
further supports our previously described equal DMT1 protein expression levels between 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells16. Furthermore, our data suggest 
that DMT1 is not responsible for a significant amount of Mn uptake in these HD striatal 
cells.   
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Figure IV. 2. The small molecule DMT-1 inhibitor (NSC306711) exhibits opposite 
effects on net Mn uptake and cellular storage between primary cortical astrocytes 
and neuronal HD striatal cells. (A) Cultured primary rat cortical astrocytes (gray) were 
plated in 96 well plates, pre-incubated for 30 mins and exposed to 100µM MnCl2 with or 
without the indicated concentrations of NSC306711 for 6 hours. N = 3; 12 
wells/exposure condition. (*) Indicates a significant effect of inhibitor on net Mn uptake 
levels (p<0.01, post hoc t-test). Mean total Mn levels (±SDEV) are plotted as indicated. 
(B) Wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells were pre-
incubated and exposed to 100µM MnCl2 with or without the indicated concentrations of 
NSC306711 for 6 hours. N = 3; 6 wells/exposure condition. Mean total Mn levels 
(±SEM) are plotted as indicated. Mn levels in (A) and (B) were normalized to dsDNA 
content on a per well basis. (*) Indicates a significant effect of genotype on net Mn 
uptake (p < 0.001, repeated measures ANOVA).  
 
Broad calcium channels, mPTP, and PPARγ modulators show minimal effect on Mn 
uptake and cellular storage properties in neuronal HD striatal cells 
Previous studies examining Mn-transporters in mammalian cells have 
demonstrated or suggested that Ca2+ channels such as voltage- and ligand-gated, store-
operated Ca2+ channels, and the mitochondrial Ca2+ uniporter contribute to cellular Mn 
uptake26,47,51-56. Furthermore, expression of mutant HTT induces altered Ca2+ homeostasis 
via modulation of calcium channels57-60. Based on the link between Ca2+-mediated Mn 
uptake and mutant HTT effects on Ca2+ channels, we reasoned that broad-based Ca2+ 
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channel blockers, 2-APB and RuR would exhibit a stronger inhibition of Mn uptake in 
wild-type STHdh(Q7/Q7) compared to mutant STHdh(Q111/Q111) cells if the hypothesis that 
decreased Ca2+ channel activity is the basis for the Mn accumulation deficit observed in 
mutant HD striatal cells. After 30 minutes pre-treatment of neuronal HD striatal cells 
with 2-APB and RuR and 6 hours MnCl2 exposure with or without the indicated Ca2+ 
channel blockers in media, we observed minimal effect of the inhibitors on Mn 
accumulation (Figure IV. 3.A. and 3.B.). In addition, the PPARγ pathway has been 
indicated to regulate mitochondrial function via modulation of mitochondrial membrane 
potential and reactive oxygen species (ROS) production29,30. Furthermore, the 
mitochondrial function in mutant STHdh(Q111/Q111) cells has also been reported to be 
impaired31,32,61-65. Thus, we hypothesized that expression of mutant HTT would impair 
the mitochondrial regulatory function of metal homeostasis via the PPARγ mediated 
pathway and/or mPTP. To test this hypothesis, we utilized a PPARγ agonist (Roz) and 
antagonist (GW9662), as well as mPTP antagonist (CsA) as previously described for 2-
APB and RuR and failed to observe an influence of either the PPARγ mediated pathway 
and mPTP on mutant Mn uptake and accumulation deficit (Figure IV.  3.C. and 3.D.). 
However, a comparison of Mn accumulation levels between genotypes by repeated 
measures ANOVA revealed a significant decrease in mutant STHdh(Q111/Q111) Mn 
accumulation (p<0.001) compared to wild-type STHdh(Q7/Q7) cells with or without the 
inhibitors. (Figure IV. 3.A. - 3.D.). These data suggest that 2-APB, RuR, CsA, Roz, and 
GW9962 blockable channels are not involved in the impaired Mn uptake and cellular 
storage phenotype observed in mutant STHdh(Q111/Q111) cells. 
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Figure IV. 3. Metal transporter modulators show minimal effect on Mn uptake and 
accumulation in neuronal HD striatal cells despite strong Mn uptake deficit in 
mutant cells. Cultured wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) 
cells were exposed to 100µM MnCl2 with or without (A) 10 µM 2-APB, (B) 1 µM RuR, 
(C) 2 µM CsA, and (D) 20 µM Roz and 40 µM GW9662 inhibitors for 6 hours. N = 3; 6 
wells/exposure condition. (*) Indicates a significant effect of genotype on net Mn uptake 
(p < 0.001, repeated measures ANOVA). Mean total Mn levels (±SEM) for (A), (B), (C), 
and (D) are plotted as indicated. 
 
Examination of the putative Mn transporter, HIP14, protein levels in HD striatal cells 
 Based on the minimal contribution of known Mn transporters, including DMT1, 
TfR, and others in the diminished mutant Mn uptake and cellular storage phenotype, we 
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sought to investigate the functions of other putative Mn transporter systems in the mutant 
Mn phenotype. Importantly, the HIP14 transporter mediates Mn and other divalent metal 
transport and is modulated by mutant HTT expression66,67. Based on the intriguing 
relationship between Mn affinity for the HIP14 transporter and the regulatory effects of 
mutant HTT on HIP14 function, we examined the protein expression levels of HIP14 in 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells following MnCl2 exposure. We 
found a significant main effect of genotype on HIP14 protein levels by ANOVA (Table 
IV. 2.). In addition, we demonstrate a significant decrease (approximately 40%) in basal 
mutant STHdh(Q111/Q111) HIP14 protein expression levels (p<0.05, t-test) compared to 
wild-type STHdh(Q7/Q7) cells. Finally, we observed a non-statistical trend towards down-
regulation of HIP14 protein levels in wild-type STHdh(Q7/Q7) cells following increasing 
exposure concentrations of MnCl2. (Figure IV. 4.A.). 
 
	   155 
 
Figure IV. 4. Mutant HD striatal cells exhibit significant decrease in HIP14 protein 
levels compared to wild-type. Wild-type STHdh(Q7/Q7) (blue) and mutant 
STHdh(Q111/Q111) (red) cell lysates were harvested after 27 hrs exposure to the indicated 
MnCl2  concentrations versus vehicle control and analyzed by western blot for HIP14 and 
β-actin. (A) Representative blots of each genotype-exposure group are shown. (B) 
Quantification of HIP14 protein levels in the HD striatal cells are represented as a bar 
graph. N = 3 sets per genotype per exposure groups. Mean levels (±SEM) are normalized 
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to β-actin as a percent of the untreated wild-type vehicle (N = 3). (*) Indicates significant 
differences in HIP14 expression levels between the wild-type and mutant cells (p < 
0.001, Univariate ANOVA) 
 
 
Table IV. 2. Repeated measures ANOVA results of HIP14 protein levels in striatal 
HD cells (Figure IV. 4.). 
 
HD striatal cells are resistant to Mg2+, Sr2+, and Ca2+ induced cytotoxicity 
We have previously excluded a role for the transferrin-mediated metal transporter 
pathway as a major transporter underlying the Mn accumulation deficit in mutant HD 
cells by using saturated Fe3+ levels to outcompete Mn uptake via the transferrin pathway 
in cultured HD striatal cells16. To further characterize the metal transporter/channel defect 
in mutant HD striatal cells, we utilized excess levels of the divalent metals, Mg2+, Sr2+, 
and Ca2+, which share similar transport systems with Mn2+66. Prior to investigation of the 
competitive effects of excess Mg2+, Sr2+, and Ca2+ on Mn transport, we examined the 
potential cytotoxic effects of the above divalent metals on the striatal HTT cells. The 
premise behind this experiment was to identify the optimal concentrations of Mg2+, Sr2+, 
and Ca2+ levels that when used in excess amounts would exhibit no toxicity, but 
outcompete Mn for its shared transporter with Mg2+, Sr2+, and Ca2+ in the HD striatal 
	   157 
cells. We exposed the HD striatal cells to 1 and 10 mM Mg2+, Sr2+, and Ca2+ based on the 
reported concentrations of the above divalent metal ions to influence other metal ion 
transport68-72. Following 27 hrs exposure of HD striatal cells to 1 and 10 mM Mg2+, Sr2+, 
and Ca2+, we observed no effect on cell viability between wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells (Figure IV. 5.). In addition, we observed no significant 
differences in cell survival for both genotypes when compared to vehicle-exposed (Figure 
IV. 5.). Importantly, we confirmed that wild-type HD striatal cells are significantly (p < 
0.001, repeated measures ANOVA) more susceptible to Mn-induced toxicity than 
mutants following 50 µM MnCl2 exposure and when compared to vehicle-exposed cells 
(Figure IV. 5.). This data indicates that the chosen concentrations of excess Mg2+, Sr2+, 
and Ca2+ do not exhibit cytotoxic effects and are optimal for its usage as divalent metal 
ion inhibitors and competitors of Mn uptake and cellular storage properties in the HD 
striatal cells.  
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Figure IV. 5. High levels of Ca2+, Mg2+, and Sr2+ are not toxic in HD striatal cells. 
Wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells were exposed to 
different concentrations of the indicated metal ions for 27 hrs in media. N = 3; 6 
wells/exposure condition. (*) Indicates a significant effect of genotype as well as Mn 
exposure on net Mn uptake (p < 0.001, repeated measures ANOVA). Mean total Mn 
levels of the 95% confidence interval are plotted as indicated. 
  
Excess Mg2+, Sr2+, and Ca2+ substantially inhibit Mn uptake and accumulation 
To further characterize the metal transporter/channel defect in mutant HD striatal 
cells, we utilized the non-toxic divalent metals, Mg2+, Sr2+, and Ca2+, which share similar 
transport systems with Mn2+66. We reasoned that if expression of mutant HTT impairs the 
function of a known or novel transporter/channel shared between Mg2+, Sr2+, Ca2+, and 
	   159 
Mn2+, then co-exposure of Mn and excess levels of Mg2+, Sr2+, or Ca2+ would outcompete 
Mn for its shared transporter. Thus, decreasing Mn uptake and accumulation in wild-type 
HTT expressing cells to similar levels found in mutant HTT expressing cells, as well as 
potentially decrease mutant Mn uptake and accumulation. After 1 hr co-exposure of wild-
type and mutant HTT cells to 100 µM MnCl2 with or without 1 and 10 mM MgCl2 in 
HEPES salt buffer, repeated-measures ANOVA showed a significant main effect of Mg2+ 
(F(2, 8) = 43.705, p<0.001) and genotype (F(1, 4) = 52.47, p <0.01), but not an genotype by 
Mg2+ interaction (F(2, 8) = 1.101, p<0.378) (Figure IV. 6.A. and Table IV. 3.A.). 
Nevertheless, we found similar inhibitory effects on net Mn uptake and cellular storage 
with excess Sr2+ and Ca2+ in wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells. In 
fact repeated measures ANOVA showed a significant main effect of Sr2+ (F(2, 8) = 103.1, 
p<0.001), genotype (F(1, 4) = 13.03, p <0.05), and an exposure by genotype interaction 
(F(2, 8) = 10.40, p<0.01) (Figure IV. 6.B. and Table IV. 3.B.) on Mn uptake and storage. In 
addition, we observed a main effect of Ca2+ (F(2, 8) = 101.6, p<0.001) and genotype by 
Ca2+ interaction (F(2, 8) = 19.66, p <0.01), but no genotype effect (F(1, 4) = 0.038, p = 
0.191) on Mn uptake and cellular storage (Figure IV. 6.C. and Table IV. 3.C.) by 
repeated measures ANOVA. Interestingly, we demonstrate that at least 1 mM Mg2+ and 
Sr2+ co-exposed with 100 µM MnCl2 is sufficient to occlude and diminish Mn uptake in 
wild-type STHdh(Q7/Q7) to similar levels observed in mutant STHdh(Q111/Q111) cells 
following 100µM MnCl2 exposure (Figure III. 6.A. and 6.B.). Nevertheless, we observed 
an approximately 4-fold inhibitory effect of 1mM Ca2+ and 100 µM MnCl2 on wild-type 
Mn uptake and storage, albeit no effect on mutant Mn uptake and cellular storage (Figure 
IV. 6.C.).  In fact, co-exposure of wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
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cells to 1mM Ca2+ and 100 µM MnCl2 completely abolished the observed Mn uptake and 
cellular storage differences between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
cells (Figure IV. 6.C.). In general, we show a substantial inhibition of Mn uptake and 
accumulation in wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells following 
exposure to Mn and excess, but non-toxic levels of  Mg2+, Sr2+, or Ca2+ ions. 
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Figure IV. 6. Excess Mg2+, Sr2+, and Ca2+ substantially inhibit Mn uptake and 
accumulation in neuronal HD striatal cells. Wild-type STHdh(Q7/Q7) (blue) and mutant 
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STHdh(Q111/Q111) (red) cells were cultured in a 96 well tissue culture plate and exposed to 
100 µM MnCl2 with  or without (A) 1 mM and 10mM MgCl2, (B) 1 mM and 10mM 
SrCl2 and (C) 1 mM and 10mM CaCl2 in HEPES salt buffer for 1 hr. Net Mn uptake and 
accumulation was assessed by CFMEA. Mean total Mn levels (±SEM) are plotted as 
indicated. N = 3; 6 wells/exposure condition. (*) Indicates a significant effect of the 
tested excess metal ion on net Mn uptake (p < 0.005, repeated measures ANOVA).  
 
 
Table IV. 3. Repeated measures ANOVA results of excess Mg2+, Sr2+, and Ca2+ ions 
effects on net Mn uptake and cellular storage in striatal HTT cells (Figure IV. 6.). 
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Functional relationship between differential Mn uptake, cellular Mn pools, and oxidative 
injury in neuronal HD striatal cells 
We have previously reported that expression of mutant HTT decreases Mn 
cytotoxicty compared to wild-type HD striatal cells over a wide range of 
concentrations17. Moreover, we have provided experimental evidence in chapter III for 
differential cellular Mn storage between wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells following Mn exposure (Figure III. 3.). To examine the functional 
relationship between cellular Mn pools and the temporal induction of oxidative stress that 
may underlie the differences in Mn-induced cytotoxicity in the HD striatal cells, we 
utilized the DCF assay to measure changes in ROS levels following MnCl2 exposure. 
Following equal loading of wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells with 
DCF and exposure to vehicle, MnCl2, CdCl2, and H2O2 for 5, 15, and 30 minutes, the 
mean vehicle-only ROS level for each genotype at the indicated exposure duration was 
compared to the MnCl2, CdCl2, and H2O2 induced ROS levels at the respective exposure 
durations. We observed a significant increase in ROS production (p<0.05; post hoc t-test) 
induced by MnCl2, CdCl2, and H2O2 above baseline levels at all the evaluated time points 
with the exception of wild-type H2O2 ROS levels at 30 minutes (Figure IV. 7.C.) After 5 
minutes MnCl2 exposure in HEPES salt buffer, repeated-measures ANOVA showed a 
significant main effect of Mn (F(1, 4) = 41.31, p<0.01), genotype (F(1, 4) = 12.49, p <0.05), 
and genotype by Mn interaction (F(1, 4) = 30.17, p<0.01) on ROS production (Figure IV. 
7.A and Table IV. 4.A.). In addition, we demonstrate a significant main effect of Mn (F(1, 
4) = 83.06, p<0.01), genotype (F(1, 4) = 119.4, p <0.001), and genotype by Mn interaction 
(F(1, 4) = 39.20, p<0.05) following 15 minutes exposure and by repeated measures 
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ANOVA (Figure IV. 7.B. and Table IV. 4.B.).  Moreover, 30 minutes MnCl2 exposure 
showed a main effect of Mn (F(1, 4) = 46.94, p<0.01), genotype (F(1, 4) = 121.2, p <0.001), 
and genotype by Mn interaction (F(1, 4) = 12.93, p<0.05); repeated measures ANOVA 
(Figure IV. 7.C. and Table IV. 4.C.). Conversely, we observed a time-dependent increase 
in vehicle-only/basal ROS levels (p<0.01, post hoc t-test) (Figure IV. 7.A. – 7.C.). 
Nevertheless, we noticed a time-dependent increase in mutant STHdh(Q111/Q111) to H2O2 
stimulated ROS generation (p<0.01) when compared to wild-type STHdh(Q7/Q7) cells 
(Figure IV. 7.A. – 7.C.).  Moreover, we did not observe a genotypic difference in CdCl2 
induced ROS production at 5, 15, or 30 minutes exposure. In addition, we noticed no 
difference in ROS levels between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
cells following exposure to CoCl2 for 5, 15, and 30 minutes (data not shown).  
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Figure IV. 7. Temporal- and concentration-dependent Mn uptake in HD striatal 
cells is functionally related to the cellular Mn pools that contribute to oxidative 
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stress. Wild-type STHdh(Q7/Q7) (blue) and mutant STHdh(Q111/Q111) (red) cells were 
cultured in a 96 well tissue culture plate, and equally loaded with DCF. Cells were 
exposed to MnCl2, CdCl2, and H2O2 in HEPES salt buffer for (A) 5, (B) 15, and (C) 30 
minutes. The effects of MnCl2, CdCl2, and H2O2 induced oxidative stress were assessed 
by DCF assay. Dashed horizontal line (---) represents baseline/vehicle-only ROS levels at 
each time point. N = 3; 6 wells/exposure condition. Mean ROS levels (±SDEV) are 
plotted as indicated.  
 
Table IV. 4. Repeated measures ANOVA results of functional relationship between 
differential cellular Mn pools and oxidative stress levels in striatal HTT cells (Figure 
IV. 7.).  Vehicle, MnCl2, CdCl2, and H2O2 exposures of striatal HTT cells for (A) 5 
minutes, (B) 15 minutes, and (C) 30 minutes. 
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Conclusions 
We systematically dissected and functionally examined the role of known and 
putative Mn transporters in the diminished Mn uptake and cellular storage deficits in 
mutant HD striatal cells. Our data strongly suggest that Mn transport dynamics in the HD 
striatal cells are temperature-dependent (Figure IV. 1.). Moreover, we have provided 
experimental evidence to suggest that the mutant STHdh(Q111/Q111) Mn transport kinetic 
deficits are independent of the known Mn transporters, including; DMT1, 2-APB, RuR, 
mPTP, Roz, and GW9662 blockable transporters/channels (Figure IV. 2 and 3). 
Nevertheless, we demonstrate that the putative Mn transporter, HIP14 is significantly 
decreased in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells. In 
addition, we show a significant reduction in basal HIP14 protein levels in mutant 
STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells (Figure IV. 4. and Table IV. 
2.). Moreover, excess non-toxic levels of Mg2+, Sr2+, and Ca2+ significantly impedes Mn 
uptake and cellular storage in the HD striatal cells (Figure IV. 5., 6.A. – 6.C., and Table 
IV. 3.). Importantly, we show that excess levels of at least 1 mM Sr2+ and Ca2+ are 
sufficient to abolish the phenotypic Mn uptake and cellular storage differences between 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells (Figure IV. 6.B. and 6.C.). 
Finally, we demonstrate that the time-dependent differences in Mn uptake and cellular 
storage properties discussed in chapter III as well as the differential vulnerability to Mn-
induced cytotoxicity between wild-type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells17 are 
functionally related to the cellular Mn pools that contribute to oxidative stress (Figure IV. 
7.A. – 7.C.).  
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Our data demonstrate the influence of temperature on net Mn transport dynamics 
(uptake, storage, and efflux) in the neuronal HD striatal cells and is in agreement with the 
previously reported temperature-dependence on Mn uptake and flux across the blood 
brain barrier73. Indeed, the overall ~ 4 – 6 fold or 50-80% decrease in net Mn uptake 
transport dynamics for both genotypes at 4°C and 33°C following 1 hr MnCl2 exposure 
(Figure IV. 1A. and 1.B.) provides further evidence that the Mn influx across the plasma 
membranes of HD striatal cells is not mediated by a simple diffusion transport process, 
but rather an active protein-mediated transport system. Importantly, it is highly unlikely 
that the temperature-dependent effect on Mn uptake and cellular storage in the HD 
striatal cells were mainly due to changes in the random movements of Mn2+ particles 
across the membrane due to modifications in the kinetic energy of our exposure system 
(Brownian motion) at 4°C. Indeed, the kinetic energy in our exposure system can be 
calculated using the following equation: E = (3 kT)/2, where E, K, and T are the kinetic 
energy, Boltzman constant, and temperature. If the temperature-dependent effects that we 
observed in the HD striatal cells were solely based on changes in the kinetic energy of 
Mn2+ particles in our system, we would have expected a ~15% decrease, rather than the 
50-80% diminished Mn transport dynamics. Furthermore, the similar effects of 
temperature on Mn uptake and cellular storage in both wild-type and mutant HD striatal 
cells suggest that the impaired major Mn transport system in mutant HD striatal cells is 
not a temperature-sensitive metal transporter. Although we did not directly investigate the 
energy-dependence on Mn transport in the HD striatal cells by using mitochondrial 
complex or ATP synthetase inhibitors, it is likely that changes in temperature conditions 
would decrease cellular ATP production in a Mn concentration- and genotype-dependent 
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manner in the HD striatal cells.  
We have previously demonstrated that DMT1 protein levels are unchanged16 as 
well as similar Cu2+, Co2+, Fe3+, Ni2+, Pb2+, and Zn2+ induced cytoxicity between wild-
type STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells17. In fact, the aforementioned metals 
are substrates for DMT1 with either lower or higher affinities than Mn (II)49. We 
examined and demonstrate that inhibition of DMT1 function with the small molecule 
inhibitor, NSC30671146, fail to impede the Mn uptake and cellular storage differences 
between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells (Figure IV. 2.B.). 
Moreover, we observed a non-significant trend towards an increase in Mn uptake in both 
genotypes following co-exposure with MnCl2 and NSC306711 (Figure IV. 2.B.). 
Conversely, we report that NSC306711 inhibits Mn uptake in a concentration-dependent 
manner in primary rat astrocyte cultures (Figure IV. 2.A.). In addition, we observed 
similar modulatory effects on net Mn uptake and cellular storage properties in the HD 
striatal cells and primary astrocytes using another small molecule DMT1 inhibitor, 
NSC75600 (data not shown). It is unlikely that the opposite effects of the DMT1 
inhibitors on Mn uptake and cellular storage in the neuronal HD striatal cells compared to 
primary astrocytes was due to cell-type specific inhibitory actions. The most likely 
explanation is that neurons and glial (astrocytes) may utilize different modes and Mn 
transporters/channels for Mn uptake. Interestingly, we demonstrated a subtle but 
significant decrease in net Mn accumulation levels in primary astrocytes compared to 
wild-type neuronal HD striatal cells (Figure IV. 2.A. and 2.B.). Although the difference 
in Mn accumulation levels between neuronal HD striatal cells and glial (astrocytes) was 
assessed at a single Mn concentration and exposure time-point, it is possible that in vivo 
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glial cells (astrocytes) might be regulating the amount of Mn that accumulates in neurons 
by sequestering Mn as a neuroprotective mechanism. Thus, this may explain the 
previously reported increased Mn accumulation levels observed in astrocytes following 
Mn exposure71,72. In spite of the similar DMT1 protein expression levels in the neuronal 
HD striatal cells16, it is still unknown if the DMT1 expressed is functional. We find that 
mutant Mn uptake and cellular storage deficits are independent of 2-APB and RuR 
blockable channels such as store-operated calcium channel and the Ca2+ uniporter (Figure 
IV. 2.A. and 2.B.). Furthermore, we report that the altered Mn uptake and cellular storage 
difference between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells is likely not 
due to deranged regulation of Mn homeostasis via the PPARγ pathway or the mPTP  
(Figure IV. 2.C. and 2.D.). 
Emerging experimental evidence has elucidated the role of novel candidate metal 
transporters, such as HIP14, HIP14L proteins, and others in mediating Mn2+ and other 
divalent metals (Mg2+, Sr2+, and others) transport66,67. Here we report that HIP14 protein 
levels is significantly decreased in mutant STHdh(Q111/Q111) cells compared to wild-type 
STHdh(Q7/Q7) (Figure IV. 5.A. and 5.B and Table IV. 2.). In addition we show that the 
basal HIP14 protein levels in mutant STHdh(Q111/Q111) is significantly diminished 
compared to wild-type STHdh(Q7/Q7) cells (Figure IV. 5.A., 5.B., and Table IV. 2.). 
Moreover, we observed a non-statistical trend towards down regulation of HIP14 protein 
expression levels in response to increasing MnCl2 exposure (Figure IV. 5.A. and 5.B). 
Interestingly, previous experimental evidence has demonstrated reduced interaction 
between mutant HTT and HIP14 proteins and significant inhibition of the HIP14 
transporter function by excess Ca2+ levels66. Thus, we examined the cytotoxic effects and 
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influence of excess levels of the two highest affinity cations (Mg2+, Sr2+) for the HIP14 
transporter and the specific HIP14 cation inhibitor (Ca2+) on Mn uptake and storage. We 
demonstrate that excess levels of Mg2+, Sr2+, and Ca2+ are not toxic to the HD striatal 
cells (Figure IV. 5.) and significantly inhibit Mn uptake (Figure IV. 6 and Table IV. 3.). 
Importantly we show that excess levels (1 and 10 mM) of Mg2+, Sr2+, and Ca2+ do not 
induce cytotoxicity in the HD striatal cells (Figure IV. 4.). Moreover, the Mn uptake and 
cellular storage differences between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
cells is completely eliminated with either 10 mM Mg2+, 1mM Sr2+ or 1mMCa2+ (Figure 
IV. 6.A – 6.C and Table IV. 3.). Furthermore, we demonstrate that the magnitude of 
excess Ca2+ inhibition of Mn uptake in wild-type cells is substantially greater than that of 
mutant cells. Our findings from the HIP14 protein expression and the influence of excess 
metals on Mn uptake and cellular storage suggest that the major Mn transporter 
underlying decreased Mn uptake and cellular storage in mutant HD striatal cells is a 
shared transporter between Mn2+, Mg2+, Sr2+, and Ca2+. Finally, the metal transporter(s) 
involved in the mutant Mn uptake and cellular storage properties are efficiently blockable 
by excess Mg2+, Sr2+, and Ca2+ and possess higher affinity for Mg2+, Sr2+, and Ca2+ 
compared to Mn2+. Given the structural and cation selectivity similarities between HIP14 
and HIP14L and reduced interaction between mutant HTT and HIP14 proteins66, it is 
possible that the mutant STHdh(Q111/Q111) Mn uptake and cellular storage deficit may be 
due to mutant HTT induced impairment in HIP14 and/or HIP14L transporter function.  
Williams and colleagues have previously demonstrated that when the cellular Mn 
uptake levels are the same between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
cells, the degree of Mn induced toxicity is matched16. However, the relationship between 
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cellular Mn pools and the differential Mn induced cytotoxicity between wild-type 
STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells is still unknown. Furthermore, there is 
evidence to support and suggest that metal ions can induce the generation of ROS 
through the Fenton-Harber Weiss reactions to cause cell death74,75. We demonstrate that 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells significantly generate ROS 
levels in a time-dependent manner and above baseline levels following exposure to 
MnCl2 and H2O2 (Figure IV. 7.A. – 7.C.). We observed a concentration- and time-
dependent decrease in Mn stimulated ROS generation in mutant STHdh(Q111/Q111) 
compared to wild-type cells using the DCF assay (Figure IV. 7.A. - 7.C. and Table IV. 
4.). In addition, we have previously demonstrated a concentration- and time-dependent 
decrease in mutant Mn uptake kinetics and cellular Mn storage compared to wild-type 
STHdh(Q7/Q7) cells (Figure III. 3.A. and 3.B.). Interestingly, MacDonald and colleagues 
utilized a chemiluminescent H2O2 detection kit to monitor intracellular H2O2 
concentrations as a read-out of ROS production in the same HD striatal cells and reported 
a significant reduction in mutant STHdhQ111/Q111 ROS levels compared to wild-type 
STHdh(Q7/Q7) cells9. However, we observed the opposite effect at 5, 15, and 30 minutes 
exposure to H2O2 (Figure IV. 7.A. - 7.C.). This difference may possibly be due to the 
specificity and detection limits of the assays been used for ROS assessment. Specifically, 
the DCF assay is a fluorometric assay that does not discriminate between the types of free 
radicals generated in the cell to cause changes in ROS levels. However, the 
cheluminescent assay is a luminescent assay that specifically measures intracellular H2O2 
concentration as a direct correlation of intracellular ROS levels. In spite of the time-
dependent increase in H2O2 stimulated ROS production in wild-type cells at 5,15, and 30 
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minutes, we did not observe a significant increase in ROS levels above baseline at 30 
minutes (Figure IV.  7.C.). This may be due to maximal ROS production in the wild-type 
STHdh(Q7/Q7) cells and unlikely due to saturation of free intracellular DCF molecules for 
free radical binding. Moreover, mutant STHdhQ111/Q111 cells that were equally loaded with 
DCF dye exhibited increased ROS levels above baseline after 30 minutes exposure to 
H2O2.   Finally, this data suggest that the differential- and temporal-dependent Mn uptake, 
and net cellular Mn pools between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) 
cells may be functionally related to the rate of oxidative injury induction. This 
phenomenon may underlie the differential vulnerability of Mn-induced cytoxicity 
between wild-type and mutant HD striatal cells. It is noteworthy that the functional 
relationship between cellular Mn pools and oxidative injury demonstrated in the HD 
striatal cells might not be the primary mechanism underlying striatal specific 
degeneration of medium spiny neurons in HD patients. In fact, it is highly likely that a 
combination of diminished cellular Mn levels, impaired Mn-dependent and other 
antioxidant activities, altered mitochondrial function, oxidative injury, diminished ATP 
levels, decreased neuroprotective roles of glial cells, protein aggregation, and 
upregulation of cell death mechanisms might underlie the in vivo mutant HTT expressing 
striatal-specific degeneration. 
 
 
 
 
	   174 
References 
1.	   Bates,	  G.P.	  History	  of	  genetic	  disease:	  the	  molecular	  genetics	  of	  Huntington	  disease	  -­‐	  a	  history.	  Nat	  Rev	  Genet	  6,	  766-­‐73	  (2005).	  
2.	   Walker,	  F.O.	  Huntington's	  disease.	  Lancet	  369,	  218-­‐28	  (2007).	  
3.	   Group,	  H.s.D.C.R.	  A	  novel	  gene	  containing	  a	  trinucleotide	  repeats	  that	  is	  expanded	  and	  unstable	  on	  Huntington’s	  disease	  chromosomes.	  Cell	  72,	  971-­‐983	  (1993).	  
4.	   Cowan,	  C.M.	  &	  Raymond,	  L.A.	  Selective	  neuronal	  degeneration	  in	  Huntington's	  disease.	  Curr	  Top	  Dev	  Biol	  75,	  25-­‐71	  (2006).	  
5.	   Borrell-­‐Pages,	  M.,	  Zala,	  D.,	  Humbert,	  S.	  &	  Saudou,	  F.	  Huntington's	  disease:	  from	  huntingtin	  function	  and	  dysfunction	  to	  therapeutic	  strategies.	  Cell	  Mol	  
Life	  Sci	  63,	  2642-­‐60	  (2006).	  
6.	   Dexter,	  D.T.,	  Carayon,	  A.,	  Javoy-­‐Agid,	  F.,	  Agid,	  Y.,	  Wells,	  F.R.,	  Daniel,	  S.E.,	  Lees,	  A.J.,	  Jenner,	  P.	  &	  Marsden,	  C.D.	  Alterations	  in	  the	  levels	  of	  iron,	  ferritin	  and	  other	  trace	  metals	  in	  Parkinson's	  disease	  and	  other	  neurodegenerative	  diseases	  affecting	  the	  basal	  ganglia.	  Brain	  114	  (	  Pt	  4),	  1953-­‐75	  (1991).	  
7.	   Dexter,	  D.T.,	  Jenner,	  P.,	  Schapira,	  A.H.	  &	  Marsden,	  C.D.	  Alterations	  in	  levels	  of	  iron,	  ferritin,	  and	  other	  trace	  metals	  in	  neurodegenerative	  diseases	  affecting	  the	  basal	  ganglia.	  The	  Royal	  Kings	  and	  Queens	  Parkinson's	  Disease	  Research	  Group.	  Ann	  Neurol	  32	  Suppl,	  S94-­‐100	  (1992).	  
8.	   Lumsden,	  A.L.,	  Henshall,	  T.L.,	  Dayan,	  S.,	  Lardelli,	  M.T.	  &	  Richards,	  R.I.	  Huntingtin-­‐deficient	  zebrafish	  exhibit	  defects	  in	  iron	  utilization	  and	  development.	  Hum	  Mol	  Genet	  16,	  1905-­‐20	  (2007).	  
9.	   Lee,	  J.M.,	  Ivanova,	  E.V.,	  Seong,	  I.S.,	  Cashorali,	  T.,	  Kohane,	  I.,	  Gusella,	  J.F.	  &	  MacDonald,	  M.E.	  Unbiased	  gene	  expression	  analysis	  implicates	  the	  huntingtin	  polyglutamine	  tract	  in	  extra-­‐mitochondrial	  energy	  metabolism.	  PLoS	  Genet	  3,	  e135	  (2007).	  
	   175 
10.	   Gómez-­‐Esteban,	  J.C.,	  Lezcano,	  E.,	  Zarranz,	  J.J.,	  Velasco,	  F.,	  Garamendi,	  I.,	  Pérez,	  T.	  &	  Tijero	  ,	  B.	  Monozygotic	  twins	  suffering	  from	  Huntington's	  disease	  show	  different	  cognitive	  and	  behavioural	  symptoms.	  European	  Neurology	  57,	  26-­‐30	  (2007).	  
11.	   Georgiou,	  N.,	  Bradshaw,	  J.L.,	  Chiu,	  E.,	  Tudor,	  A.,	  O'Gorman,	  L.	  &	  Phillips,	  J.G.	  Differential	  clinical	  and	  motor	  control	  function	  in	  a	  pair	  of	  monozygotic	  twins	  with	  Huntington's	  disease.	  Mov	  Disord	  14,	  320-­‐5	  (1999).	  
12.	   Friedman,	  J.H.,	  Trieschmann,	  M.E.,	  Myers,	  R.H.	  &	  Fernandez,	  H.H.	  Monozygotic	  twins	  discordant	  for	  Huntington	  disease	  after	  7	  years.	  Arch	  
Neurol	  62,	  995-­‐7	  (2005).	  
13.	   Anca,	  M.H.,	  Gazit,	  E.,	  Loewenthal,	  R.,	  Ostrovsky,	  O.,	  Frydman,	  M.	  &	  Giladi,	  N.	  Different	  phenotypic	  expression	  in	  monozygotic	  twins	  with	  Huntington	  disease.	  Am	  J	  Med	  Genet	  A	  124A,	  89-­‐91	  (2004).	  
14.	   Garcia,	  M.,	  Vanhoutte,	  P.,	  Pages,	  C.,	  Besson,	  M.J.,	  Brouillet,	  E.	  &	  Caboche,	  J.	  The	  mitochondrial	  toxin	  3-­‐nitropropionic	  acid	  induces	  striatal	  neurodegeneration	  via	  a	  c-­‐Jun	  N-­‐terminal	  kinase/c-­‐Jun	  module.	  J	  Neurosci	  
22,	  2174-­‐84	  (2002).	  
15.	   van	  Dellen,	  A.,	  Grote,	  H.E.	  &	  Hannan,	  A.J.	  Gene-­‐environment	  interactions,	  neuronal	  dysfunction	  and	  pathological	  plasticity	  in	  Huntington's	  disease.	  Clin	  
Exp	  Pharmacol	  Physiol	  32,	  1007-­‐19	  (2005).	  
16.	   Williams,	  B.B.,	  Kwakye,	  G.F.,	  Wegrzynowicz,	  M.,	  Li,	  D.,	  Aschner,	  M.,	  Erikson,	  K.M.	  &	  Bowman,	  A.B.	  Altered	  manganese	  homeostasis	  and	  manganese	  toxicity	  in	  a	  Huntington's	  disease	  striatal	  cell	  model	  are	  not	  explained	  by	  defects	  in	  the	  iron	  transport	  system.	  Toxicol	  Sci	  117,	  169-­‐79	  (2010).	  
17.	   Williams,	  B.B.,	  Li,	  D.,	  Wegrzynowicz,	  M.,	  Vadodaria,	  B.K.,	  Anderson,	  J.G.,	  Kwakye,	  G.F.,	  Aschner,	  M.,	  Erikson,	  K.M.	  &	  Bowman,	  A.B.	  Disease-­‐toxicant	  screen	  reveals	  a	  neuroprotective	  interaction	  between	  Huntington's	  disease	  and	  manganese	  exposure.	  J	  Neurochem	  112,	  227-­‐37	  (2010).	  
18.	   Mena,	  I.,	  Honuchi,	  K.	  &	  Lopez,	  G.	  Factors	  enhancing	  entrance	  of	  manganese	  into	  brain	  iron	  deficiency	  and	  age.	  J.	  Nucl	  Med	  15(1974).	  
	   176 
19.	   Aschner,	  M.	  &	  Aschner,	  J.L.	  Manganese	  neurotoxicity:	  cellular	  effects	  and	  blood-­‐brain	  barrier	  transport.	  Neurosci	  Biobehav	  Rev	  15,	  333-­‐40	  (1991).	  
20.	   Rabin,	  O.,	  Hegedus,	  L.,	  Bourre,	  J.M.	  &	  Smith,	  Q.R.	  Rapid	  brain	  uptake	  of	  manganese(II)	  across	  the	  blood-­‐brain	  barrier.	  J	  Neurochem	  61,	  509-­‐17	  (1993).	  
21.	   Murphy,	  V.A.,	  Wadhwani,	  K.C.,	  Smith,	  Q.R.	  &	  Rapoport,	  S.I.	  Saturable	  transport	  of	  manganese(II)	  across	  the	  rat	  blood-­‐brain	  barrier.	  J	  Neurochem	  57,	  948-­‐54	  (1991).	  
22.	   Aschner,	  M.	  &	  Gannon,	  M.	  Manganese	  (Mn)	  transport	  across	  the	  rat	  blood-­‐brain	  barrier:	  saturable	  and	  transferrin-­‐dependent	  transport	  mechanisms.	  
Brain	  Res	  Bull	  33,	  345-­‐9	  (1994).	  
23.	   Gunter,	  T.E.	  &	  Puskin,	  J.S.	  Manganous	  ion	  as	  a	  spin	  label	  in	  studies	  of	  mitochondrial	  uptake	  of	  manganese.	  Biophys	  J.	  ,	  625-­‐35	  (1972).	  
24.	   Liccione,	  J.J.	  &	  Maines,	  M.D.	  Selective	  vulnerability	  of	  glutathione	  metabolism	  and	  cellular	  defense	  mechanisms	  in	  rat	  striatum	  to	  manganese.	  J	  Pharmacol	  
Exp	  Ther	  247,	  156-­‐61	  (1988).	  
25.	   Kalia,	  K.,	  Jiang,	  W.	  &	  Zheng,	  W.	  Manganese	  accumulates	  primarily	  in	  nuclei	  of	  cultured	  brain	  cells.	  Neurotoxicology	  29,	  466-­‐70	  (2008).	  
26.	   Gavin,	  C.E.,	  Gunter,	  K.K.	  &	  Gunter,	  T.E.	  Manganese	  and	  calcium	  transport	  in	  mitochondria:	  implications	  for	  manganese	  toxicity.	  Neurotoxicology	  20,	  445-­‐53	  (1999).	  
27.	   Zwingmann,	  C.,	  Leibfritz,	  D.	  &	  Hazell,	  A.S.	  Energy	  metabolism	  in	  astrocytes	  and	  neurons	  treated	  with	  manganese:	  relation	  among	  cell-­‐specific	  energy	  failure,	  glucose	  metabolism,	  and	  intercellular	  trafficking	  using	  multinuclear	  NMR-­‐spectroscopic	  analysis.	  J	  Cereb	  Blood	  Flow	  Metab	  23,	  756-­‐71	  (2003).	  
28.	   Archibald,	  F.S.	  &	  Tyree,	  C.	  Manganese	  poisoning	  and	  the	  attack	  of	  trivalent	  manganese	  upon	  catecholamines.	  Arch	  Biochem	  Biophys	  256,	  638-­‐50	  (1987).	  
29.	   Gunter,	  T.E.,	  Miller,	  L.M.,	  Gavin,	  C.E.,	  Eliseev,	  R.,	  Salter,	  J.,	  Buntinas,	  L.,	  Alexandrov,	  A.,	  Hammond,	  S.	  &	  Gunter,	  K.K.	  Determination	  of	  the	  oxidation	  
	   177 
states	  of	  manganese	  in	  brain,	  liver,	  and	  heart	  mitochondria.	  J	  Neurochem	  88,	  266-­‐80	  (2004).	  
30.	   Gunter,	  K.K.,	  Aschner,	  M.,	  Miller,	  L.M.,	  Eliseev,	  R.,	  Salter,	  J.,	  Anderson,	  K.	  &	  Gunter,	  T.E.	  Determining	  the	  oxidation	  states	  of	  manganese	  in	  NT2	  cells	  and	  cultured	  astrocytes.	  Neurobiol	  Aging	  27,	  1816-­‐26	  (2006).	  
31.	   Quintanilla,	  R.A.,	  Jin,	  Y.N.,	  Fuenzalida,	  K.,	  Bronfman,	  M.	  &	  Johnson,	  G.V.	  Rosiglitazone	  treatment	  prevents	  mitochondrial	  dysfunction	  in	  mutant	  huntingtin-­‐expressing	  cells:	  possible	  role	  of	  peroxisome	  proliferator-­‐activated	  receptor-­‐gamma	  (PPARgamma)	  in	  the	  pathogenesis	  of	  Huntington	  disease.	  J	  Biol	  Chem	  283,	  25628-­‐37	  (2008).	  
32.	   Glass,	  C.K.	  &	  Ogawa,	  S.	  Combinatorial	  roles	  of	  nuclear	  receptors	  in	  inflammation	  and	  immunity.	  Nat	  Rev	  Immunol	  6,	  44-­‐55	  (2006).	  
33.	   Aschner,	  M.,	  Guilarte,	  T.R.,	  Schneider,	  J.S.	  &	  Zheng,	  W.	  Manganese:	  recent	  advances	  in	  understanding	  its	  transport	  and	  neurotoxicity.	  Toxicol	  Appl	  
Pharmacol	  221,	  131-­‐47	  (2007).	  
34.	   Fox,	  J.H.,	  Kama,	  J.A.,	  Lieberman,	  G.,	  Chopra,	  R.,	  Dorsey,	  K.,	  Chopra,	  V.,	  Volitakis,	  I.,	  Cherny,	  R.A.,	  Bush,	  A.I.	  &	  Hersch,	  S.	  Mechanisms	  of	  copper	  ion	  mediated	  Huntington's	  disease	  progression.	  PLoS	  One	  2,	  e334	  (2007).	  
35.	   Molina-­‐Holgado,	  F.,	  Hider,	  R.C.,	  Gaeta,	  A.,	  Williams,	  R.	  &	  Francis,	  P.	  Metals	  ions	  and	  neurodegeneration.	  Biometals	  20,	  639-­‐54	  (2007).	  
36.	   Wright,	  R.O.	  &	  Baccarelli,	  A.	  Metals	  and	  neurotoxicology.	  J	  Nutr	  137,	  2809-­‐13	  (2007).	  
37.	   Choi,	  C.J.,	  Anantharam,	  V.,	  Martin,	  D.P.,	  Nicholson,	  E.M.,	  Richt,	  J.A.,	  Kanthasamy,	  A.	  &	  Kanthasamy,	  A.G.	  Manganese	  upregulates	  cellular	  prion	  protein	  and	  contributes	  to	  altered	  stabilization	  and	  proteolysis:	  relevance	  to	  role	  of	  metals	  in	  pathogenesis	  of	  prion	  disease.	  Toxicol	  Sci	  115,	  535-­‐46	  (2010).	  
38.	   Firdaus,	  W.J.,	  Wyttenbach,	  A.,	  Giuliano,	  P.,	  Kretz-­‐Remy,	  C.,	  Currie,	  R.W.	  &	  Arrigo,	  A.P.	  Huntingtin	  inclusion	  bodies	  are	  iron-­‐dependent	  centers	  of	  oxidative	  events.	  FEBS	  J	  273,	  5428-­‐41	  (2006).	  
	   178 
39.	   Kwakye,	  G.F.,	  Li,	  D.	  &	  Bowman,	  A.B.B.	  Novel	  high-­‐throughput	  assay	  to	  assess	  cellular	  manganese	  levels	  in	  a	  striatal	  cell	  line	  model	  of	  Huntington’s	  disease	  confirms	  a	  deficit	  in	  manganese	  accumulation.	  Neurotoxicology	  (2011).	  
40.	   Cattaneo,	  E.	  &	  Conti,	  L.	  Generation	  and	  characterization	  of	  embryonic	  striatal	  conditionally	  immortalized	  ST14A	  cells.	  J	  Neurosci	  Res	  53,	  223-­‐34	  (1998).	  
41.	   Milakovic,	  T.	  &	  Johnson,	  G.V.	  Mitochondrial	  respiration	  and	  ATP	  production	  are	  significantly	  impaired	  in	  striatal	  cells	  expressing	  mutant	  huntingtin.	  J	  Biol	  
Chem	  280,	  30773-­‐82	  (2005).	  
42.	   Trettel,	  F.,	  Rigamonti,	  D.,	  Hilditch-­‐Maguire,	  P.,	  Wheeler,	  V.C.,	  Sharp,	  A.H.,	  Persichetti,	  F.,	  Cattaneo,	  E.	  &	  MacDonald,	  M.E.	  Dominant	  phenotypes	  produced	  by	  the	  HD	  mutation	  in	  STHdh(Q111)	  striatal	  cells.	  Hum	  Mol	  Genet	  
9,	  2799-­‐809	  (2000).	  
43.	   Aschner,	  M.,	  Mullaney,	  K.J.,	  Wagoner,	  D.,	  Lash,	  L.H.	  &	  Kimelberg,	  H.K.	  Intracellular	  glutathione	  (GSH)	  levels	  modulate	  mercuric	  chloride	  (MC)-­‐	  and	  methylmercuric	  chloride	  (MeHgCl)-­‐induced	  amino	  acid	  release	  from	  neonatal	  rat	  primary	  astrocytes	  cultures.	  Brain	  Res	  664,	  133-­‐40	  (1994).	  
44.	   Kreutz,	  C.,	  Bartolome	  Rodriguez,	  M.M.,	  Maiwald,	  T.,	  Seidl,	  M.,	  Blum,	  H.E.,	  Mohr,	  L.	  &	  Timmer,	  J.	  An	  error	  model	  for	  protein	  quantification.	  
Bioinformatics	  23,	  2747-­‐53	  (2007).	  
45.	   Ehrich,	  M.	  &	  Sharova,	  L.	  In	  vitro	  methods	  for	  detecting	  cyto-­‐toxcity.	  Curr.	  
Protoc.	  Toxicol.	  3,	  6.2.11-­‐6.2.12	  (2000).	  
46.	   Buckett,	  P.D.	  &	  Wessling-­‐Resnick,	  M.	  Small	  molecule	  inhibitors	  of	  divalent	  metal	  transporter-­‐1.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol	  296,	  G798-­‐804	  (2009).	  
47.	   Au,	  C.,	  Benedetto,	  A.	  &	  Aschner,	  M.	  Manganese	  transport	  in	  eukaryotes:	  the	  role	  of	  DMT1.	  Neurotoxicology	  29,	  569-­‐76	  (2008).	  
48.	   Erikson,	  K.M.	  &	  Aschner,	  M.	  Increased	  manganese	  uptake	  by	  primary	  astrocyte	  cultures	  with	  altered	  iron	  status	  is	  mediated	  primarily	  by	  divalent	  metal	  transporter.	  Neurotoxicology	  27,	  125-­‐30	  (2006).	  
	   179 
49.	   Gunshin,	  H.,	  Mackenzie,	  B.,	  Berger,	  U.V.,	  Gunshin,	  Y.,	  Romero,	  M.F.,	  Boron,	  W.F.,	  Nussberger,	  S.,	  Gollan,	  J.L.	  &	  Hediger,	  M.A.	  Cloning	  and	  characterization	  of	  a	  mammalian	  proton-­‐coupled	  metal-­‐ion	  transporter.	  Nature	  388,	  482-­‐8	  (1997).	  
50.	   Bowman,	  A.B.,	  Erikson,	  K.M.	  &	  Aschner,	  M.	  Manganese	  -­‐	  The	  two	  faces	  of	  essentiality	  and	  neurotoxicity.	  in	  Metals	  and	  Neurodegeneration	  (ed.	  Huang,	  S.)	  (Research	  Signpost,	  Kerala,	  India,	  2010).	  
51.	   Shibuya,	  I.	  &	  Douglas,	  W.W.	  Calcium	  channels	  in	  rat	  melanotrophs	  are	  permeable	  to	  manganese,	  cobalt,	  cadmium,	  and	  lanthanum,	  but	  not	  to	  nickel:	  evidence	  provided	  by	  fluorescence	  changes	  in	  fura-­‐2-­‐loaded	  cells.	  
Endocrinology	  131,	  1936-­‐41	  (1992).	  
52.	   Heilig,	  E.A.,	  Thompson,	  K.J.,	  Molina,	  R.M.,	  Ivanov,	  A.R.,	  Brain,	  J.D.	  &	  Wessling-­‐Resnick,	  M.	  Manganese	  and	  iron	  transport	  across	  pulmonary	  epithelium.	  Am	  J	  
Physiol	  Lung	  Cell	  Mol	  Physiol	  290,	  L1247-­‐59	  (2006).	  
53.	   Riccio,	  A.,	  Mattei,	  C.,	  Kelsell,	  R.E.,	  Medhurst,	  A.D.,	  Calver,	  A.R.,	  Randall,	  A.D.,	  Davis,	  J.B.,	  Benham,	  C.D.	  &	  Pangalos,	  M.N.	  Cloning	  and	  functional	  expression	  of	  human	  short	  TRP7,	  a	  candidate	  protein	  for	  store-­‐operated	  Ca2+	  influx.	  J	  
Biol	  Chem	  277,	  12302-­‐9	  (2002).	  
54.	   Gavin,	  C.E.,	  Gunter,	  K.K.	  &	  Gunter,	  T.E.	  Manganese	  and	  calcium	  efflux	  kinetics	  in	  brain	  mitochondria.	  Relevance	  to	  manganese	  toxicity.	  Biochem	  J	  266,	  329-­‐34	  (1990).	  
55.	   Kazuhiko,	  N.,	  Kawasaki,	  F.	  &	  Kita,	  H.	  Mn	  and	  Mg	  influxes	  through	  Ca	  channels	  of	  motor	  nerve	  terminals	  are	  prevented	  by	  verapamil	  in	  frogs.	  Brain	  Research	  
510,	  289-­‐295	  (1990).	  
56.	   Fukuda,	  J.	  &	  Kawa,	  K.	  Permeation	  of	  manganese,	  cadmium,	  zinc,	  and	  beryllium	  through	  calcium	  channels	  of	  an	  insect	  muscle	  membrane.	  Science	  
190,	  309-­‐311	  (1977).	  
57.	   Bezprozvanny,	  I.	  Inositol	  1,4,5-­‐tripshosphate	  receptor,	  calcium	  signalling	  and	  Huntington's	  disease.	  Subcell	  Biochem	  45,	  323-­‐35	  (2007).	  
	   180 
58.	   Williams,	  A.,	  Sarkar,	  S.,	  Cuddon,	  P.,	  Ttofi,	  E.K.,	  Saiki,	  S.,	  Siddiqi,	  F.H.,	  Jahreiss,	  L.,	  Fleming,	  A.,	  Pask,	  D.,	  Goldsmith,	  P.,	  O'Kane,	  C.J.,	  Floto,	  R.A.	  &	  Rubinsztein,	  D.C.	  Novel	  targets	  for	  Huntington's	  disease	  in	  an	  mTOR-­‐independent	  autophagy	  pathway.	  Nat	  Chem	  Biol	  4,	  295-­‐305	  (2008).	  
59.	   Tang,	  T.S.,	  Tu,	  H.,	  Chan,	  E.Y.,	  Maximov,	  A.,	  Wang,	  Z.,	  Wellington,	  C.L.,	  Hayden,	  M.R.	  &	  Bezprozvanny,	  I.	  Huntingtin	  and	  huntingtin-­‐associated	  protein	  1	  influence	  neuronal	  calcium	  signaling	  mediated	  by	  inositol-­‐(1,4,5)	  triphosphate	  receptor	  type	  1.	  Neuron	  39,	  227-­‐39	  (2003).	  
60.	   Panov,	  A.V.,	  Gutekunst,	  C.A.,	  Leavitt,	  B.R.,	  Hayden,	  M.R.,	  Burke,	  J.R.,	  Strittmatter,	  W.J.	  &	  Greenamyre,	  J.T.	  Early	  mitochondrial	  calcium	  defects	  in	  Huntington's	  disease	  are	  a	  direct	  effect	  of	  polyglutamines.	  Nat	  Neurosci	  5,	  731-­‐6	  (2002).	  
61.	   Mazziotta,	  J.C.,	  Phelps,	  M.E.,	  Pahl,	  J.J.,	  Huang,	  S.C.,	  Baxter,	  L.R.,	  Riege,	  W.H.,	  Hoffman,	  J.M.,	  Kuhl,	  D.E.,	  Lanto,	  A.B.,	  Wapenski,	  J.A.	  &	  et	  al.	  Reduced	  cerebral	  glucose	  metabolism	  in	  asymptomatic	  subjects	  at	  risk	  for	  Huntington's	  disease.	  N	  Engl	  J	  Med	  316,	  357-­‐62	  (1987).	  
62.	   Coles,	  C.J.,	  Edmondson,	  D.E.	  &	  Singer,	  T.P.	  Inactivation	  of	  succinate	  dehydrogenase	  by	  3-­‐nitropropionate.	  J	  Biol	  Chem	  254,	  5161-­‐7	  (1979).	  
63.	   Beal,	  M.F.	  Huntington's	  disease,	  energy,	  and	  excitotoxicity.	  Neurobiol	  Aging	  
15,	  275-­‐6	  (1994).	  
64.	   Lesort,	  M.,	  Tucholski,	  J.,	  Zhang,	  J.	  &	  Johnson,	  G.V.	  Impaired	  mitochondrial	  function	  results	  in	  increased	  tissue	  transglutaminase	  activity	  in	  situ.	  J	  
Neurochem	  75,	  1951-­‐61	  (2000).	  
65.	   Alston,	  T.A.,	  Mela,	  L.	  &	  Bright,	  H.J.	  3-­‐Nitropropionate,	  the	  toxic	  substance	  of	  Indigofera,	  is	  a	  suicide	  inactivator	  of	  succinate	  dehydrogenase.	  Proc	  Natl	  
Acad	  Sci	  U	  S	  A	  74,	  3767-­‐71	  (1977).	  
66.	   Goytain,	  A.,	  Hines,	  R.M.	  &	  Quamme,	  G.A.	  Huntingtin-­‐interacting	  proteins,	  HIP14	  and	  HIP14L,	  mediate	  dual	  functions,	  palmitoyl	  acyltransferase	  and	  Mg2+	  transport.	  J	  Biol	  Chem	  283,	  33365-­‐74	  (2008).	  
	   181 
67.	   Gitler,	  A.D.,	  Chesi,	  A.,	  Geddie,	  M.L.,	  Strathearn,	  K.E.,	  Hamamichi,	  S.,	  Hill,	  K.J.,	  Caldwell,	  K.A.,	  Caldwell,	  G.A.,	  Cooper,	  A.A.,	  Rochet,	  J.C.	  &	  Lindquist,	  S.	  Alpha-­‐synuclein	  is	  part	  of	  a	  diverse	  and	  highly	  conserved	  interaction	  network	  that	  includes	  PARK9	  and	  manganese	  toxicity.	  Nat	  Genet	  41,	  308-­‐15	  (2009).	  
68.	   Bond,	  G.H.	  &	  Hudgins,	  P.M.	  Inhibition	  of	  human	  red	  cell	  Nak-­‐ATPase	  by	  magnesium	  and	  potassium.	  Biochem	  Biophys	  Res	  Commun	  66,	  645-­‐50	  (1975).	  
69.	   Plishker,	  G.A.	  Effects	  of	  cadmium	  and	  zinc	  on	  calcium	  uptake	  in	  human	  red	  blood	  cells.	  Am	  J	  Physiol	  247,	  C143-­‐9	  (1984).	  
70.	   Shawki,	  A.	  &	  Mackenzie,	  B.	  Interaction	  of	  calcium	  with	  the	  human	  divalent	  metal-­‐ion	  transporter-­‐1.	  Biochem	  Biophys	  Res	  Commun	  393,	  471-­‐5	  (2010).	  
71.	   Wedler,	  F.C.,	  Ley,	  B.W.	  &	  Grippo,	  A.A.	  Manganese(II)	  dynamics	  and	  distribution	  in	  glial	  cells	  cultured	  from	  chick	  cerebral	  cortex.	  Neurochem	  Res	  
14,	  1129-­‐35	  (1989).	  
72.	   Aschner,	  M.,	  Gannon,	  M.	  &	  Kimelberg,	  H.K.	  Manganese	  uptake	  and	  efflux	  in	  cultured	  rat	  astrocytes.	  J	  Neurochem	  58,	  730-­‐5	  (1992).	  
73.	   Fitsanakis,	  V.A.,	  Piccola,	  G.,	  Aschner,	  J.L.	  &	  Aschner,	  M.	  Characteristics	  of	  manganese	  (Mn)	  transport	  in	  rat	  brain	  endothelial	  (RBE4)	  cells,	  an	  in	  vitro	  model	  of	  the	  blood-­‐brain	  barrier.	  Neurotoxicology	  27,	  60-­‐70	  (2006).	  
74.	   Milatovic,	  D.,	  Yin,	  Z.,	  Gupta,	  R.C.,	  Sidoryk,	  M.,	  Albrecht,	  J.,	  Aschner,	  J.L.	  &	  Aschner,	  M.	  Manganese	  induces	  oxidative	  impairment	  in	  cultured	  rat	  astrocytes.	  Toxicol	  Sci	  98,	  198-­‐205	  (2007).	  
75.	   Zhang,	  P.,	  Hatter,	  A.	  &	  Liu,	  B.	  Manganese	  chloride	  stimulates	  rat	  microglia	  to	  release	  hydrogen	  peroxide.	  Toxicol	  Lett	  173,	  88-­‐100	  (2007).	  	  
 
  
182 
CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
Discussion 
 The novel findings of these studies include (1) development, optimization, and 
validation of a high-throughput assay, CFMEA, to measure Mn levels and transport 
dynamics in cultured HD striatal cells, (2) development of an efficient quantitative 
normalization assay, PicoGreen assay, to measure dsDNA levels in cultured cells post 
CFMEA analyses, (3) functional characterization and identification of the impaired Mn 
transport kinetics (uptake, cellular storage, and efflux) in mutant HD striatal cells, (4) 
dissection of metal transporter systems and identification of a putative Mn transporter 
that may underlie the disrupted Mn homeostasis in mutant HD striatal cells, and (5) 
determination of the relationship between Mn uptake, cellular Mn pools, Mn induced 
cytotoxicity, and oxidative stress in wild-type and mutant HD striatal cells. 
 
Development of CFMEA and PicoGreen assays 
 In our quest to develop CFMEA, we optimized the essential assay conditions and 
parameters required for efficient and accurate detection of the detergent-extracted cellular 
Mn levels in cultured cells. Contrary to the previous reports of a temperature–dependent 
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subcellular localization of fura-2 in cells loaded with fura-2 AM and measured at F340/380 
ratio1-3, we report minimal influence of temperature on Mn-fura-2 interaction at the Ca2+ 
isosbestic wavelength, excitation at 360 nm (Ex360) in a cell-free system (Figure II. 1.B.). 
The disparity between our findings and that of the single-cell loaded fura-2 studies may 
be due to the following: (i) diminished activity of intracellular esterases to cleave the AM 
portion of the fura-2 dye at lower temperatures and not necessarily a direct influence of 
temperature on the Ca2+-fura-2 interaction; (ii) temperature-dependent sequestration of 
fura-2 dye into organelles4,5 that would decrease the availability of free cytosolic fura-2 
dye to be detected; (iii) differences in the excitation wavelengths used to measure the 
temperature-dependent effects on fura-2 fluorescence, for example: Ex360 versus Ex340/380 
nm. In fact, measurements of intracellular Ca2+ levels using Ex340/380 nm excitation ratio 
has been suggested to decrease the variability induced by differences in cellular fura-2 
loading, disparities in the thickness of cells, and potential dye leakage during detection of 
intracellular Ca2+ concentrations in cells1,4. Based on the photochemical properties of 
fura-2 and changes in membrane potential, it is likely that the temperature-dependent 
changes previously reported in the fura-2 loaded cells might be due in part by (a) 
photodegradation or bleaching of fura-2 dye that may be interpreted as temperature-
induced decrease in fura-2 fluorescence or (b) rupturing of membranes and efficient fura-
2 dye leakage into the extracellular milieu. 
Given the unique quenching relationship between fura-2 concentration, Mn 
detection limits, and the expected cellular Mn levels in cultured cells following MnCl2 
exposure, it was crucial for us to examine the optimal fura-2 concentration required for 
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the precise and accurate detection limits of extracted cellular Mn levels in the cells. This 
was achieved by (a) estimation of the maximum Mn concentration that could possibly be 
present in the cultured cells or animal tissues following MnCl2 exposure for the preferred 
duration and (b) generation of Mn-fura-2 standard curves that spanned the expected 
cellular Mn concentration, which enabled efficient back calculation of extracted Mn 
levels in cells or tissues following MnCl2 exposure. Although the recommended Mn 
detection window by fura-2 is applicable to any generated Mn-fura-2 standard curves, the 
experimenter may modify the recommended detection window (10% - 85%). However, it 
is important that the newly defined Mn detection window obtained by extrapolating the 
minimum and maximum %MAX values on the Mn-fura-2 standard curve fit within the 
optimal detection range of the sigmoidal Mn-fura-2 standard curve. Importantly, it is 
critical to ensure that the number of cultured cells used in the experiment is above the 
minimum number of cells (~ 5,000 cells per well in a 96 tissue culture plate, empirically 
determined by us) required for Mn detection by CFMEA. The quantitative relationship 
between Mn and fura-2 fits with a Michaelis-Menten one-site specific saturation-binding 
kinetics6. However, to enable efficient back calculation of Mn concentrations from 
changes in fura-2 fluorescence, it is necessary to switch the axes of the Mn-standard 
curve and represent %MAX fura-2 values and Mn concentration on the x and y-axes, 
respectively. The binding curve data obtained when the axes are switched tightly fit to 
exponential and logarithmic curves generated using Microsoft excel non-linear regression 
analysis. Thus, enabling a direct back calculation of extracted Mn levels from 
experimentally determined %MAX values. Conversely, other curves (polynomial, linear, 
etc) may also be used to model the mathematical relationship between Mn and fura-2 
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depending on the range of Mn concentrations used to generate the Mn-fura-2 standard 
curve. In fact, it is necessary to generate Mn-fura-2 standard curve alongside Mn-
exposure experiments to accurately quantify extracted cellular Mn levels using the same 
fura-2 containing extraction buffer. This will decrease any experimental variability 
caused by changes in the concentration or volume of fura-2 added during the preparation 
of the extraction buffer. Interestingly, low Mn concentration samples (1 – 100 nM) used 
to generate Mn-fura-2 standard curves between independent experiments demonstrated 
moderate variability (Figure II. 3.A.). This might be due to low sensitivity of the plate 
reader at those concentrations. This variability can be minimized by averaging the RFU 
values of the 0 µM Mn samples within each independent standard curve and defining this 
value as the 100% maximal fluorescence for that experiment. In addition, normalization 
of the RFU values of each well as %MAX to the 100% maximal fluorescence value for 
representation on the Mn-fura-2 standard curve decreases experimental variability. 
We have shown that the ideal detergent concentration for Mn extraction from the 
cultured HD striatal cell is 0.1% Triton X-100 (Figure II. 1C.). Furthermore, we have 
demonstrated that detergent is required for the detection of fura-2 quenching by CFMEA, 
suggesting that extracellular Mn is not a significant component of the Mn detected by 
CFMEA. However, we observed minimal influence of Triton X-100 on baseline fura-2 
fluorescence relative to SDS. In addition, the unexpected biphasic increase in fura-2 RFU 
of both baseline control and cell extracts from 0 to 1% SDS may possibly be due to an 
interaction between SDS and fura-2. Interestingly, previous experimental evidence has 
suggested that SDS can exist either as monomers or micellar aggregates in aqueous 
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solutions depending on the total concentration, ionic strength, and temperature. 
Moreover, increasing total concentration of SDS at a given ionic strength impedes the 
ability to measure increases in monomer concentration above the critical micelle 
concentration7. The lack of a concentration-response relationship observed in SDS might 
be due to alteration in the critical micelle concentration used for Mn extraction in the 
cultured HD striatal cells (Figure II. 1.B). The cellular Mn extraction conditions that we 
have demonstrated are ideal for many cultured cells including primary cultured astrocytes 
(Figure IV. 1.A.). However, if the experimenter chooses to optimize the extraction 
conditions for the cultured cells used for cellular Mn uptake and transport kinetic studies 
due to known physical, chemical, or other interferences with the described cellular Mn 
extraction conditions, it is important to consider the critical micelle concentration of the 
chosen detergent concentration. For example higher concentrations of Triton X-100 and 
SDS (>1%) impedes efficient cellular Mn extraction from the cultured cells8.  
 The quenching effect of metal ions other than Mn2+ on fura-2 and the ability of 
Zn2+ to increase fura-2 fluorescence at the Ca2+ isosbestic wavelength, 360 nm (Figure II. 
4. and II. 5., Table II. 2.) that we identified may be caused by (i) similar or higher 
affinities of those metals for the fura-2 molecule, (ii) the bandwidth of filter [Ex360 
(bandwidth of filter = ± 35 nm)] overlapping with known wavelengths of fura-2 that are 
influenced by other metal ions, or (iii) molecular crowding theory of metal ions on fura-2 
molecules. Endogenous heavy metal ions are known to influence fura-2 fluorescence 
(increase or decrease) in single cell loaded fura-2 AM at Ex340/380 excitation ratio9-15. 
Although theoretically metal ions are not supposed to have any effect on fura-2 
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fluorescence at the Ca2+ isosbestic wavelength, we observed that Fe2+, Co2+, Ni2+, Cu2+, 
and Cd2+ quenched while Zn2+ increased the fura-2 fluorescence in an in vitro cell-free 
assay. Zn2+ binds to fura-2 molecule with a high affinity (Kd = 1.5 nM)16 and induce 
similar but increased shifts in the isosbestic excitation wavelength to 376 nm10. This may 
explain why we observed ~20% maximum increase with 100 µM Zn2+ in our studies. Our 
findings of other metal ions, excluding Mn, to quench fura-2 fluorescence at the Ca2+ 
isosbestic wavelength support the previously reported effects of heavy metal ions 
including, Mn2+, Fe2+, and Cu2+ to quench fura-2 fluorescence over a wide excitation 
wavelengths (300 – 400 nm) range including the Ca2+ isosbestic wavelength (360 nm) in 
single cell loaded fura-2 AM10. However, Snitsarev and colleagues did not examine the 
contribution of Ni2+, Co2+, and Cd2+ on fura-2 fluorescence at 360 nm. This may be due 
to their low abundance or affinity for fura-2 in cells. Our data identify the influence of 
other metal ions on fura-2 fluorescence at 360 nm. Secondly, we used an excitation filter 
of 360 nm with a bandwidth of ± 35 nm that overlaps with the excitation wavelengths 
(340 and 380 nm) of fura-2, which can be potentially influenced by metal ions. Thirdly, 
molecular crowding is thought to occur when metal ions cluster around metal-bound 
fluorophores, such as fura-2, and occlude the fluorescence to cause decrease in 
fluorescence. We have observed an unexpected fura-2 quenching effect (~10%) with Ca2+ 
concentrations above 10 µM regardless of the concentration of Mn present in the assay. It 
is possible that the competitive quenching effect of Ca2+ may be due to changes in the 
fura-2 and Mn binding stoichiometry that would induce molecular crowding of fura-2 by 
Ca2+ ions and decreases its fluorescence. In addition, we have demonstrated a 
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concentration-dependent decrease in the relationship between Ca2+ bound fura-2 at the 
isosbestic wavelength (Figure II. 5.A.). 
Not only do Co2+ and Cu2+ quench fura-2 fluorescence in a concentration-
dependent manner, but also they competitively interfere with Mn-fura-2 interaction at 
concentrations above 1 µM (Figure II. 5.C. and data not shown). Interestingly, other 
metal ions (for, example Zn2+ that mimics Ca2+ binding to the fura-2 molecule) have been 
reported to compete with Ca2+ for binding to fura-2 and decrease the affinity of fura-2 for 
Ca2+ binding in single cell loaded fura-2 AM at F340/380 excitation ratio10. Chelation of 
Zn2+ abolishes the competitive effect of Zn2+ on the Ca2+-fura-2 interaction and enhances 
Ca2+ induced amplitude changes in fura-2 fluorescence10. This suggests the need to 
control for endogenous metal ions from cell-extracts used in CFMEA analysis. Due to 
that fact that a metal chelator capable of chelating all other metal ions with the exception 
of Mn is currently not available, we extract Mn from cultured cells in a large volume of 
fura-2 detergent-based extraction buffer (100 µL) and this substantially reduces the 
concentration of endogenous metal ions that may competitively influence Mn-fura-2 
interaction. In addition, we normalize extracted cellular Mn levels from MnCl2 exposed 
cells to vehicle-only before further normalization of extracted cellular Mn levels to 
dsDNA on a per well basis using PicoGreen assay. Thus, accounting for possible changes 
in basal metal ion influence on the accuracy and specificity of CFMEA to measure Mn 
levels. 
Given that other metal ions influenced fura-2 fluorescence at the Ca2+ isosbestic 
wavelength, we were cognizant about their effects on the accuracy and specificity of Mn 
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detection by CFMEA. We have validated the accuracy and specificity of CFMEA by two 
alternative Mn supplementation assays (Figure II. 6.A. and 6.B.) and the gold standard 
technique for detecting Mn levels, GFAAS (Figure II. 7.). Importantly, we showed that 
both CFMEA and GFAAS were capable of detecting comparable changes in net Mn 
levels in cultured HD striatal cells and exhibited similar Mn detection sensitivities at the 
tested concentrations. In addition, our findings from the Mn supplementation tests 
indicate that CFMEA is proficient in accurately and specifically measuring Mn 
concentrations in both Mn spiked extracted cultured HD striatal cells and fura-2 
containing extraction buffer. In addition, CFMEA validation by GFAAS further suggests 
that the above-discussed metal ions’ influence on fura-2 fluorescence is substantially 
decreased under the optimized cellular Mn extraction conditions. Nevertheless, it is 
noteworthy that CFMEA may fail to provide accurate measurements of cellular Mn levels 
following exposure to mixtures of toxicants containing multiple fura-2 binding metals if 
levels reach concentrations high enough to influence fura-2 fluorescence. On the other 
hand, given the substantial affinity of Cu2+, Co2+, Ni2+, and Fe2+ for fura-2, it is likely that 
CFMEA could be adapted for studies examining the cellular uptake of these other metals.  
Due to insufficient protein levels to be detected by standard protein assays, we 
developed the PicoGreen assay (described in chapter II) to enable normalization of 
cellular Mn levels to dsDNA post CFMEA analyses. Although the emission spectra of 
fura-2 and PicoGreen overlapped, we observed no effect of fura-2 on PicoGreen 
fluorescence (data not shown). It is important that the solution is prepared in a plastic 
container instead of glass surfaces as this may cause absorption of the PicoGreen reagent. 
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Given that PicoGreen reagent is susceptible to photodegradation, the working solution 
must be covered in foil to protect from light or store in the dark. In addition, 96 well 
tissue culture plates containing cell-extracts and dsDNA standard curve must be protected 
from light. During the preparation of dsDNA standards for PicoGreen normalization 
assay, it is important that the components of the extraction buffer used to prepare the 
dsDNA standards and for extraction of cellular Mn cells are treated the same and contain 
similar levels of contaminants. Although the CFMEA and PicoGreen assays described in 
this thesis was used to measure and normalize cellular Mn uptake and transport kinetics 
in striatal cells and primary astrocyte cells cultured in 96 well plate format to dsDNA, the 
parameters of the assays can be modified to assess cellular Mn transport dynamics using 
different culture plate formats, cultured cell densities, and cell types. Specifically, to 
assess cellular Mn uptake and transport dynamics in larger cell densities, cultured cells 
can be plated on 12 or 48 wells tissue culture plates. This would enable the usage of 
standard protein detection methods to normalize extracted cellular Mn levels to protein 
levels instead of utilization of the PicoGreen dsDNA assay.  
The amount of time required to measure cellular Mn uptake and transport 
dynamics in cultured cells by CFMEA can be divided into five phases: (1) biological 
preparation, (2) transport incubations, (3) generation of Mn-fura-2 standard curve, (4) 
normalization, and (5) data analysis. The first phase requires significantly more time than 
the other four phases. The preparation of cultured cells, which includes trypsinization, 
cell counting, and plating in the 96 well tissue culture plates require ~ 10 - 15 minutes per 
96 well plate. If Mn uptake and transport dynamics are assessed in cells that grow in 
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suspension, this time would vary depending on the method being used to prepare the 
cells. The transport incubations typically require ~ 5 - 10 minutes preparation of working 
MnCl2 solutions from stocks. Cultured cells exposed to MnCl2 in HEPES salt exposure 
buffer or Krebs Ringers buffer require ~ 3 - 5 minutes per 96 well plate pre-wash two 
times with 200 µL of either of the indicated serum-free exposure buffers. In contrast to 
the duration necessary for the first phase and preparatory steps of the second phase, the 
actual Mn transport incubations are done in real time. The duration required for metal 
transport incubation could be as early as 5 minutes and dependent on the type of cultured 
cells, experimental design, exposure buffer, and concentration of MnCl2 used for 
exposure. Furthermore, generation of a cell-free Mn-fura-2 standard curve necessitates ~ 
5 minutes per experiment. It takes ~ 2 minutes per 96 well plate per assay to measure 
changes in fura-2 fluorescence in the fluorometric plate reader. The PicoGreen assay 
requires ~ 5 minutes to load a 96 well plate with DNA standards and ~ 5 minutes 
incubation of standards with PicoGreen reagent. In addition, an ~ 2 - 4 minutes per 96 
well tissue culture plate is required to transfer cell extracts into a new 96 well plate before 
incubation with PicoGreen reagent for ~ 5 minutes and ~ 2 minutes per 96 well tissue 
culture plate to measure PicoGreen fluorescence with a fluorometric plate reader. The 
duration of the fifth phase is flexible and depends on practice, experimenter’s speed of 
data analysis and familiarity to Microsoft excel linear regression analysis. It typically 
takes ~ 5 - 7 minutes per 96 well plate for complete analysis of cellular Mn levels and 
normalization by DNA. Depending on the experimental set-up, duration and 
concentration of MnCl2, and familiarity with Microsoft Excel non-linear regression 
analysis, approximately ten to twenty 96-well plates can be assayed and scored in one 
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day. In comparison, GFAAS and other traditional Mn detection assays can take several 
days to weeks (personal communication) to analyze the same experimental samples. 
Finally, we report that CFMEA provides a high-throughput, feasible, accurate, and 
inexpensive assessment of cellular Mn levels in cultured cells. This assay provided a 
rapid means to evaluate Mn transport kinetics in cellular toxicity and disease models. 
 
Manganese transport dynamics in HD striatal cells 
We have found that expression of mutant HTT protein significantly reduces net 
Mn accumulation in a broad concentration-17 and time-dependent manner compared to 
wild-type STHdh(Q7/Q7) cells using CFMEA analysis (Figure III.1.A. and B.). The 
concentration-dependent decrease in mutant STHdh(Q111/Q111)  cells further supports the 
previously published decreased net Mn accumulation in mutant STHdh(Q111/Q111) cells 
compared to wild-type by GFAAS18. In addition, other studies using radiotracer 54Mn 
have demonstrated that Mn uptake and accumulation in glial cells (astrocytes) occurs in a 
concentration- and time-dependent manner. Moreover, cultured astrocytes not only 
proficiently transports Mn, but contain glutamine synthetase (an astrocyte specific 
manganoprotein) which accounts for ~ 80% of net Mn levels in the brain19-21. To the best 
of my knowledge, no studies have directly and simultaneously measured Mn 
accumulation levels in astrocytes versus neurons cultured from the same animal in the 
same or different brain tissue. The current evidence to support substantial Mn uptake in 
astrocytes were all conducted in primary astrocytic cultures. However, our current 
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findings showed a subtle but significant increase in net Mn accumulation in the neuronal 
wild-type HD striatal cells compared to the primary astrocytes following 100 µM MnCl2 
exposure in media for 6 hrs (Figure IV. 2.). The incongruities between our findings and 
the previously reported bulk astrocytic Mn accumulation following Mn exposure might 
be due to (a) differences in species – murine neuronal HD cells versus rat primary 
astrocytes, (b) brain-region specificity and affinity for Mn accumulation  – striatum 
versus cortex, and (c) immortalized HD cell line versus primary astrocytes. It is likely 
that under in vivo conditions, glial cells (astrocytes) might be regulating the amount of 
Mn that accumulates in neurons via the sequestration of Mn into intracellular 
compartments. However, in the absence of astrocytes, neurons lose their neuroprotective 
mechanism against Mn induced toxicity. Thus, resulting in excess Mn accumulation 
compared to astrocytes. In fact, we demonstrated that the decreased Mn accumulation in 
mutant HD striatal cells can be observed as early as 1 hr following 50 µM MnCl2 
exposure in HEPES salt buffer and media (Figure III. 2.A. and 2.B.). Interestingly, we 
found an increase in the magnitude of net Mn accumulation between wild-type 
STHdh(Q7/Q7) and mutant STHdh(111/Q111)   cells  exposed for 6 hrs compared to 27 hrs 
exposure (Figure III. 1.B.). The enhanced magnitude might possible be due to temporal 
activation of known and putative Mn transporters22. Nevertheless, other studies not 
directly assessing metals have demonstrated that dopamine transporters regulate effective 
concentrations of dopamine at the synaptic cleft in a time-dependent activation 
manner23,24. In essence, it is possible that during the first couple of hours following 
MnCl2 exposure, only the primary/major Mn transporters are activated to mediate Mn 
transport. However, by 27 hrs MnCl2 exposure, other secondary and tertiary Mn 
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transporter systems may also be activated to compensate for the significant decrease in 
mutant Mn uptake. It is possible that by 27 hrs MnCl2 exposure, wild-type STHdh(Q7/Q7) 
cells might be approaching their maximum cellular Mn storage capacity. Thus, activation 
of the secondary or tertiary Mn transporter may only be substantially beneficial in 
mediating the latent mutant STHdh(Q111/Q111)  Mn uptake and eventually decrease the fold 
difference in Mn accumulation when compared to wild-type STHdh(Q7/Q7) cells. It is 
unlikely that the decreased magnitude of net Mn accumulation between wild-type 
STHdh(Q7/Q7) and mutant STHdh(111/Q111)   cells  exposed for 27 hrs is due to the effects of 
cell debris following Mn accumulation and concomitant cell death on the accuracy of 
CFMEA and PicoGreen assays. This is mainly because cultured and exposed cells are 
efficiently washed three times with 200 µL PBS before cellular Mn extraction is 
performed by CFMEA and subsequent dsDNA using PicGreen normalization. Our data 
strongly argues for future assessment of Mn transport dynamics in media or other buffers 
at earlier time points. This would enable efficient characterization of Mn transport 
kinetics in the HD striatal cells. Moreover, the compensatory Mn transport system 
activation is unlikely directly regulated by mutant HTT expression, albeit it could 
potentially mask discrete Mn transport kinetics and transporter functions between wild-
type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111)  cells.  
We have combined both CFMEA and the traditional fura-2 loaded Mn-quenching 
assays to examine Mn transport kinetics in the HD striatal cells. The characterization of 
Mn2+ uptake and saturation in the HD striatal cells by measurements of instantaneous 
kinetics and time-dependency, as well as net cellular Mn storage in the cultured HD 
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striatal cells (Figure III. 3.A, 3.B., Table III. 1., and Table III. 2.) have further elucidated 
the transport dynamics in the HD striatal cells. Specifically, we have shown that 
expression of mutant HTT decreases the instantaneous and net Mn uptake kinetics as 
early as 2 minutes following MnCl2 exposure (Figure III. 3.A., Table III. 1., and Table 
III. 2.). In addition, our findings demonstrated that the maximum Mn uptake or saturation 
rate in the mutant STHdh(Q111/Q111) cells is observed between 15 and 30 minutes. 
Moreover, both wild-type and mutant HD striatal cells exhibit a similar initiation of Mn 
saturation time point (~15 minutes) (Figure III.3.A.). Importantly, we found significant 
differences (p<0.001) in the initial slope of Mn uptake kinetics between wild-type and 
mutant HTT striatal cells during the first 5 minutes following exposure to 100 and 250 
µM MnCl2 (Table III. 2.). The above findings from the uptake kinetics in the HD striatal 
cells strongly points to impaired Mn uptake in mutant STHdh(Q111/Q111) cells compared to 
wild-type STHdh(Q7/Q7). Moreover, we have demonstrated that mutant STHdh(Q111/Q111) 
cells have decreased Mn saturation rate or storage capacity compared to wild-type 
STHdh(Q7/Q7) following MnCl2 exposure (Figure III. 3.A. and Table III. 1.). Our findings 
are consistent with the previously reported time-dependence of Mn uptake and saturation 
kinetics using radiotracer 54Mn (II) in cultured primary astrocytes19,20,25,26. In fact, a 
recent study conducted in human intestinal Caco-2 cell line and Mn levels and transport 
kinetics measured by the atomic absorption spectrophotometer reported similar findings 
to what we observed in the HD striatal cells22. Specifically, the authors demonstrated a 
substantial time- and concentration-dependent increase in Mn uptake. In addition, they 
demonstrated a biphasic Mn transport kinetic; first slow phase that lasted for ~ 45 
minutes followed by a faster linear phase, which exhibited ~ 5-fold increase in Mn uptake 
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by 3.5 hrs compared to the slow phase following exposure with 100 µM MnCl2. 
Furthermore, they observed a preliminary lagged period or Mn saturation transport 
kinetics in the Caco-2 Mn exposed cells between 15 and 30 minutes22. All the above 
mentioned and discussed studies fit with our findings of Mn uptake and cellular Mn 
storage in the HD striatal cells. In addition, the faster linear phase Mn transport reported 
by Leblondel and colleagues22 further supports our idea of a time-dependent activation of 
Mn transporters (Figure III. 1.B.). On the other hand, it was unclear whether the changes 
we observed in Mn uptake and cellular storage were mainly due to changes in cytosolic 
Mn as the loaded fura-2 dye may not be efficiently sequestered into organelles to detect 
Mn levels. Moreover, Tsien and colleagues have suggested a temperature-dependent 
sequestration of fura-2 into organelles4,5. Thus, our data demonstrates that the prevalent 
cellular Mn pool involved in the diminished cellular Mn storage in mutant HD striatal 
cells compared to wild-type encompasses both cytosolic and net organelle-accumulated 
Mn (Figure III. 3.B.).  
Despite the previous reports that Mn accumulates in brain organelles including 
mitochondria27,28, nucleus29, lysosomes30, and golgi31, it is still unknown how mutant 
HTT modulates Mn sequestration into the aforementioned organelles. However, recent 
studies have suggested that wild-type HTT is necessary for normal regulation of the 
transferrin receptor, crucial for iron homeostasis, recycling of endosomes, associates and 
regulates trafficking of nuclei and perinuclear membrane organelles (endoplasmic 
reticulum, golgi, mitochondria, and endosomes)32,33. Based on our findings of decreased 
instantaneous Mn uptake kinetics and cellular Mn storage in mutant HD striatal cells 
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compared to wild-type, the aforementioned relationship amongst wild-type HTT, metal 
homeostasis, and trafficking of organelles that accumulate Mn, it is possible that the 
mutant HTT protein may be functioning in the following ways to result in the decreased 
Mn uptake and cellular storage deficits; (a) protein level: mutant HTT may directly or 
indirectly associate with a primary/major Mn transporter on the plasma membrane or 
known Mn accumulation organelle(s) and down-regulate its function by changing its 
conformational state, which would result in reduced Mn uptake and cellular storage, (b) 
messenger RNA level: mutant HTT may impair the translation of major Mn transporter 
transcript levels, (c) protein interactions: mutant HTT may associate and impair the 
trafficking of known Mn accumulation organelles, and (d) proteasomal function: 
expression of mutant HTT may result in the upregulation of the activity and function of 
the proteasome, which would in turn result in uncontrolled degradation of a known or 
putative Mn transporters as well as other essential proteins. Thus, decreasing the 
efficiency of the HD striatal cells to uptake, accumulate, and efflux Mn when exposed to 
identical Mn concentrations as wild-type. We demonstrated a critical need to equally 
ascertain that both wild-type and mutant HD striatal cells have similar intracellular Mn 
levels prior to assessment of Mn efflux kinetics. We demonstrated a substantial time-
dependent increase in wild-type STHdh(Q7/Q7) Mn efflux kinetics compared to mutant 
STHdh(Q111/Q111) cells following exposure to identical concentrations of MnCl2 (Figure 
III. 4.A.). However, after similar intracellular Mn levels of wild-type STHdh(Q7/Q7) and 
mutant STHdh(Q111/Q111) cells, we showed that both wild-type STHdh(Q7/Q7) and mutant 
STHdh(Q111/Q111) cells exhibit similar net Mn efflux kinetics (Figure III. 4.B.). 
Unfortunately, the precise nature of Mn efflux mechanism in the HD striatal cells is 
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unknown. However, previous reports have suggested the existence of discrete cellular Mn 
pools19,20. The cellular Mn pools involved in Mn efflux can be categorized into 3 
different classes: (i) fast phase, (ii) slow equilibrium, and (iii) irreversibly bound Mn 
efflux that are unavailable for efflux. 
Furthermore, Aschner and Wedler have demonstrated biphasic Mn efflux kinetic 
profiles in cultured astrocytes19,20. Thus, it is possible that both wild-type STHdh(Q7/Q7) 
and mutant STHdh(Q111/Q111) cells possess similar Mn efflux pools following equal 
intracellular Mn levels. However, at different intracellular Mn levels, wild-type HD 
striatal cells may efficiently efflux more Mn compared to mutant. This may possibly be 
the means by which wild-type HD striatal cells efficiently regulate net Mn uptake and 
cellular storage, which is impaired in mutant HTT striatal cells (Figure III. 3, Table III. 
1., and Table III. 2.). It is likely that we did not observe the previously reported biphasic 
relationship in Mn efflux19,20 in the HD striatal cells due to rapid efflux and loss of 
detectable cellular Mn pools that contribute to the biphasic Mn efflux kinetics during the 
repeated media changes aspect of the efflux experiment. Moreover, our data is consistent 
with the previously reported evidence of predominant interactions between Mn and 
cytosolic proteins in hepatocytes and chick glial cells studies19,20,34. In fact, 
approximately 80% of plasma Mn is bound to beta1-globulin protein35. Although there 
has been discrepancies in the affinity of Mn and other metals such as Cd and Zn to 
preferentially bind to albumin36,37 our current findings suggest that extracellular Mn binds 
with high-affinity to serum proteins, for example; albumin and beta1-globulin, other 
proteins, small anions such as nitrate (NO3-) and sulfate (SO42-), in the extracellular Mn 
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exposure media and decrease the availability and concentration of extracellular Mn for 
cellular uptake (Figure III. 2.B.). Hence, it is unlikely that expression of mutant HTT may 
modify the interactions between cytosolic Mn and proteins to decrease their availability 
for Mn efflux as we observed similar effects on net Mn uptake and cellular storage in 
both genotypes following exposure in HEPES salt buffer (Figure III. 2.A.). Nevertheless, 
our efflux data following similar intracellular Mn levels further supports the previously 
published evidence of similar ferroportin-1 (the suggested Mn exporter) protein levels in 
both genotypes. Based on the Mn uptake, cellular storage, and similar efflux following 
equivalent intracellular Mn levels in the HD striatal cells, our data indicate and suggest 
that the decreased Mn accumulation in mutant HD striatal cells compared to mutant 
(Figure III. 2.A. and 2.B.) is due to decreased Mn uptake, diminished cellular Mn storage, 
and not efficient efflux compared to wild-type STHdh(Q7/Q7) cells. 
 
The nature, types, and roles of known and putative Mn transporters in neuronal HD 
striatal cells’ Mn transport 
In our quest to investigate the Mn transporter implicated in the mutant HD striatal 
Mn transport deficits, we explored the nature of Mn transport by comparing the net Mn 
uptake and cellular Mn storage following MnCl2 exposure at 33°C or 4°C (on ice). Our 
data is consistent with the previously reported decreased net Mn accumulation at 4°C 
versus 33°C19. Specifically, 50 – 80 % decrease in net Mn uptake and cellular Mn storage 
between 4°C and 33°C (Figure IV. 1.A. and 1.B.). Furthermore, our findings indicate that 
the major Mn transport system(s) in the HD striatal cells is temperature-responsive 
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(Figure IV. 1.A. and 1.B.). In fact, our temperature-dependence on Mn uptake suggest 
that Mn influx across the plasma membranes of HD striatal cells is not mediated by a 
simple diffusion transport process, but rather an active protein-mediated transport system. 
Importantly, it is highly unlikely that the temperature-dependent effect on Mn uptake and 
cellular storage in the HD striatal cells were mainly due to changes in the random 
movements of Mn2+ particles across the membrane due to modifications in the kinetic 
energy of our exposure system (Brownian motion) at 4°C. Finally, the phenotypic 
differences in Mn uptake and cellular storage in both wild-type and mutant HD striatal 
cells following a change in temperature suggest that the major dysfunctional Mn 
transporter in mutant HD striatal cells is not a temperature-sensitive metal transporter.  
Our findings suggest that DMT1, 2-APB, RuR, mPTP, Roz, and GW9662 
blockable transporters/channels are not responsible for the mutant STHdh(Q111/Q111) Mn 
transport kinetic deficits (Figure IV. 2.B., and 3.). In fact, we have previously 
demonstrated that DMT1 protein levels are unchanged18. Despite the differential 
affinities of DMT1 for other metal transport, including Cu2+, Co2+, Fe3+, Ni2+, Pb2+, and 
Zn2+38, none of these metals showed differences in cytoxicity between wild-type 
STHdhQ7/Q7 and mutant STHdhQ111/Q111 cells18. For example, we demonstrated that while 
the specific DMT1 inhibitor, NSC30671139, occluded Mn uptake and accumulation in a 
concentration-dependent manner in primary astrocytes, it failed to inhibit Mn uptake and 
cellular Mn storage in the neuronal HD striatal cells (Figure IV. 2.A.). The opposite 
effects of the inhibitor on Mn uptake and cellular Mn storage may possibly be due to 
distinct Mn transporter systems in neurons and glial (astrocytes). In spite of the similar 
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DMT1 protein expression levels in the neuronal HD striatal cells18, it is unknown if the 
expressed DMT1 transporter is functional. Our current and previously reported data18 
suggest that DMT1 may not be the major Mn transporter impaired in mutant expressing 
HTT striatal cells 
SOCCs have been reported to transport Mn in cells40. Interestingly, mutant HTT 
associates with the inositol triphosphate 3 receptor (IP3R) and increases the sensitivity of 
the receptor pore opening permeability, which causes excess calcium release and altered 
mitochondrial function to cause cell death41,42. However, we demonstrated that utilization 
of 2-APB, which inhibits both SOCCs and inositol triphosphate receptor showed no 
effect on Mn uptake and cellular Mn storage in either wild-type or mutant cells (Figure 
IV. 2A.) Conversely, RuR has been used to occlude the Ca2+ uniporter function on 
isolated mitochondria43,44. However, it is unknown if RuR crosses the plasma membrane 
to exert its actions on the Ca2+ uniporter. It is possible that RuR may modulate other 
transporters on the plasma membrane that do not participate in Mn uptake. This may 
explain why RuR had no effect on the Mn transport and storage capacity in the HD 
striatal cells (Figure IV. 2.B.). The mitochondria have been suggested to regulate metal 
ion homeostasis through the PPARγ pathway by modulating the mitochondrial membrane 
potential and reactive oxygen species (ROS) production45,46. However, neither the PPARγ 
antagonist (GW9662) nor agonist (Roz) altered Mn uptake and storage capacity in either 
wild-type or mutant cells (Figure IV. 2.D.) Previous studies that utilized the PPARγ 
modulators in the HD striatal cells measured changes in the mitochondrial activity 
following incubation with or without GW9662, Roz, and mitochondrial toxins for 24-48 
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hrs. However, we observed an ~ 40% and ~ 60% cell survival in mutants and wild-type 
cells, respectively when compared to vehicle-only and following 27 hrs exposure with 
identical concentrations of GW9662 (40 µM) in the same HD striatal cells (data not 
shown). Furthermore, we found an opposite vulnerability effect with 20 µM Roz on wild-
type (~75%) and mutant (55%) cell survival after 27 hrs exposure (data not shown). 
Although our Mn uptake studies with the PPARγ modulators were conducted at 6 hrs, it 
is likely that these modulators may be acting on other pathways rather than the proposed. 
In addition, the toxicity induced by the PPARγ modulators is of great concern for future 
studies aimed at utilizing them to understand mitochondrial regulation of metal 
homeostasis or function. Nevertheless, CsA was incapable of mitigating the decreased 
Mn uptake and storage deficits in mutant HD striatal cells (Figure IV. 2. C.) Based on our 
findings, it is possible to suggest that the mitochondrial may be involved in minor roles or 
uninvolved in the mutant Mn accumulation deficit. 
Emerging experimental evidence have identified and suggested HIP14 and 
HIP14L as candidate proteins/metal transporters of Mn and other metal ions transport in 
cells. In addition, both HIP14 and HIP14L have different affinities for different metal 
ions47,48. HIP14 and HIP14L are palmitoyl transferases implicated in Mn2+ and other 
metals (Mg2+, Sr2+, Ni2+, Cu2+, Ba2+, Zn2+, Fe2+, Co2+, Ca2+ transport47,48. In fact, HIP14 is 
primarily expressed in neurons and on membranes of the golgi and endoplasmic 
reticulum, organelles that are known to accumulate Mn47. Furthermore, expression of 
mutant HTT is known to decrease HIP14 interaction with HTT and its ability to 
palmitoylate the HTT protein47. We have shown that HIP14 protein levels is significantly 
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reduced in mutant STHdh(Q111/Q111) cells compared to wild-type STHdh(Q7/Q7) (Figure IV. 
4.A. and 4.B). In addition, we have revealed significantly diminished (~40%) basal 
HIP14 protein levels in mutant STHdh(Q111/Q111) compared to wild-type STHdh(Q7/Q7) cells 
(Figure IV. 4.A. and 4.B.). Interestingly, previous reports have demonstrated significant 
inhibition of the HIP14 transporter function by excess (2 mM) Ca2+ levels47. We have 
shown that excess levels (1 and 10 mM) of the two highest HIP14 affinity cations (Mg2+, 
Sr2+) and Ca2+ (specific HIP14 inhibitor cation) are not toxic in both genotypes (Figure 
IV. 5.) and inhibit Mn uptake and cellular Mn storage in the HD striatal cells (Figure IV. 
6. and Table Iv. 3.). We examined the influence of excess levels of the low affinity 
cations for HIP14 such as Cu2+ and Co2+ and observed similar quenching effect in both 
wild-type and mutant HD striatal cells (data not shown). However, Cu2+ and Co2+ 
substantially quenched fura-2 fluorescence making it impossible to quantify their effects 
on Mn uptake and cellular Mn storage in the HD striatal cells. Our findings from the 
HIP14 protein expression levels and the influence of excess metals on Mn uptake and 
cellular Mn storage indicate that the impaired Mn transporter underlying mutant Mn 
uptake and storage capacity deficit is a shared transporter between Mn2+, Mg2+, Sr2+ and 
Ca2+. Furthermore, the altered Mn transporter is efficiently blocked by excess Mg2+, Sr2+, 
and Ca2+ and possesses higher affinity for Mg2+, Sr2+, and Ca2+ compared to Mn2+. Given 
the structural and cation selectivity, similarities between HIP14 and HIP14L, and reduced 
interaction between mutant HTT and HIP14 proteins47, it is possible that the mutant 
STHdh(Q111/Q111) Mn uptake and cellular storage deficit may be due to mutant HTT 
induced impairment in HIP14 and/or HIP14L transporter function. It is still unclear at 
what level of Mn transport does HIP14 possibly modulate. It is possible that HIP14 may 
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be functioning in a dual Mn regulation mechanism; (a) HIP14 may be expressed on the 
plasma membrane of cells to mediate the Mn uptake into cells. (b) Upon Mn influx into 
cells, HIP14 may associate with HTT and palmitolyate it for its normal functions in metal 
homeostasis. However mutant HTT could possibly decrease the palmitoylation of HTT 
and further decrease the intracellular trafficking of Mn dependent proteins to cause the 
decreased net Mn uptake and accumulation. 
 
Relationship between Mn uptake, cellular Mn pools, and oxidative stress  
Metals including Cu2+ and Mn2+ are known to be modifiers of PD by either 
accumulating in the brain and causing PD-like symptoms or increasing the risk of 
developing the disease49,50. Exposure to metals increase the risk of neurodegenerative 
diseases via the production of ROS by the Fenton-Harber Weiss reactions to cause 
oxidative stress, which damages lipids, proteins, DNA, and further depletes ATP to cause 
cell death51-53. It was unclear how the demonstrated differences in Mn uptake and storage 
capacity (Figure III. 3.) are functionally related to the previously reported cytoxicity 
difference between wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells18. We have 
shown that although wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells 
significantly generate ROS levels in a time-dependent manner and above baseline levels 
following exposure to MnCl2, mutant STHdh(Q111/Q111) cells exhibited decreased Mn 
induced ROS production compared to wild-type (Figure IV. 7.A. – 7.C., and Table IV. 
4.). In addition, we have also demonstrated a concentration- and time-dependent decrease 
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in mutant Mn uptake kinetics and cellular Mn storage compared to wild-type 
STHdh(Q7/Q7) cells (Figure III.  3.A. and 3.B. and Figure III. 1.A. and 1.B.). Our findings 
suggest a functional relationship between Mn uptake, cellular Mn pools that could 
directly or indirectly induce Mn-induced ROS production to cause cell death. This 
phenomenon may cause the differential vulnerability of Mn-induced cytoxicity between 
wild-type STHdh(Q7/Q7) and mutant STHdh(Q111/Q111) cells18. However, our findings do not 
directly provide the underlying mechanism for striatal specific degeneration of medium 
spiny neurons in HD brains. 
Nevertheless, mutant HTT expression54-61 and Mn exposure62-66 have been 
previously reported to increase ROS production in the brain. Furthermore, MacDonald 
and colleagues have previously utilized a chemiluminescent H2O2 detection kit to 
monitor intracellular H2O2 concentrations as a read-out of ROS production in HD striatal 
cells and reported a significant reduction in mutant STHdhQ111/Q111 ROS levels compared 
to wild-type STHdh(Q7/Q7) cells67. However, we observed the opposite effect at 5, 15, and 
30 minutes exposure to H2O2. The discrepancy between our findings and the previour 
report might possibly be due to the following: (i) specificity and detection limits of assays 
been used for ROS detection. Specifically, the DCF assay does not distinguish between 
the types of free radicals generated in the cell to cause changes in ROS levels. However, 
the cheluminescent assay is a luminescent assay that specifically measures intracellular 
H2O2 concentration as a direct correlation of intracellular ROS levels. In addition, other 
factors that may cause the differences between the two assays used to monitor ROS levels 
in cells may be due to (ii) type of oxidative stress biomarkers measured. For example, 8-
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hydroxy-2-deoxyguanosine (OH(8)dG54 versus isoprostanes62, (iii) Differences in the 
cell-types used to examine oxidative stress63,64, and (iii) Mode of ROS stimulation in in 
vivo HD models (chemically induced 3-nitropropionic acid or malonate inhibitors)56 
versus metals. Despite the known link between metals and ROS production, and the 
relationship between mutant HTT and ROS generation, none of the above studies have 
examined a combinatorial effect of both; specifically, the synergistic effect of metals 
(Mn) and mutant HTT expression on ROS production in cells. It is noteworthy that the 
functional relationship between cellular Mn pools and oxidative injury demonstrated in 
the HD striatal cells might not be the primary mechanism underlying striatal specific 
degeneration of medium spiny neurons in HD patients. In fact, it is highly likely that a 
combination of diminished cellular Mn levels, impaired Mn-dependent and other 
antioxidant activities, altered mitochondrial function, oxidative injury, diminished ATP 
levels, decreased neuroprotective roles of glial cells, protein aggregation, and 
upregulation of cell death mechanisms might underlie the in vivo mutant HTT expressing 
striatal-specific degeneration. Despite the decreased Mn uptake and accumulation in 
mutant STHdhQ111/Q111 cell lines and YAC128 mouse models of HD, diminished 
susceptibility of mutant STHdhQ111/Q111 cell lines to Mn induced cytotoxicity, and 
reduced ROS levels in mutant HD striatal cell lines compared to wild-type18, the striatum 
in animal models and HD patients are the most vulnerable in the disease. Given that the 
enzymatic activities of several manganoproteins have been reported to be reduced in HD 
patients and animal models68-73 as well as Dexter and colleagues reporting no change in 
Mn levels in HD postmortem brains due to a small sample size74, it is possible that the 
neuroprotective effects of Mn in vivo may be regulated by other factors including, cell 
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types (astrocytes, microglial), age of disease onset, and changes in other metal 
homeostasis that are difficult to control in our in vitro HD striatal cells. Prior to the 
clinical manifestation of HD, the brain tightly regulates metal ions including Mn2+, Cu2+, 
and Fe2+ that may be required as cofactors for enzymatic functions necessary for medium 
spiny neuron function and survival in the striatum. However, as the disease progresses, 
mutant HTT protein might aberrantly via direct or indirect means regulate metal 
homeostasis that would result in the reported increase in Fe2+ (56%) and Cu2+ (48%) 
levels in the brain70. If the demands of Mn2+ as a cofactor for manganoproteins in the 
striatum were substantially higher than other brain regions, then the dysregulated metal 
ions including Mn2+ in the brain would eventually cause decreased neuroprotection of 
medium spiny neurons in the striatum. Furthermore, the Mn-dependent antioxidants (Mn-
SOD2, arginase)68,71, astrocyte specific Mn-dependent enzyme (glutamine 
synthetase)69,70, and Mn-dependent energy production enzyme (pyruvate carboxylase)72,73 
would be altered as reported. It is possible that the substantial changes in Fe2+ (56%) and 
Cu2+ (48%) levels in HD brain70 may directly induce ROS production through the 
Fenton-Harber Weiss reactions to cause oxidative stress, which would damage lipids, 
proteins, DNA, and further depletes ATP to cause cell death51-53 or indirectly alter 
mitochondrial function, induce protein aggregation, and down-regualate the activity and 
function of the proteasome. In the neuronal HD striatal cell lines that lack the in vivo 
neuroprotective functions of astrocytes, they might possibly be regulating metal ion 
homeostasis in a completely different manner compared to what exists in vivo. For 
example, mutant HD striatal cells that lack the in vivo astrocyte sequestration of excess 
Mn may downregulate HIP14 or other putative Mn transporters as a defensive response 
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to increased Mn above endogenous levels. This would explain the decreased Mn uptake 
and cellular storage, diminished basal HIP14 protein levels, and reduced ROS production 
in mutant HD striatal cells compared to wild-type.  
 
Future directions 
To completely understand the disease-toxicant interaction between HD and Mn 
and translate our findings as beneficial or detrimental to the variability in age of disease 
onset, severity, disease progression, and selective neuropathology of HD, further studies 
would have to be conducted. Future studies would have to examine the contribution of 
other putative Mn transporters in the HD-Mn interaction. Given that our findings ruled 
out several known Mn transporters as culprits of the decreased Mn uptake and storage 
capacity deficits in mutant HTT expressing cells, it would be essential to examine the 
role of the suggested putative Mn transporters HIP14L, PARK9, and others in Mn uptake. 
Based on our findings of decreased HIP14 protein levels in mutant HD striatal cells and 
inhibition of the Mn uptake and cellular Mn storage by the non-toxic two highest affinity 
cations (Mg2+, Sr2+) of the HIP14 transporter and its selective cation inhibitor (Ca2+), 
future studies would have to knockdown HIP14 and or HIP14L levels in wild-type 
neuronal HD striatal cells to determine if that phenocopies the decreased basal expression 
of HIP14 in mutant HD strital cells. In addition, changes in Mn uptake, cellular storage 
and efflux kinetics in the HIP14 knockdown wild-type HD striatal cells should be 
examined and compared to the controls (wild-type and mutant HD striatal cells). 
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Furthermore, overexpression of HIP14 and/or HIP14L in mutant HD striatal cells would 
have to be performed to further substantiate the role of HIP14 in the diminished Mn 
transport dynamics in mutant expressing HTT striatal cells. Furthermore, previous studies 
have demonstrated an inverse correlation between the polyQ repeat length in the HTT 
protein and HIP14 interaction47,75. Moreover, HIP14 is known to palmitolyate the HTT 
and other proteins75. Future studies would have to investigate the effect of Mn exposure 
on HIP14 transcript levels in the neuronal HD striatal cells. Interestingly, what is also not 
known is the effect of metals, for example Mn on HIP14 palmitoylation activity. It would 
be important to explore the effects of Mn on the temporal and spatial localization of 
HIP14 and HTT proteins at the cellular level, as well as their interactions by performing 
immunostaining and other biochemical assays. Although previous studies have reported 
HIP14 localization on the golgi and endoplasmic reticulum membrane47,75, they did not 
show HIP14 expression on the plasma membrane. It is still unclear whether HIP14 and/or 
HIP14L proteins are expressed on the plasma membrane. Future studies should perform 
biotinylation assays to determine HIP14 and HIP14L expression on the plasma 
membrane. Finally, with the current availability of specific HIP14 inhibitors76,77, the 
functions of HIP14 in metal transport and homeostasis in other neurodegenerative 
diseases can be efficiently investigated.   
  On the other hand, Gitler and colleagues have implicated PARK9 as a Mn 
transporter in a yeast model of PD48. However, it is still unknown whether PARK9 
mediates Mn uptake in in vitro and in vivo models. Future studies would have to ascertain 
PARK9 as a Mn transporter in other in vitro (neuronal HD striatal cells) and in vivo 
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animal models of HD (YAC128, BAC225) and other neurodegenerative diseases. In 
addition, understanding the effect of Mn on PARK9 protein and transcript expression 
levels would further support PARK9 as a Mn-responsive gene. Once PARK9 has been 
confirmed as a Mn-responsive gene, future experiments would have to modulate its 
expression and function to test its role in the HD-Mn interaction. This would be achieved 
through PARK9 overexpression and knockdown studies. Furthermore, development of 
small molecules that modulate PARK9 activity and function would enable future studies 
to screen for the role of PARK9 in metal transport and homeostasis, as well as other 
pathophysiological pathways implicated in neurodegenerative diseases. Although the 
exact function of PARK9 is unknown, it is generally thought to be a transmembrane 
cationic metal transporter that shuttles cations, including Mn across the cell. Biochemical 
studies have demonstrated that the highest and lowest PARK9 mRNA levels are localized 
within the substantia nigra and cerebellum respectively78. However, it is still unknown if 
PARK9 is expressed on the plasma membrane of cells. Future studies should investigate 
PARK9 expression on membranes and if Mn exposure alters the localization and function 
of PARK9 protein in the neuronal HD striatal cells. 
 It is likely that the above discussed putative transporters and other yet to be 
identified metal transporters may underlie the decreased Mn uptake and cellular storage 
in mutant HD striatal cells. However, an important aspect for better understanding of the 
disease-toxicant interaction and metal transporters would require the combination of both 
in vitro and in vivo animal models. In the case of HIP14 and PARK9 functions as metal 
transporters in in vivo animal models, future studies should examine similar experimental 
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ideas as discussed above for the neuronal HD striatal cells. The recently developed 
transgenic mouse model (YAC128-HIP14 knock out) of HD79 permits the investigation 
of the mutant HTT-Mn interaction in the context of a mouse model that lacks HIP14. 
This would enable future studies to ascertain whether HIP14 is the primary Mn 
transporter underlying decreased Mn accumulation in the HD striatal cells and striatum of 
YAC128 mouse model of HD. Moreover, future studies should actively consider 
generating transgenic animal models of HIP14L and PARK9 to better examine metals, 
for example, Mn transport and homeostasis. In addition, it would important to understand 
whether the CAG repeat length modulates Mn transport dynamics in the context of 
HIP14, HIP14L, and PARK9 expression levels in both in vitro and in vivo mouse models 
of HD. Given the affinity of HIP14 for other divalent metals (Mg2+, Sr2+, Ni2+, Ca2+, 
Ba2+, Zn2+), it is possible that HIP14 may mediate metal induced toxicity in other 
neurodegenerative diseases. Future studies should also consider examining the role of 
other putative Mn transporters, such as TRPM7, homomeric purinoreceptors, and the 
citrate transporters in both the neuroal HD striatal cells and in vivo animal models of HD 
(YAC128, BAC225). Importantly, future studies shown explore the sequential or 
simultaneous contribution of multiple known or putative Mn transporters in the mutant 
HTT-Mn interaction. 
 Availability of the high-throughput assay (CFMEA) has enabled for efficient 
dissection of Mn transporter systems and Mn transport dynamics in the neuronal HD 
striatal cells. However, we still don’t know the nature of the impaired Mn transporter. 
Thus, future experiments should use CFMEA, traditional fura-2 loaded kinetic assays, 
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and biochemical techniques to investigate whether the impaired transporter is energy-
dependent and modulated by changes in pH. Findings from these studies in addition to 
our findings of similar response of wild-type and mutant HD striatal cells to net Mn 
uptake and cellular storage following changes in temperature (Figure IV. 1.) would 
enable future studies to focus on known metal transporters that fall within those 
categories. Furthermore, we have demonstrated decreased net cellular Mn storage in 
mutant HD striatal cells compared to wild-type following Mn exposure (Figure III. 3.A. 
and 3.B.). However, we still do not know the cellular compartments responsible for the 
Mn deficit. Given the conflicting reports to support either the mitochondria or nuclei as 
the cellular organelle that accumulates the primary pool of Mn in the cell 29,43,80, future 
studies should consider performing subcellular fractionation experiments in the neuronal 
HD striatal cells and the striatum of YAC128 mouse models of HD. In these experiments 
organelles, such as mitochondria, endoplasmic reticulum, and nuclei would have to be 
fractionated either pre and post Mn exposures. It is crucial that the experimenters 
consider the integrity of the organelles during subcellular fraction. For example, while 
other studies have shown that it is essential to add substrates, such as pyruvate, during 
subcellular fractionation of the mitochondria, other researchers have argued against it. It 
is important that future studies perform their subcellular fractionation by either adding or 
excluding substrates. Finally, future studies should also examine the temporal and spatial 
Mn accumulation in the brain of mouse models of HD. 
 It is still unclear if the selective neuropathology in the striatum of HD brains is 
caused by oxidative stress, mitochondrial dysfunction, protein aggregation, or altered 
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metal homeostasis. It is possible that all these pathways converge to exacerbate the 
phenotypic variabilities in HD. Future studies should consider examining other 
biomarkers of oxidative stress, such as isoprostanes following Mn exposure in the 
neuronal HD striatal cells and YAC128 mouse model of HD. Secondly, understanding 
how Mn exposure may alter mitochondrial function through membrane fragmentation, 
production of ROS, or decreasing ATP levels would provide great insights into the 
initiating factors and the understanding of how mutant HTT may modulate these 
pathways to cause striatal specific degeneration. In addition future experiments should 
assess ROS production in primary neuronal, astrocytic, and mixed cultures to investigate 
cell-type specific response to Mn exposure. Moreover, examination of the mitochondrial 
integrity following Mn exposure would be important in understanding the differential 
vulnerability in Mn induced cytotoxicity between wild-type and mutant neuronal HD 
strial cells. These studies could be performed alongside other Mn transport kinetic studies 
and assessed by CFMEA. 
 Given the promising future of induced pluripotent stem (IPS) cell research, it 
would be very important for future studies to translate our findings in the neuronal HD 
striatal cells and YAC128 mouse model into patients. The generation of medium spiny 
neurons from HD patient skin biopsy would enable for high-throughput screening of 
metals and other toxicants that exhibit gene-environment interaction with mutant HTT. In 
addition, these studies may elucidate some primary pathophysiological mechanisms in 
HD neuropathology that has not yet been observed in in vitro and in vivo animal models.  
  
214 
An important long-term goal would be to provide therapeutic interventions for 
HD patients from our findings. However, there are some crucial hurdles that must be 
overcome prior to our ability to recommend low concentrations of Mn for HD patients. 
(i) We would need to ascertain the appropriate Mn exposure concentrations that are 
capable of retarding medium spiny neuron degeneration, disease progression, symptoms, 
and decrease age of onset without possessing toxic effects in animal models of HD. (ii) 
Investigate the required and physiologically relevant concentrations of Mn that can be 
used in development of a drug to ameliorate the phenotypic symptoms of HD and most 
importantly not have major side effects in HD patients. (iii) We would need to certify that 
the newly developed Mn-rich drugs when administered in the brain would be efficiently 
metabolized and not end up accumulating in the basal ganglia regions or other known Mn 
accumulation organs and cause Manganism, (iv) Determine the optimal drug efficacy 
window in HD patients - pre versus during onset of disease symptomology, and (ii) types 
of HD - juvenile versus adult; as the cerebellum that does not accumulate Mn also 
degenerates in juvenile HD. 
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